0001729149-23-000111.txt : 20230809 0001729149-23-000111.hdr.sgml : 20230809 20230809161942 ACCESSION NUMBER: 0001729149-23-000111 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 68 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230809 DATE AS OF CHANGE: 20230809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VIEMED HEALTHCARE, INC. CENTRAL INDEX KEY: 0001729149 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38973 FILM NUMBER: 231155476 BUSINESS ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 BUSINESS PHONE: 337.504.3802 MAIL ADDRESS: STREET 1: 625 E. KALISTE SALOOM RD. CITY: LAFAYETTE STATE: LA ZIP: 70508 10-Q 1 vmd-20230630.htm 10-Q vmd-20230630
0001729149false2023Q2--12-31P1YP3Y00017291492023-01-012023-06-3000017291492023-07-20xbrli:shares00017291492023-06-30iso4217:USD00017291492022-12-3100017291492023-04-012023-06-3000017291492022-04-012022-06-3000017291492022-01-012022-06-30iso4217:USDxbrli:shares0001729149us-gaap:CommonStockMember2021-12-310001729149us-gaap:AdditionalPaidInCapitalMember2021-12-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001729149us-gaap:RetainedEarningsMember2021-12-3100017291492021-12-310001729149us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100017291492022-01-012022-03-310001729149us-gaap:CommonStockMember2022-01-012022-03-310001729149us-gaap:RetainedEarningsMember2022-01-012022-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001729149us-gaap:CommonStockMember2022-03-310001729149us-gaap:AdditionalPaidInCapitalMember2022-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001729149us-gaap:RetainedEarningsMember2022-03-3100017291492022-03-310001729149us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001729149us-gaap:CommonStockMember2022-04-012022-06-300001729149us-gaap:RetainedEarningsMember2022-04-012022-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001729149us-gaap:CommonStockMember2022-06-300001729149us-gaap:AdditionalPaidInCapitalMember2022-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001729149us-gaap:RetainedEarningsMember2022-06-3000017291492022-06-300001729149us-gaap:CommonStockMember2022-12-310001729149us-gaap:AdditionalPaidInCapitalMember2022-12-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001729149us-gaap:RetainedEarningsMember2022-12-310001729149us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-3100017291492023-01-012023-03-310001729149us-gaap:CommonStockMember2023-01-012023-03-310001729149us-gaap:RetainedEarningsMember2023-01-012023-03-310001729149us-gaap:CommonStockMember2023-03-310001729149us-gaap:AdditionalPaidInCapitalMember2023-03-310001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001729149us-gaap:RetainedEarningsMember2023-03-3100017291492023-03-310001729149us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001729149us-gaap:CommonStockMember2023-04-012023-06-300001729149us-gaap:RetainedEarningsMember2023-04-012023-06-300001729149us-gaap:CommonStockMember2023-06-300001729149us-gaap:AdditionalPaidInCapitalMember2023-06-300001729149us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001729149us-gaap:RetainedEarningsMember2023-06-30vmd:state0001729149vmd:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-30xbrli:pure0001729149vmd:MedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001729149vmd:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001729149vmd:MedicareAndMedicaidMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-12-310001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicaidMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2023-04-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2022-04-012022-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-06-300001729149us-gaap:RevenueFromContractWithCustomerMembervmd:MedicareAndMedicaidMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-06-300001729149vmd:SolvetServicesLLCMember2023-06-300001729149vmd:VentilatorRentalMember2023-04-012023-06-300001729149vmd:VentilatorRentalMember2022-04-012022-06-300001729149vmd:VentilatorRentalMember2023-01-012023-06-300001729149vmd:VentilatorRentalMember2022-01-012022-06-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2023-04-012023-06-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2022-04-012022-06-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2023-01-012023-06-300001729149vmd:OtherDurableMedicalEquipmentRentalsMember2022-01-012022-06-300001729149vmd:EquipmentSalesMember2023-04-012023-06-300001729149vmd:EquipmentSalesMember2022-04-012022-06-300001729149vmd:EquipmentSalesMember2023-01-012023-06-300001729149vmd:EquipmentSalesMember2022-01-012022-06-300001729149vmd:COVID19ResponseSalesMember2023-04-012023-06-300001729149vmd:COVID19ResponseSalesMember2022-04-012022-06-300001729149vmd:COVID19ResponseSalesMember2023-01-012023-06-300001729149vmd:COVID19ResponseSalesMember2022-01-012022-06-300001729149us-gaap:ServiceMember2023-04-012023-06-300001729149us-gaap:ServiceMember2022-04-012022-06-300001729149us-gaap:ServiceMember2023-01-012023-06-300001729149us-gaap:ServiceMember2022-01-012022-06-300001729149us-gaap:InterestRateSwapMember2022-01-012022-12-3100017291492020-04-012020-04-3000017291492021-11-012021-11-3000017291492022-01-012022-01-310001729149vmd:HomeMedicalProductsIncMember2023-06-010001729149vmd:HomeMedicalProductsIncMember2023-06-012023-06-010001729149us-gaap:LineOfCreditMembervmd:HomeMedicalProductsIncMembervmd:A5YearRevolvingCreditFacilityMemberus-gaap:RevolvingCreditFacilityMember2023-06-012023-06-010001729149vmd:DelayedDrawTermLoanFacilityMemberus-gaap:LineOfCreditMembervmd:HomeMedicalProductsIncMembervmd:TermLoanFacilityMember2023-06-012023-06-010001729149vmd:HomeMedicalProductsIncMember2023-01-012023-06-300001729149vmd:EquipmentMedicalMember2023-06-300001729149vmd:EquipmentMedicalMember2022-12-310001729149vmd:FurnitureAndEquipmentMember2023-06-300001729149vmd:FurnitureAndEquipmentMember2022-12-310001729149us-gaap:LandMember2023-06-300001729149us-gaap:LandMember2022-12-310001729149us-gaap:BuildingMember2023-06-300001729149us-gaap:BuildingMember2022-12-310001729149us-gaap:LeaseholdImprovementsMember2023-06-300001729149us-gaap:LeaseholdImprovementsMember2022-12-310001729149us-gaap:VehiclesMember2023-06-300001729149us-gaap:VehiclesMember2022-12-310001729149vmd:EquipmentMedicalMember2023-01-012023-06-300001729149vmd:EquipmentMedicalMember2022-01-012022-12-310001729149us-gaap:LineOfCreditMembervmd:A2018SeniorCreditFacilityMember2022-11-290001729149vmd:BuildingTermNoteMemberus-gaap:NotesPayableToBanksMember2019-05-300001729149vmd:BuildingTermNoteMemberus-gaap:NotesPayableToBanksMemberus-gaap:InterestRateSwapMember2019-05-300001729149vmd:A2019TermNoteMemberus-gaap:NotesPayableToBanksMember2019-09-190001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:NotesPayableToBanksMemberus-gaap:RevolvingCreditFacilityMember2022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-11-292022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMembersrt:MaximumMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-11-292022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMembersrt:MinimumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2022-11-292022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMembersrt:MaximumMemberus-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMember2022-11-292022-11-290001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMembervmd:A2022SeniorCreditFacilitiesClosingDateOfDecember312024Member2023-01-012023-06-300001729149vmd:A2022SeniorCreditFacilitiesMembervmd:A2022SeniorCreditFacilitiesClosingDateOfMarch312025Memberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-06-300001729149vmd:A2019TermNoteMemberus-gaap:LineOfCreditMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-06-300001729149vmd:A2022SeniorCreditFacilitiesMemberus-gaap:RevolvingCreditFacilityMember2023-06-300001729149us-gaap:NotesPayableToBanksMember2023-06-300001729149us-gaap:NotesPayableToBanksMember2022-12-310001729149vmd:EquipmentFinancingObligationMembersrt:MinimumMember2023-06-010001729149vmd:EquipmentFinancingObligationMembersrt:MaximumMember2023-06-010001729149vmd:EquipmentFinancingObligationMember2023-06-300001729149us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueMeasurementsRecurringMember2023-06-300001729149us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:FairValueMeasurementsRecurringMember2022-12-310001729149us-gaap:CommonStockMember2023-01-012023-06-300001729149vmd:OmnibusPlanMember2020-06-110001729149vmd:OmnibusPlanMember2020-06-112020-06-110001729149us-gaap:CommonStockMembervmd:OmnibusPlanMember2020-06-110001729149us-gaap:RestrictedStockUnitsRSUMember2023-06-300001729149us-gaap:EmployeeStockOptionMember2023-04-012023-06-300001729149us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001729149us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001729149us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001729149us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001729149us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001729149us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001729149us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-3000017291492022-01-012022-12-310001729149us-gaap:CommonStockMember2023-01-012023-06-300001729149us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-01-012023-06-300001729149us-gaap:RestrictedStockUnitsRSUMember2022-12-310001729149us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001729149us-gaap:PhantomShareUnitsPSUsMember2023-01-012023-06-300001729149us-gaap:PhantomShareUnitsPSUsMember2022-12-310001729149us-gaap:PhantomShareUnitsPSUsMember2023-06-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-012022-06-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-300001729149us-gaap:PhantomShareUnitsPSUsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-06-300001729149us-gaap:PhantomShareUnitsPSUsMember2022-01-012022-06-3000017291492020-03-3100017291492020-12-282020-12-2800017291492021-05-31vmd:patient00017291492021-11-30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-Q
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____ to _____

Commission file number: 001-38973

Viemed Healthcare, Inc.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
 N/A
(State or other jurisdiction of
incorporation or organization)
 
(IRS Employer
Identification Number)
   
 
625 E. Kaliste Saloom Rd.
Lafayette, LA 70508
 
(Address of principal executive offices, including zip code)
 
(337) 504-3802
 
(Registrant’s telephone number, including area code)
   
Securities registered pursuant to Section 12(b) of the Act:
   
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Shares, no par valueVMDThe Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  x    No  ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☐
 
Accelerated filer ☒
 Non-Accelerated filer ☐ 
Smaller reporting company ☒
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  x

As of July 20, 2023, there were 38,400,422 common shares of the registrant outstanding.

VIEMED HEALTHCARE, INC.
TABLE OF CONTENTS
June 30, 2023 and 2022
Page


PART I - FINANCIAL INFORMATION

Item 1. Financial Statements
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Expressed in thousands of U.S. Dollars, except outstanding shares)
NoteAt
June 30, 2023		At
December 31, 2022
(Unaudited)(Audited)
ASSETS
Current assets
Cash and cash equivalents$10,224 $16,914 
Accounts receivable, net217,893 15,379 
Inventory24,476 3,574 
Income tax receivable101,029 26 
Prepaid expenses and other assets2,327 3,849 
Total current assets$35,949 $39,742 
Long-term assets
Property and equipment, net472,884 67,743 
Finance lease right-of-use assets6538 — 
Operating lease right-of-use assets6516 694 
Equity investments21,942 2,155 
Debt investment22,110 2,000 
Deferred tax asset103,844 3,119 
Identifiable intangibles, net3688 — 
Goodwill329,759 — 
Other long-term assets9887 1,590 
Total long-term assets$113,168 $77,301 
TOTAL ASSETS$149,117 $117,043 
LIABILITIES
Current liabilities
Trade payables$6,167 $2,650 
Deferred revenue5,960 4,624 
Accrued liabilities515,509 11,092 
Finance lease liabilities, current portion6375 — 
Operating lease liabilities, current portion 6395 495 
Current debt63,169 — 
Total current liabilities$31,575 $18,861 
Long-term liabilities
Accrued liabilities8637 889 
Finance lease liabilities, less current portion 6143 — 
Operating lease liabilities, less current portion6143 199 
Long-term debt612,114 — 
Total long-term liabilities$13,037 $1,088 
TOTAL LIABILITIES$44,612 $19,949 
Commitments and Contingencies9— — 
SHAREHOLDERS' EQUITY
Common stock - No par value: unlimited authorized; 38,400,422 and 38,049,739 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively
8$17,850 $15,123 
Additional paid-in capital13,488 12,125 
Retained earnings73,167 69,846 
TOTAL SHAREHOLDERS' EQUITY$104,505 $97,094 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$149,117 $117,043 
See accompanying notes to the condensed consolidated financial statements
Page 3
VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
(Expressed in thousands of U.S. Dollars, except share and per share amounts)
(Unaudited)
Three Months Ended June 30,Six Months Ended June 30,
Note2023202220232022
Revenue2$43,311 $33,310 $82,867 $65,565 
Cost of revenue17,205 12,920 32,757 25,432 
Gross profit$26,106 $20,390 $50,110 $40,133 
Operating expenses
Selling, general and administrative20,563 17,536 40,325 33,312 
Research and development758 672 1,538 1,304 
Stock-based compensation81,471 1,271 2,862 2,576 
Depreciation298 243 538 480 
Loss (gain) on disposal of property and equipment117 (110)95 (124)
     Other (income) expense, net(2)(223)(83)(664)
Income from operations$2,901 $1,001 $4,835 $3,249 
Non-operating income and expenses
Income from equity method investments137 446 172 769 
Interest income (expense), net620 (59)69 (123)
Net income before taxes3,058 1,388 5,076 3,895 
Provision for income taxes10728 421 1,229 1,166 
Net income$2,330 $967 $3,847 $2,729 
Other comprehensive income (loss)
Change in unrealized gain/loss on derivative instruments, net of tax— 59 — 222 
Other comprehensive income (loss)$— $59 $— $222 
Comprehensive income$2,330 $1,026 $3,847 $2,951 
Net income per share
Basic11$0.06 $0.02 $0.10 $0.07 
Diluted11$0.06 $0.02 $0.10 $0.07 
Weighted average number of common shares outstanding:
Basic 1138,324,249 38,773,580 38,240,902 39,195,317 
Diluted1140,676,951 39,752,928 40,383,616 40,056,953 

See accompanying notes to the condensed consolidated financial statements
Page 4

VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
(Expressed in thousands of U.S. Dollars, except share and per share amounts)
(Unaudited)
Common StockAdditional paid-in capitalAccumulated other comprehensive lossTotal Shareholders'
equity
SharesAmountRetained
earnings
Shareholders' equity, December 31, 202139,640,388$14,014 $7,749 $(278)$73,335 $94,820 
Stock-based compensation - options— — 820 — — 820 
Stock-based compensation - restricted stock units— — 485 — — 485 
Shares issued for vesting of restricted stock units67,010 334 (334)— — — 
Shares redeemed to pay income tax(23,742)— — — (119)(119)
Shares repurchased under share repurchase program(389,878)— — — (1,887)(1,887)
Change in accumulated other comprehensive loss, net of tax— — — 163 — 163 
Net income— — — — 1,762 1,762 
Shareholders' equity, March 31, 202239,293,778 $14,348 $8,720 $(115)$73,091 $96,044 
Stock-based compensation - options— — 757 — — 757 
Share-based compensation - restricted stock units— — 514 — — 514 
Shares repurchased under share repurchase program(960,689)— — — (5,114)(5,114)
Change in accumulated other comprehensive loss, net of tax— — — 59 — 59 
Net income— — — — 967 967 
Shareholders' equity, June 30, 202238,333,089 $14,348 $9,991 $(56)$68,944 $93,227 
Common StockAdditional paid-in capitalAccumulated other comprehensive lossTotal Shareholders'
equity
SharesAmountRetained
earnings
Shareholders' equity, December 31, 202238,049,739$15,123 $12,125 $— $69,846 $97,094 
Stock-based compensation - options— — 348 — — 348 
Stock-based compensation - restricted stock units— — 1,043 — — 1,043 
Exercise of options108,370 544— — — 544 
Shares issued for vesting of restricted stock units183,036 1,429 (1429)— — — 
Shares redeemed to pay income tax(64,756)— — — (505)(505)
Net income— — — — 1,517 1,517 
Shareholders' equity, March 31, 202338,276,389 $17,096 $12,087 $— $70,858 $100,041 
Stock-based compensation - options— — 301 — — 301 
Stock-based compensation - restricted stock units— — 1,170 — — 1,170 
Exercise of options119,356 684 — — — 684 
Shares issued for vesting of restricted stock units6,655 70 (70)— — — 
Shares redeemed to pay income tax(1,978)— — — (21)(21)
Net income— — — — 2,330 2,330 
Shareholders' equity, June 30, 202338,400,422 $17,850 $13,488 $— $73,167 $104,505 











See accompanying notes to the condensed consolidated financial statements
Page 5

VIEMED HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Expressed in thousands of U.S. Dollars)
(Unaudited)
Six Months Ended June 30,
Note20232022
Cash flows from operating activities
Net income$3,847 $2,729 
Adjustments for:
Depreciation9,968 7,136 
Change in inventory reserve— (1,418)
Stock-based compensation expense82,862 2,576 
Distributions of earnings received from equity method investments392 612 
Income from equity method investments(172)(769)
Income from debt investment(110)— 
Loss (gain) on disposal of property and equipment95 (124)
Deferred income tax (benefit) expense(725)745 
Changes in working capital, net of effects from acquisitions:
Accounts receivable, net(500)(1,464)
Inventory(320)1,022 
Prepaid expenses and other assets2,076 (634)
Trade payables(488)(243)
Deferred revenue604 649 
Accrued liabilities1,593 (87)
Income tax payable/receivable(1,003)1,362 
Net cash provided by operating activities$18,119 $12,092 
Cash flows from investing activities
Purchase of property and equipment(10,759)(10,989)
Investment in equity investments(7)(121)
Cash paid for acquisition of HMP, net of cash acquired3(27,121)— 
Proceeds from sale of property and equipment41,775 615 
Net cash used in investing activities$(36,112)$(10,495)
Cash flows from financing activities
Proceeds from exercise of options81,228 — 
Proceeds from term notes65,000 — 
Principal payments on term notes6(1,357)(78)
Proceeds from revolving credit facilities68,000 — 
Payments on revolving credit facilities(1,005)(872)
Shares redeemed to pay income tax8(526)(119)
Shares repurchased under the share repurchase program8— (7,001)
Repayments of lease liabilities(37)(13)
Net cash provided by (used in) financing activities$11,303 $(8,083)
Net decrease in cash and cash equivalents(6,690)(6,486)
Cash and cash equivalents at beginning of year16,914 28,408 
Cash and cash equivalents at end of period$10,224 $21,922 
Supplemental disclosures of cash flow information
Cash paid during the period for interest$169 $128 
Cash paid (received) during the period for income taxes, net of refunds$3,093 $(940)
Supplemental disclosures of non-cash transactions
Non-cash change in debt from the reclassification of debt issuance costs(748)— 
See accompanying notes to the condensed consolidated financial statements
Page 6

VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022

1.    Nature of Business and Operations

Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.

The Company’s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol "VMD" and in Canada on the Toronto Stock Exchange under the symbol "VMD.TO".

2. Summary of Significant Accounting Policies

Principles of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Basis of Consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.


Page 7
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Segment Reporting

The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure based on ASC 280, Segment Reporting.

Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the six months ended June 30, 2023, the Company's evaluation takes into consideration such factors as historical bad debt and billing modification experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.

The estimates and charge-offs for the allowance for doubtful accounts for each reporting period were as follows:
June 30, 2023June 30, 2022
Balance, beginning of year$8,483 $7,031 
Provision for uncollectible accounts7,579 6,300 
Amounts charged off(5,055)(3,948)
Balance, end of period$11,007 $9,383 

Included in accounts receivable at June 30, 2023 are amounts due from Medicare and Medicaid representing 35% and 6%, respectively, and 41% combined, of total outstanding receivables. As of December 31, 2022, 48% of total outstanding receivables were amounts due from Medicare and Medicaid.

Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Medicare revenues44 %46 %45 %47 %
Medicaid revenues9 %9 %9 %9 %
Total Medicare and Medicaid53 %55 %54 %56 %

Inventory

Inventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.

Page 8
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.

Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Equity investments

Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2.

The following table details the Company’s equity investments:
June 30, 2023December 31, 2022
Equity method investments$595 $816 
Other equity investments1,347 1,339 
Balance, end of period$1,942 $2,155 

The Company's equity method investments include a 49% equity interest in Solvet Services, LLC, an entity which provides health care support services to state and federal governments. Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with any subsequent adjustments made to the carrying amount of the investment for the Company’s proportionate share of income or loss. Distributions received from the investee reduce the Company’s carrying value of the investment. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of June 30, 2023 that would impair the carrying value of equity method investments.

Other equity investments include an equity interest in VeruStat, Inc., a remote patient monitoring entity, and an equity interest in DMEscripts, LLC, an e-prescribing platform. Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2023 on its investments in equity securities without a readily determinable fair value.

Debt Investment

The Company's debt investment is a variable rate secured convertible note issued by Healthcare DX, Inc. (d/b/a ModoHealth) on December 21, 2022, classified as an available-for-sale debt instrument. Accrued interest is due upon the 18 month maturity of the note and is included in the amortized cost basis at each reporting period. At each financial statement date until a conversion event, the debt instrument is required to be remeasured at fair value. Changes in unrealized gains and losses are included in accumulated other comprehensive income, net of tax effect, until realized.



Page 9
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Valuation of Goodwill

Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. During the three months ended June 30, 2023 the Company evaluated the events and changes that could indicate that goodwill might be impaired and concluded that an interim test was not necessary.

Comprehensive income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company's comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.

Revenue recognition

Revenue from a customer consists of sales and rentals of home medical equipment and patient medical services. Patient revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Patient revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).

For commercial payors, HME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with HME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any HME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which varies based on the type of equipment rental, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.

Page 10
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues.

The revenues from each major source are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$25,712 $22,736 $50,859 $44,254 
    Other durable medical equipment rentals8,419 4,912 15,325 9,271 
Revenue from sales and services under Topic 606
    Equipment and supply sales
6,778 3,245 11,542 6,282 
    COVID-19 response sales and services
— 183 — 2,278 
    Service revenues
2,402 2,234 5,141 3,480 
Total revenues$43,311 $33,310 $82,867 $65,565 

Revenue Accounting under Topic 842

The Company leases HME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.

Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date equipment is delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Revenue Accounting under Topic 606

The Company sells HME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the HME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.
Page 11
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022

For staffing services, performance obligations in the staffing agreements are satisfied over time when the customer simultaneously receives and consumes the benefits provided. Accordingly, revenues from staffing services are recognized on an hourly basis as services are rendered by the job site employee in both principal and agent arrangements.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on equipment sales, sleep study services, staffing services, or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of June 30, 2023.

Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.

Interest rate swaps

The Company utilized an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the 2019 Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.

The Company recognized any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.

Page 12
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
During the year ended December 31, 2022, the Company settled its interest rate swap in connection with the refinancing of its credit facilities and recognized the realized gain of $0.2 million in Other Income.

Income taxes

The Company is subject to income taxes in numerous U.S. jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations.

Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.

CARES Act Funds Received

The Company received a general distribution payment from the Provider Relief Fund of $3.5 million in April 2020, a targeted distribution payment of $1.5 million in November 2021, and a general distribution payment of $0.4 million in January 2022. The U.S. Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. There is no US GAAP guidance for for-profit health care entities that receive government grants that are not in the form of an income tax credit, revenue from a contract with a customer or a loan. As such, for-profit entities must determine the appropriate accounting treatment by analogy to other guidance such as International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, in International Financial Reporting Standards. Under IAS 20, the Company determined that upon receipt of funds, it fully complied with the conditions attached to the grant. The Company recognized the distributions received from the Provider Relief Fund in the income statement in full during the period of receipt. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. The Company is not aware of any such modifications as of June 30, 2023

Recently adopted accounting pronouncements

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. While the adoption of ASC 326 could result in a higher allowance recorded in the future for credit losses on receivables within the scope of the standard due to the prescribed measurement principles, the impact of the adoption on the Company's consolidated financials statements was not material.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, the Company's condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting
Page 13
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about their obligations that are outstanding at the end of the reporting period. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company does not expect the update to affect the recognition, measurement, or financial statement presentation of supplier finance program obligations, but is evaluating the impact of the update on related disclosures upon adoption.
Page 14
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022

3.     Business Combinations

On June 1, 2023, Viemed, Inc., a wholly-owned subsidiary of the Company, completed the acquisition of Home Medical Products, Inc., (“HMP”), which operates in Tennessee, Alabama, and Mississippi. The Company acquired 100% of the equity ownership of HMP in exchange for approximately $29.4 million in cash or cash payable, subject to customary post-closing net working capital and other adjustments. Approximately $15 million of the purchase consideration was funded by cash on hand, $8 million was funded by a borrowing on the 2022 Revolving Credit Facility, and $5 million was funded by a borrowing on the 2022 Term Loan Facility.

The results of HMP’s operations have been included in the consolidated financial statements since the date of acquisition. The Company expensed $254,000 of acquisition costs in conjunction with the acquisition for the six months ended June 30, 2023. These costs include system conversion and integrating operations charges, as well as legal and consulting expenses, and are included in selling, general, and administrative expense in the accompanying consolidated statements of income and comprehensive income.

The following table summarizes the consideration paid and estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The Company is in the process of obtaining third-party valuations of certain fixed assets and identifiable intangible assets; thus, the provisional measurements of property plant and equipment, trade names, non-compete agreements, and goodwill are subject to change. The fair value of accounts receivables acquired is $2.0 million, with the gross contractual amount being $2.9 million. The Company expects $0.9 million to be uncollectible.

Purchase Price
Cash paid or payable$29,417 
Identifiable Assets
Cash and cash equivalents921 
Accounts receivable2,014 
Inventory582 
Prepaid expenses and other assets535 
Property and equipment, net4,358 
Lease assets743 
Identifiable intangibles688 
Other long-term assets25 
TOTAL ASSETS9,866 
Identifiable Liabilities
Trade payables2,144 
Deferred revenue732 
Accrued liabilities1,195 
Current portion of lease liabilities536 
Current debt4,558 
Long-term lease liabilities207 
Long-term debt836 
TOTAL LIABILITIES10,208 
Net assets (liabilities) acquired(342)
Resulting goodwill$29,759 

Goodwill resulted from a combination of synergies and cost savings, and further expansion into Tennessee, Alabama, and Mississippi. All of the goodwill is deductible for income tax purposes. There are no contingent consideration arrangements included in the transaction.
Page 15
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022


4.     Property and Equipment

The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment.

The following table details the Company’s fixed assets:
June 30, 2023December 31, 2022
Medical equipment$103,571 $93,893 
Furniture and equipment3,115 2,792 
Land2,566 2,566 
Buildings7,129 7,043 
Leasehold improvements344 296 
Vehicles1,129 1,052 
Less: Accumulated depreciation(44,970)(39,899)
Property and equipment, net of accumulated depreciation and amortization$72,884 $67,743 

Depreciation in the amount of $4,908,000 and $3,497,000 is included in cost of revenue for the three months ended June 30, 2023 and 2022, respectively, and in the amount of $9,430,000 and $6,656,000 for the six months ended June 30, 2023 and 2022, respectively. Medical equipment purchases with a cost of $2,526,000 and $738,000 were included in accounts payable at June 30, 2023 and December 31, 2022, respectively.


5.     Current Liabilities

The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
June 30, 2023December 31, 2022
Accrued trade payables $2,735 $2,254 
Accrued commissions payable737 608 
Accrued bonuses payable4,329 3,708 
Accrued vacation and payroll2,450 1,484 
Current portion of phantom share liability 1,483 1,704 
Purchase price payable1,376 — 
Accrued other liabilities2,399 1,334 
Total accrued liabilities$15,509 $11,092 

Page 16
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
6.     Debt

2018 Senior Credit Facility

On February 20, 2018, the Company entered a Commercial Business Loan Agreement (the "2018 Senior Credit Facility") that provided for Term Loans and Lines of Credit with Hancock Whitney Bank. Until November 29, 2022, the Company maintained a line of credit in the amount of $10.0 million under the 2018 Senior Credit Facility. On May 30, 2019, the Company entered into a term note (“Building Term Note”) under the 2018 Senior Credit Facility in the principal amount of $4.8 million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. In connection with the Building Term Note, the Company entered into an interest rate swap transaction ("Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%. On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “2019 Term Note") under the 2018 Senior Credit Facility in the principal amount of $5.0 million and bearing an annual interest rate of 4.60%. The proceeds of the 2019 Term Note were utilized for general corporate purposes. The 2019 Term Note matured on September 19, 2022 at which time the entire unpaid balance of principal and interest was repaid in full. In connection with the entry in to the 2022 Senior Credit Facilities on November 29, 2022, the Company retired the 2018 Senior Credit Facility, and repaid all outstanding interest and principal in full.

2022 Senior Credit Facilities

On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.

The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions.

The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.

The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:


•Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.

•Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.

The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2023.

Page 17
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
The 2022 Senior Credit Facilities includes provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $30.0 million.

Financing costs and commitment fees related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method.

The recorded balances associated with the 2022 Senior Credit Facilities are as follows:
June 30, 2023December 31, 2022
Outstanding balance$13,000 $— 
Financing costs and commitment fees(748)— 
Less:
Current portion of notes payable(250)— 
Net long-term notes payable$12,002 $— 

Medical Equipment Financing

As a result of the acquisition of HMP, the Company assumed equipment financing obligations consisting of installment payments for medical equipment which secure the financing. The financing obligations are payable in monthly installments through 2026 and include interest at rates ranging from 0% to 7.99%. As of June 30, 2023, $3 million of the outstanding medical equipment financing obligations is presented on the condensed consolidated balance sheets as short term debt and $0.1 million is presented as long term debt, based on the scheduled repayment dates.


7.     Fair Value Measurement

Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.


Page 18
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Assets Measured at Fair Value on a Recurring Basis

The Company measures certain assets at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.

The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:
At June 30, 2023
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$2,078 $— $— $2,078 
  Available for sale debt instrument— — 2,110 2,110 
Total$2,078 $— $2,110 $4,188 

At December 31, 2022
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$11,005 $— $— $11,005 
  Available for sale debt instrument$— $— $2,000 $2,000 
Total$11,005 $— $2,000 $13,005 

Available for Sale Debt Instrument

The fair value of the Company’s available for sale debt instrument approximates its amortized cost basis due to the short maturity and indexed interest rate terms. The fair value is classified within Level 3 in the fair value hierarchy as the Company evaluates adjustments using a combination of observable and unobservable inputs, such as operating results of the counterparty as well observable prices in transactions of debt and equity instruments of the issuing counterparty when available. As of June 30, 2023, the analysis resulted in no adjustments to the carrying value impacting unrealized gains or losses. All changes to measured fair value during the period were the result of accrued interest.

Assets Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets at fair value on a nonrecurring basis. These assets include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns.

The Company had no material adjustments of assets measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.

Page 19
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
8.     Shareholders' Equity

Authorized share capital

The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value.

Issued and outstanding share capital

The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 38,400,422 and 38,049,739 shares were issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.

For the six months ended June 30, 2023, the Company acquired and cancelled 66,734 common shares at a cost of $0.5 million to satisfy employee income tax withholding associated with RSUs vesting. The Company’s retained earnings were reduced by the amount paid for the shares repurchased and cancelled.

Stock-based compensation

Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed 7,758,211 shares (equal to 20% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 common shares. As of June 30, 2023, the Company had outstanding options of 4,244,000 and RSUs of 1,123,000 associated with common shares under the Omnibus Plan.

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Stock-based compensation - options$301 $757 $649 $1,577 
Stock-based compensation - restricted stock units1,170 514 2,213 999 
Total$1,471 $1,271 $2,862 $2,576 

At June 30, 2023, there was approximately $889,000 of total unrecognized pre-tax stock option expense under the Company's equity compensation plans, which is expected to be recognized over a weighted-average period of 1.32 years. As of June 30, 2023, there was approximately $4,780,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.26 years.


Page 20
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Options

The following table summarizes stock option activity for the six months ended June 30, 2023:
Number of options
 (000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate intrinsic value(2)
Balance December 31, 20224,497 $5.26 6.9 years$11,356 
Issued— — 
Exercised(228)5.51 
Expired / Forfeited(25)6.47 
Balance June 30, 20234,244 $5.24 6.4 years$19,290 
(1)For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.
(2)The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing share price of the Company's common stock on the last trading day of the period ($9.78).

The aggregate intrinsic value of options outstanding was $19,290,197 and options exercisable were $16,579,787 at June 30, 2023. For the six months ended June 30, 2023, 228,000 common shares were issued pursuant to the exercise of stock options.

At June 30, 2023, the Company had 3,415,000 exercisable stock options outstanding with a weighted average exercise price of $4.93 and a weighted average remaining contractual life of 6.0 years. At December 31, 2022, the Company had 2,841,000 exercisable stock options outstanding with a weighted average exercise price of $4.53 and a weighted average remaining contractual life of 6.1 years.

The fair value of the stock options has been charged to the Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the six months ended June 30, 2023.

Restricted stock units

The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a one or three-year period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.

The following table summarizes RSU activity for the six months ended June 30, 2023:
Number of RSUs (000's)Weighted average grant priceWeighted average remaining contractual life
Aggregate intrinsic value(1)
Balance December 31, 2022629 $5.62 0.88 years$4,755 
Issued702 7.87 
Vested(190)5.56 
Expired / Forfeited(18)6.70 
Balance June 30, 20231,123 $7.02 1.26 years$10,986 
(1)The aggregate intrinsic value of time-based RSUs outstanding was based on the Company's closing stock price on the last trading day of the period ($9.78).

During the six months ended June 30, 2023, the Company issued 702,206 RSUs with a vesting term of three years and a fair value of $5.6 million. During the three months ended June 30, 2023, the Company issued no RSUs.
Page 21
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022

Phantom share units

The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period.

The following table summarizes phantom share unit activity for the six months ended June 30, 2023:
Number of phantom share units (000's)
Value of share equivalents(1)
Balance December 31, 2022513 $3,878 
Issued176 1,401 
Vested(239)(578)
Expired / Forfeited(20)(196)
Balance June 30, 2023430 $4,200 
(1)The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s stock at that time, the value of issued share equivalents is based on the market price of the Company’s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $9.78 on June 30, 2023.

The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at June 30, 2023 is $2,120,000, with $1,483,000 of this amount included in current accrued liabilities and the remaining portion of $637,000 included in long-term accrued liabilities.

The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense (benefit) associated with the phantom share units for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Selling, general, and administrative$687 $538 $1,837 $949 

The Company paid cash settlements of $2,309,000 and $1,389,000 during the six months ended June 30, 2023 and 2022, respectively, pertaining to vestings of cash-settled phantom share units.

Page 22
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
9.     Commitments and Contingencies

The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters.

Legal Proceedings

As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the “Purchase Order”) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment. The Company ultimately prepaid $1.4 million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the “State Court”) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (“Reconventional Demand”) with the State Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties completed discovery on July 17, 2023. The Company filed a Motion for Summary Judgment on June 9, 2023. The Court has set an August 28, 2023 hearing on that motion and has set a date for a non-jury trial on October 30, 2023.

The Company continues to believe that it has valid legal and equitable grounds to recover its outstanding prepayment as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. The Company has determined that a loss related to the Reconventional Demand is not probable, and thus has not accrued a liability related to this claim. Although a loss may be reasonably possible, the Company does not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of June 30, 2023, outstanding funds in the amount of $0.9 million related to undelivered respiratory equipment are included within other long-term assets.


Page 23
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
Governmental and Regulatory Matters

From time to time the Company is involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure or exclusion from participation in government healthcare programs.

In May of 2021, a final report and recommendation (“Report”) was issued by the OIG regarding an audit by OIG of claims relating to 100 of the Company’s non-invasive ventilation at home (“NIVH”) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believed that the Report ignored each patient’s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applied clinical guidelines that were contrary to CMS’s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. In November 2021, the Company filed Reconsideration Appeals with CMS's designated Qualified Independent Contractor ("QIC"). Based on its review, the QIC determined that approximately 77% of the claims it reviewed were medically necessary and properly payable under Medicare rules and regulations, overturning OIG’s and the MACs' initial recommendations and determinations. As a result of the QIC's reconsideration findings, reduced and recalculated principal overpayment requests totaling $1.1 million were issued by the MACs. In order to limit the assessment of interest during the appeals period, the Company remitted the associated funds to the MACs. In December 2022, an Administrative Law Judge overturned all of the remaining appealed claims and instructed the MACs to refund all funds previously remitted by the Company. Accordingly, the funds remitted to the MACs are recorded in Prepaid expenses and other assets at December 31, 2022 and were received during the six months ended June 30, 2023.

10.     Income Taxes

For the six months ended June 30, 2023, the Company recorded income tax expense of $1.2 million, which includes a discrete tax benefit of $0.1 million associated with stock-based compensation arrangements. Excluding the impact of the discrete taxes, the effective rate for the six months ended June 30, 2023 is 28.6%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year.

At June 30, 2023 and 2022, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2019.

The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.

11.     Earnings Per Share

Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate.

Page 24
VIEMED HEALTHCARE, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Tabular dollar amounts expressed in thousands of U.S. Dollars, except per share amounts)
(Unaudited)
June 30, 2023 and 2022
The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Numerator - basic and diluted:
Net income attributable to shareholders$2,330 $967 $3,847 $2,729 
Denominator:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 
Basic earnings per share$0.06 $0.02 $0.10 $0.07 
Diluted earnings per share$0.06 $0.02 $0.10 $0.07 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Stock options and other dilutive securities2,352,702 979,348 2,142,714 861,636 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 

Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.

Page 25
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with, and is qualified entirely by, our condensed consolidated financial statements (including Notes to the Condensed Consolidated Financial Statements) and the other consolidated financial information under Item 1 of this Quarterly Report on Form 10-Q. Some of the information in this discussion and analysis includes forward-looking statements that involve risk and uncertainties. Actual results and timing of events could differ from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.


Forward-Looking Statements

Certain statements and information in this Quarterly Report on Form 10-Q may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 or "forward-looking information" as such term is defined in applicable Canadian securities legislation (collectively, "forward-looking statements"). Any statements other than statements of historical information, including those that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those expressed in the forward-looking statements. These forward-looking statements are made as of the date hereof. We undertake no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by applicable law.
 
Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management regarding future events, and include, but are not limited to, statements with respect to: operating results; profitability; financial condition and resources; anticipated needs for working capital; liquidity; capital resources; capital expenditures; milestones; licensing milestones; information with respect to future growth and growth strategies; anticipated trends in our industry; our future financing plans; timelines; currency fluctuations; government regulation; unanticipated expenses; commercial disputes or claims; limitations on insurance coverage or other reimbursement; and availability of cash flow to fund capital requirements.
 
Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “potential”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes”, “projects”, or the negatives thereof or variations of such words and phrases or statements that certain actions, events or results “will”, “should”, “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative of these terms or comparable terminology.
 
Forward-looking statements are based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable. We cannot assure you, however, that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Page 26
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
By their nature, forward-looking statements involve numerous assumptions, inherent risks and uncertainties, both general and specific, including those identified under “Risk Factors” and elsewhere in this Quarterly Report on Form 10-Q and the other documents we file with the SEC, including under “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2022, and with the securities regulatory authorities in certain provinces of Canada, which contribute to the possibility that the predicted outcomes may not occur or may be delayed. The risks, uncertainties and other factors, many of which are beyond our control, that could influence actual results include, but are not limited to: the general business, market and economic conditions in the regions in which the we operate; the impact of the COVID-19 pandemic and the actions taken by governmental authorities, individuals and companies in response to the pandemic on our business, financial condition and results of operations, including on our patient base, revenues, employees, and equipment and supplies; significant capital requirements and operating risks that we may be subject to; our ability to implement business strategies and pursue business opportunities; volatility in the market price of our common shares; our novel business model; the state of the capital markets; the availability of funds and resources to pursue operations; reductions in reimbursement rates and audits of reimbursement claims by various governmental and private payor entities; dependence on few payors; possible new drug discoveries; dependence on key suppliers; granting of permits and licenses in a highly regulated business; competition; disruptions in or attacks (including cyber-attacks) on our information technology, internet, network access or other voice or data communications systems or services; the evolution of various types of fraud or other criminal behavior to which we are exposed; difficulty integrating newly acquired businesses; the impact of new and changes to, or application of, current laws and regulations; the overall difficult litigation and regulatory environment; increased competition; increased funding costs and market volatility due to market illiquidity and competition for funding; critical accounting estimates and changes to accounting standards, policies, and methods used by us; our status as an emerging growth company and a smaller reporting company; and the occurrence of natural and unnatural catastrophic events or health epidemics or concerns, such as the COVID-19 pandemic, and claims resulting from such events or concerns, as well as other general economic, market and business conditions; and other factors beyond our control.

General Matters

In this Quarterly Report on Form 10-Q, unless the context otherwise requires, the terms the "Company," "we," "us" and "our" refer to Viemed Healthcare, Inc. and its wholly-owned subsidiaries.

We were incorporated on December 14, 2016 pursuant to the Business Corporations Act (British Columbia). As of June 30, 2020, we determined that we no longer qualify as a "foreign private issuer," as defined in Rule 3b-4 of the Exchange Act, for the purposes of the informational requirements of the Exchange Act. As a result, effective January 1, 2021, we became subject to the proxy solicitation rules under Section 14 of the Exchange Act and Regulation FD, and our officers, directors, and principal shareholders became subject to the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. We will continue to file annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K with the SEC and with the relevant Canadian securities regulatory authorities on the System for Electronic Document Analysis and Retrieval (SEDAR).

We are an "emerging growth company," as defined in the JOBS Act and a "smaller reporting company" under Rule 12b-2 of the Exchange Act, and as such, we have elected to comply with certain reduced U.S. public company reporting requirements.

Unless otherwise noted herein, all references to "$" or "USD" are to the currency of the United States and references to "CAD$" or "Canadian dollars" are to the currency of Canada.

Overview

We provide an array of home medical equipment, services and supplies, specializing in post-acute respiratory care services in the United States. Our primary objective is to focus on the organic growth of the business and thereby solidify our position as one of the United States’ largest providers of in-home therapy for patients suffering from respiratory diseases. Our respiratory care programs are designed specifically for payors to have the ability to treat patients in the home for less total cost and with a superior quality of care. Our services include respiratory disease management (through the rental of various HME devices), neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, and the sale of associated supplies.

We derive the majority of our revenue through the rental of non-invasive and invasive ventilators which represented 59.4% and 68.6% of our traditional revenue, excluding COVID-19 response sales and services, for the three months ended June 30, 2023 and 2022, respectively, and 61.4% and 69.9% for the six months ended June 30, 2023 and 2022, respectively. We combine the benefits of home ventilation support with licensed Respiratory Therapists ("RTs") to drive improved patient outcomes and reduce costly hospital readmissions.

Page 27
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
We expect to grow through expansion of existing service areas as well as in new territories through a cost efficient launch that reduces location expenses. We currently serve patients in all 50 states. We expect to continue to employ more RTs in order to assure our high service model is accomplished in the home. As of June 30, 2023, we employed 330 licensed RTs, representing approximately 34% of our company-wide employee count. By focusing overhead costs on personnel that service the patient rather than physical location costs, we anticipate that we will efficiently scale our business in regions that are currently not being effectively serviced.

The continued trend of servicing patients in the home rather than in hospitals is aligned with our business objective and we anticipate that this trend will continue to offer growth opportunities for us. We expect to continue to be a solution to the rising health costs in the United States by offering more cost effective, home based solutions while increasing the quality of life for patients fighting serious respiratory diseases.

Trends Affecting our Business

On March 11, 2020, the World Health Organization designated COVID-19 as a global pandemic. Various policies and initiatives were implemented to reduce the transmission of COVID-19, including travel bans and restrictions, the postponement of non-essential medical surgeries, limiting access to medical facilities, and adoption of social distancing and remote working policies. Employee and patient safety is our first priority, and as a result, we put preparedness plans in place for our employees, especially our clinical personnel, and modified our clinical protocols to limit unnecessary patient encounters. On May 11, 2023, the COVID-19 Public Health Emergency declared by the Secretary of HHS under Public Health Service Act section 319 ("COVID-19 PHE") ended. The U.S. Food and Drug Administration has announced in the Federal Register that the Emergency Use Authorization for certain ventilators and PAP and RAD devices will be in effect until November 7, 2023, 180 days beyond the end of the COVID-19 PHE. At the end of the COVID-19 PHE, many waivers and flexibilities available during the COVID-19 pandemic will become unavailable.

While COVID-19 related measures have not had a material impact on our consolidated operating results for the six months ended June 30, 2023, we cannot predict at this time the impact that the end of the COVID-19 PHE will have on our business and financial condition. Accordingly, we cannot assure you that demand for our products and services will continue or that we will be able to maintain operations necessary to satisfy such demand, including sufficient personnel, supply chains and distributions channels.

The COVID-19 pandemic has led to significant disruptions and volatility in capital and financial markets. Broad economic factors resulting from the current COVID-19 pandemic, including high unemployment and underemployment levels and reduced consumer spending and confidence, could also affect our service mix, revenue mix, payor mix and patient base, as well as our ability to collect outstanding receivables. Business closures and layoffs in the geographic areas in which we operate may lead to increases in the uninsured and under-insured populations and adversely affect demand for our services, as well as the ability of patients and other payors to pay for services rendered. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our financial results and require an increased level of working capital. In addition, we may experience supply chain disruptions, including delays and price increases in equipment and supplies. Staffing, equipment and supplies shortages may also impact our ability to assess potential patients in hospitals and set up and treat patients in the home. If COVID-19 intensifies or if the response to contain the COVID-19 pandemic is unsuccessful, we could experience a material adverse effect on our business, financial condition, and results of operations. For additional information, see Part II - Item 1A. “Risk Factors.”

The CARES Act, which was signed into law on March 27, 2020, provides a substantial stimulus and assistance package intended to address the impact of the COVID-19 pandemic, including tax relief and government loans, grants and investments. We are continuing to monitor any effects or requirements that may result from the CARES Act as many of the provisions in the CARES Act are temporary and may require us to modify our operations and compliance procedures. CMS and other federal agencies have and are likely to issue rules and regulations to implement the CARES Act. The impact of these rules and regulations are unknown and may affect us. To the extent these provisions will expire as stated in the CARES Act, we will be required to unwind any changes.

In 2019, CMS announced the inclusion of non-invasive ventilator products on the list of products subject to the competitive bidding program in Round 2021 which covers the period of January 1, 2021 through December 31, 2023. On March 9, 2020, CMS announced that due to the COVID-19 pandemic, the United States President’s exercise of the Defense Production Act, public concern regarding access to ventilators, and the non-invasive ventilators product category being new to the competitive bidding program, non-invasive ventilators were removed as a product category from Round 2021. On October 27, 2020, CMS announced that it had removed 13 of the 15 remaining product categories from Round 2021, including oxygen and PAP devices, because the payment amounts did not achieve expected savings. As a result of these announcements, we retain the ability to continue to furnish non-invasive ventilators and oxygen and PAP devices for all of our Medicare accredited areas, however, we are uncertain if non-invasive ventilators, oxygen, and PAP devices will be included in future competitive bidding programs. The current Round 2021
Page 28
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
contracts expire on December 31, 2023 and CMS has not announced a new round of competitive bidding. Historically, CMS announces new rounds of competitive bidding and starts the process approximately 18 months prior to the contract start date.

The CARES Act introduced a new blended rate for HME furnished in non-rural or contiguous non-competitive bidding areas that is based on 75% of the adjusted fee schedule amount and 25% of the unadjusted fee schedule amount. The Consolidated Appropriations Act, 2023 further extended the 75/25 blended Medicare reimbursement rate in non-competitive bidding/non-rural areas through the end of the COVID-19 PHE or December 31, 2023, whichever is later, after which it will revert to 100% of the Medicare fee schedule.

The CARES Act also provided for a temporary suspension of the 2% payment sequestration adjustment currently applied to all Medicare fee-for-service claims. In December 2021, President Biden signed into law legislation that extended the suspension on the 2 percent payment sequestration through March 31, 2022. The payment sequestration adjustment was fixed at 1 percent from April 1, 2022 to June 30, 2022 and it returned to 2 percent on July 1, 2022.

The Statutory Pay-As-You-Go Act of 2010 ("PAYGO") required that automatic payment cuts of 4% be put into place if a statutory action is projected to create a net increase in the deficit over either five or 10 years. The enactment of the American Rescue Plan Act in 2021 would have triggered PAYGO sequestration in 2021. In the Protecting Medicare & American Farmers from Sequester Cuts Act, Congress delayed the PAYGO sequestration until January 1, 2023. The Consolidated Appropriations Act, 2023 further prevented implementation of the PAYGO Medicare 4% sequester through the end of 2024. If not renewed, the PAYGO payment adjustment could have an adverse effect on our business, financial condition and results of operations.

In its 2023 DMEPOS Fee Schedule, CMS also announced the fee schedule adjustment based on the annual change to the Consumer Pricing Index for all urban areas. Items that were subject to the competitive bidding program in former competitive bidding areas will receive a 6.4% reimbursement rate increase. Items that were subject to the competitive bidding program in non-competitive bidding areas will receive a 9.1% reimbursement rate increase. Items not subject to the competitive bidding program will receive an 8.7% reimbursement rate increase.

While we cannot predict what Medicare payment rates or coverage determinations will be in effect in future years, changes to payment rates or benefit coverages may materially impact its financial condition and results of operations.

The below table highlights summary financial and operational metrics for the last eight quarters.
(Tabular amounts expressed in thousands of U.S. Dollars, except vent patients)
For the quarter endedJune 30,
2023		March 31, 2023December 31, 2022September 30, 2022June 30, 2022March 31, 2022December 31, 2021September 30, 2021
Financial Information:
Revenue$43,311 $39,556 $37,508 $35,759 $33,310 $32,255 $31,962 $29,285 
Gross Profit$26,106 $24,004 $22,896 $21,651 $20,390 $19,743 $19,662 $18,381 
Gross Profit %60 %61 %61 %61 %61 %61 %62 %63 %
Net Income$2,330 $1,517 $2,438 $1,055 $967 $1,762 $4,087 $1,789 
Cash (As of)$10,224 $23,544 $16,914 $21,478 $21,922 $29,248 $28,408 $26,867 
Total Assets (As of)$149,117 $124,634 $117,043 $119,419 $115,904 $119,007 $117,962 $115,486 
Adjusted EBITDA(1)
$9,810 $8,328 $9,306 $6,982 $6,458 $7,273 $9,549 $7,419 
Operational Information:
Vent Patients(2)
10,005 9,337 9,306 9,127 8,837 8,434 8,405 8,200 
(1) Refer to "Non-GAAP Financial Measures" section below for definition of Adjusted EBITDA.
(2) Vent Patients represents the number of active ventilator patients on recurring billing service at the end of each calendar quarter.
Page 29
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Results of Operations

Comparison of the Three Months Ended June 30, 2023 and 2022:

The following table summarizes our results of operations for the three months ended June 30, 2023 and 2022:
Three Months Ended June 30,
2023% of Total Revenue2022% of Total Revenue$
Change		%
Change
Revenue$43,311 100.0 %$33,310 100.0 %$10,001 30.0 %
Cost of revenue 17,205 39.7 %12,920 38.8 %4,285 33.2 %
Gross profit26,106 60.3 %20,390 61.2 %5,716 28.0 %
Selling, general and administrative20,563 47.5 %17,536 52.6 %3,027 17.3 %
Research and development758 1.8 %672 2.0 %86 12.8 %
Stock-based compensation1,471 3.4 %1,271 3.8 %200 15.7 %
Depreciation298 0.7 %243 0.7 %55 22.6 %
Loss (gain) on disposal of property and equipment117 0.3 %(110)(0.3)%227 (206.4)%
Other expense (income)(2)— %(223)(0.7)%221 (99.1)%
Income from operations2,901 6.7 %1,001 3.0 %1,900 189.8 %
Non-operating income and expenses
Income from equity method investments137 0.3 %446 1.3 %(309)(69.3)%
Interest expense, net20 — %(59)(0.2)%79 (133.9)%
Net income before taxes3,058 7.1 %1,388 4.2 %1,670 120.3 %
Provision (benefit) for income taxes728 1.7 %421 1.3 %307 72.9 %
Net income$2,330 5.4 %$967 2.9 %$1,363 141.0 %

Revenue

The following table summarizes our revenue for the three months ended June 30, 2023 and 2022:
Three Months Ended June 30,
2023% of Total Revenue2022% of Total Revenue$
Change		%
Change
Net revenue from rentals
Ventilator rentals, non-invasive and invasive$25,712 59.4 %$22,736 68.3 %$2,976 13.1 %
Other durable medical equipment rentals8,419 19.4 %4,912 14.8 %3,507 71.4 %
Net revenue from sales and services
Equipment and supply sales6,778 15.6 %3,245 9.7 %3,533 108.9 %
COVID-19 response sales and services— — %183 0.5 %(183)(100.0)%
Service revenues2,402 5.6 %2,234 6.7 %168 7.5 %
Total net revenue$43,311 100.0 %$33,310 100.0 %$10,001 30.0 %

For the three months ended June 30, 2023, net revenue totaled $43.3 million, an increase of $10.0 million (or 30.0%) from the comparable period in 2022. Excluding COVID-19 response sales and services revenue, net revenue increased $10.2 million (or 30.7%) from the comparable period in 2022. The net revenue growth was associated with an increase in ventilator rental revenue of $3.0 million (or 13.1%) which can be primarily attributed to the organic expansion of our active ventilator patient base. In addition to the ventilator rental revenue growth, net revenue growth was also driven by an increase in rental revenue from other DME of $3.5 million (or 71.4%), consisting of rental revenue from continued national expansion of PAP, oxygen therapy, and percussion vest activities. Equipment and supply sales increased by $3.5 million (or 108.9%), primarily driven by the continued growth of the PAP resupply program and other sleep offerings. Service revenues increased by $0.2 million (or 7.5%) primarily due to the growth of healthcare staffing services. While ventilator rentals continue to make up the majority of our revenue, the growth of PAP and oxygen related sales and services, as well as our healthcare staffing offerings, is contributing significantly to the diversity of our overall revenue mix.
Page 30
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022

There were no COVID-19 response sales and services during the three months ended June 30, 2023, compared to $0.2 million during the three months ended June 30, 2022. The magnitude and persistence of future COVID-19 response sales and services revenue remains uncertain and is dependent on the intensity and length of the COVID-19 pandemic and the demand for ongoing services from primarily governmental customers.

The financial results of the acquired operations relating to the recent HMP acquisition (as discussed in Note 3 – Business Combinations) were reflected for just one month during the three months ended June 30, 2023, and primarily impacted sleep related products and services. We expect the HMP acquisition to have a more meaningful impact in the upcoming quarter when results of operations will be reflected for the entire period. The HMP acquisition is expected to further enhance our growth and overall profitability.

Cost of revenue and gross profit

For the three months ended June 30, 2023, cost of revenue totaled $17.2 million, an increase of $4.3 million (or 33.2%) from the comparable period in 2022. Overall gross profit percentage decreased from 61.2% in the three months ended June 30, 2022 to 60.3% in the three months ended June 30, 2023. The decline in gross profit percentage is primarily attributable to the migration of our revenue mix, which reflects our deliberate efforts towards product and service diversification, aimed at further enhancing our market position. As a result of subsiding inflationary cost pressures and the positive effects of seasonality in collection rates, gross profit percentage for our normal operations is expected to increase through the end of 2023, partially offset by the impacts of continued product and service diversification.

Selling, general and administrative expense

Selling, general, and administrative expenses as a percentage of revenue decreased to 47.5% for the three months ended June 30, 2023 compared to 52.6% for the three months ended June 30, 2022. Selling, general and administrative expenses totaled $20.6 million for the three months ended June 30, 2023, an increase of $3.0 million (or 17.3%) from the comparable prior period. The increase in overall selling, general and administrative expense as compared to the prior period is primarily attributable to additional employee related expenses to accommodate the overall growth of the Company. Our full time employee count increased from 715 on June 30, 2022 to 974 on June 30, 2023, an increase of 36.2%, which was partially due to the acquisition of HMP on June 1, 2023. Employee compensation expenses increased $2.3 million (or 22%) as a result of the increase in our employee headcount and increases in incentive and volume based compensation. We expect that current year selling, general and administrative expenses as a percentage of revenue will continue to improve through the end of 2023 due to increased efficiencies and costs stabilization relative to revenue growth.

Research and development

For the three months ended June 30, 2023, research and development expense totaled $0.8 million, an increase of $0.1 million (or 12.8%) from the comparable period in 2022. As we continue to invest in research and development related projects to support our technology initiatives, we expect that associated costs will remain consistent in 2023 relative to 2022 costs.

Stock-based compensation

For the three months ended June 30, 2023, stock-based compensation totaled $1.5 million, an increase of 15.7% from the comparable period in 2022. We anticipate that as we expand our workforce, incorporating stock-based awards as a component of employee compensation, stock-based compensation expenses will correspondingly rise. Historically, revenue growth has outpaced the growth in stock-based compensation, and as a result, the percentage of stock-based compensation relative to revenue is expected to continue declining.

Interest expense, net

As a result of the issuance of debt to fund the acquisition of HMP, we expect net interest expense to increase accordingly for the remainder of 2023.

Provision for income taxes

For the three months ended June 30, 2023, the provision for income taxes was a $0.7 million expense, compared to $0.4 million during the comparable period in 2022. The increase in income tax expense was primarily due to the increase in pre-tax income. Our annual estimated effective tax rate for 2023 is 28.6%.
Page 31
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022

Net income

For the three months ended June 30, 2023, net income was $2.3 million, an increase of $1.4 million (or 141.0%) from the comparable period in 2022. Net income as a percentage of net revenue increased from 2.9% for the three months ended June 30, 2022 to 5.4% for the three months ended June 30, 2023, primarily due to improvements in selling, general, and administrative expenses associated with increased efficiencies and stabilizing costs.


Page 32
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Comparison of the Six Months Ended June 30, 2023 and 2022:

The following table summarizes our results of operations for the six months ended June 30, 2023 and 2022:
Six Months Ended June 30,
2023% of Total Revenue2022% of Total Revenue$
Change		%
Change
Revenue$82,867 100.0 %$65,565 100.0 %$17,302 26.4 %
Cost of revenue 32,757 39.5 %25,432 38.8 %7,325 28.8 %
Gross profit50,110 60.5 %40,133 61.2 %9,977 24.9 %
Selling, general and administrative40,325 48.7 %33,312 50.8 %7,013 21.1 %
Research and development1,538 1.9 %1,304 2.0 %234 17.9 %
Stock-based compensation2,862 3.5 %2,576 3.9 %286 11.1 %
Depreciation538 0.6 %480 0.7 %58 12.1 %
Loss (gain) on disposal of property and equipment95 0.1 %(124)(0.2)%219 NM
Other expense (income)(83)(0.1)%(664)(1.0)%581 (87.5)%
Income from operations4,835 5.8 %3,249 5.0 %1,586 48.8 %
Non-operating expenses
Income from equity method investments172 0.2 %769 1.2 %(597)NM
Interest expense, net69 0.1 %(123)(0.2)%192 (156.1)%
Net income before taxes5,076 6.1 %3,895 5.9 %1,181 30.3 %
Provision for income taxes1,229 1.5 %1,166 1.8 %63 NM
Net income$3,847 4.6 %$2,729 4.2 %$1,118 41.0 %

Revenue

The following table summarizes our revenue for the six months ended June 30, 2023 and 2022:
Six Months Ended June 30,
2023% of Total Revenue2022% of Total Revenue$
Change		%
Change
Net revenue from rentals
Ventilator rentals, non-invasive and invasive$50,859 61.4 %$44,254 67.5 %$6,605 14.9 %
Other durable medical equipment rentals15,325 18.5 %9,271 14.1 %6,054 65.3 %
Net revenue from sales and services
Equipment and supply sales11,542 13.9 %6,282 9.6 %5,260 83.7 %
COVID-19 response sales and services— — %2,278 3.5 %(2,278)(100.0)%
Service revenues5,141 6.2 %3,480 5.3 %1,661 47.7 %
Total net revenue$82,867 100.0 %$65,565 100.0 %$17,302 26.4 %

For the six months ended June 30, 2023, revenue totaled $82.9 million, an increase of $17.3 million (or 26.4%) from the comparable period in 2022. Excluding COVID-19 response sales and services revenue, net revenue increased $19.6 million (or 30.9%) from the comparable period in 2022. The net revenue increase was comprised of an increase in ventilator rental revenue of $6.6 million (or 14.9%), rental revenue from other DME of $6.1 million (or 65.3%), equipment and supply sales of $5.3 million (or 83.7%), and service revenue of $1.7 million (or 47.7%). The growth in other durable medical equipment rentals and equipment and supply sales has been primarily driven by the continued national expansion of PAP, oxygen therapy, and percussion vest activities. The increase in equipment sales and supplies is primarily driven by the success of our PAP resupply program and other sleep offerings. The increase in service revenue is primarily due to the addition of our healthcare staffing offerings. While ventilator rentals continue to make up the majority of our revenue, the organic and acquired growth of PAP and oxygen related sales and services, as well as our healthcare staffing offerings, is contributing significantly to the diversity of our overall revenue mix.

Page 33
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
There were no COVID-19 response sales and services during the six months ended June 30, 2023, compared to $2.3 million during the comparable six month period in 2022. The magnitude and persistence of future COVID-19 response sales and services revenue remains uncertain and is dependent on the intensity and length of the COVID-19 pandemic and the demand for ongoing services from primarily governmental customers.

Cost of revenue and gross profit

For the six months ended June 30, 2023, cost of revenue totaled $32.8 million, an increase of $7.3 million (or 28.8%) from the comparable period in 2022. Overall gross profit percentage decreased from 61.2% for the six months ended June 30, 2022 to 60.5% for the six months ended June 30, 2023. The decline in gross profit percentage is primarily attributable to the migration of our revenue mix, which reflects our deliberate efforts towards product and service diversification, aimed at further enhancing our market position. As a result of subsiding inflationary cost pressures and the positive effects of seasonality in collection rates, gross profit percentage for our normal operations is expected to increase through the end of 2023, partially offset by the impacts of continued product and service diversification.

Selling, general and administrative expense

Selling, general, and administrative expenses as a percentage of revenue decreased to 48.7% for the six months ended June 30, 2023 compared to 50.8% for the six months ended June 30, 2022. Selling, general and administrative expenses totaled $40.3 million for the six months ended June 30, 2023, an increase of $7.0 million (or 21.1%) from the comparable period in 2022. The overall increase in selling, general and administrative expense as compared to the prior period is primarily due to additional employee related expenses to accommodate the overall growth of the Company and transaction costs related to the acquisition of HMP. Our full time employee count increased from 715 on June 30, 2022 to 974 on June 30, 2023, an increase of 36.2%, which was partially due to the acquisition of HMP on June 1, 2023. Employee compensation expenses increased $5.4 million (or 27%) as a result of the increase in our employee headcount and increases in incentive and volume based compensation. Included in this amount is a $0.9 million increase related to the impact of our phantom stock plan which is measured at fair value as of the end of the reporting period based on closing stock price. During the six months ended June 30, 2023, our stock price increased by 29.3%, resulting in an increase in the accrual of the related phantom stock expense. We expect that current year selling, general and administrative expenses as a percentage of revenue will continue to improve through the end of 2023 due to increased efficiencies and costs stabilization relative to revenue growth.

Research and development

For the six months ended June 30, 2023, research and development expense totaled $1.5 million, an increase of $0.2 million (or 17.9%) from the comparable period in 2022. As we continue to invest in research and development related projects to support our technology initiatives, we expect that associated costs will remain consistent in 2023 relative to 2022 costs.

Stock-based compensation

For the six months ended June 30, 2023, stock-based compensation totaled $2.9 million, an increase of 11.1% from the comparable period in 2022. We anticipate that as we expand our workforce, incorporating stock-based awards as a component of employee compensation, stock-based compensation expenses will correspondingly rise. Historically, revenue growth has outpaced the growth in stock-based compensation, and as a result, the percentage of stock-based compensation relative to revenue is expected to continue declining.

Interest expense, net

As a result of the issuance of debt to fund the acquisition of HMP, we expect net interest expense to increase accordingly for the remainder of 2023.

Provision for income taxes

For the six months ended June 30, 2023, the provision for income taxes was a $1.2 million expense, compared to $1.2 million during the comparable period in 2022. The resulting decrease in the overall effective tax rate as a percentage of pre-tax income was due to the impact of discrete tax benefits associated with stock-based compensation between periods. Our annual estimated effective tax rate for 2023 is 28.6%.


Page 34
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Net income

For the six months ended June 30, 2023, net income was $3.8 million, an increase of $1.1 million (or 41.0%) from the comparable period in 2022. Net income as a percentage of revenue increased from 4.2% for the six months ended June 30, 2022 to 4.6% for the six months ended June 30, 2023, primarily due to improvements in selling, general, and administrative expenses associated with increased efficiencies and stabilizing costs.

Non-GAAP Financial Measures

The Company uses Adjusted EBITDA, which is a financial measure that is not prepared in accordance with generally accepted accounting principles in the United States ("GAAP") to analyze its financial results and believes that it is useful to investors, as a supplement to U.S. GAAP measures. Management believes Adjusted EBITDA provides helpful information with respect to the Company’s operating performance as viewed by management, including a view of the Company’s business that is not dependent on the impact of the Company’s capitalization structure and items that are not part of the Company’s day-to-day operations. Management uses Adjusted EBITDA (i) to compare the Company’s operating performance on a consistent basis, (ii) to calculate incentive compensation for the Company’s employees, (iii) for planning purposes, including the preparation of the Company’s internal annual operating budget, and (iv) to evaluate the performance and effectiveness of the Company’s operational strategies. Accordingly, management believes that Adjusted EBITDA provides useful information in understanding and evaluating the Company’s operating performance in the same manner as management. In calculating Adjusted EBITDA, certain items (mostly non-cash) are excluded from net income including interest, taxes, stock based compensation, and depreciation of property and equipment. Beginning with financial results reported for periods in fiscal year 2023, Adjusted EBITDA also excludes transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions. This modification enables investors to compare period-over-period results on a more consistent basis without the effects of acquisitions. We have recast Adjusted EBITDA for prior periods when reported to conform to the modified presentation.
The following table is a reconciliation of Net income, the most directly comparable GAAP measure, to Adjusted EBITDA, on a historical basis for the periods indicated:
For the quarter endedJune 30, 2023March 31, 2023December 31, 2022September 30, 2022June 30, 2022March 31, 2022December 31, 2021September 30, 2021
Net Income$2,330 $1,517 $2,438 $1,055 $967 $1,762 $4,087 $1,789 
Add back:
Depreciation5,207 4,762 4,373 4,120 3,740 3,397 3,120 2,867 
Interest expense (income)(20)(49)32 42 59 64 69 75 
Stock-based compensation(a)
1,471 1,391 1,317 1,309 1,271 1,305 1,305 1,302 
Transaction costs(b)
94 206 — — — — — — 
Income tax expense728 501 1,146 456 421 745 968 1,386 
Adjusted EBITDA$9,810 $8,328 $9,306 $6,982 $6,458 $7,273 $9,549 $7,419 

(a) Represents non-cash, equity-based compensation expense associated with option and RSU awards.
(b) Represents transaction costs and expenses related to acquisition and integration efforts associated with recently announced or completed acquisitions.

Use of Non-GAAP Financial Measures

Adjusted EBITDA should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. It is not a measurement of our financial performance under GAAP and should not be considered as an alternative to revenue or net income, as applicable, or any other performance measures derived in accordance with GAAP or as an alternative to cash flows from operating activities as a measure of the Company's liquidity, and may not be comparable to other similarly titled measures of other companies or businesses. Adjusted EBITDA has limitations as an analytical tool and should not be considered in isolation or as a substitute for analysis of our operating results as reported under GAAP. Adjusted EBITDA does not reflect the impact of certain cash charges resulting from matters we consider not to be indicative of ongoing operations; and other companies in our industry may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.

Page 35
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Liquidity and Capital Resources

Cash and cash equivalents at June 30, 2023 was $10.2 million, compared to $16.9 million at December 31, 2022. Based on our current plan of operations, we believe this amount, when combined with expected cash flows from operations and amounts available under our line of credit will be sufficient to fund our growth strategy and to meet our anticipated operating expenses, capital expenditures, and debt service obligations for at least the next 12 months from the date of this filing. The Company utilizes short term financing arrangements with a major supplier that could be extended over a longer term if there was a need for additional liquidity.

Cash Flows

The following table summarizes our cash flows for the periods indicated:
Six Months Ended June 30,
20232022
Net Cash provided by (used in):
Operating activities$18,119 $12,092 
Investing activities(36,112)(10,495)
Financing activities11,303 (8,083)
Net decrease in cash and cash equivalents$(6,690)$(6,486)

Net Cash Provided by Operating Activities

Net cash provided by operating activities during the six months ended June 30, 2023 was $18.1 million, resulting from net income of $3.8 million, increased by non-cash net income adjustments of $12.3 million and a change in net operating liabilities of $1.7 million, which was offset by a change in net operating assets of $0.3 million. The non-cash net income adjustments primarily consisted of $10.0 million of depreciation, $2.9 million of stock-based compensation, $0.2 million gain on equity investments and a $0.7 million change in deferred tax asset. The primary changes in working capital were an increase in net accounts receivable of $0.5 million, an increase in income taxes receivable of $1.0 million, offset by a decrease in other assets of $2.1 million and an increase in accrued liabilities of $1.6 million.

Net cash provided by operating activities during the six months ended June 30, 2022 was $12.1 million, primarily resulting from net income of $2.7 million, increased by non-cash net income adjustments of $8.1 million and a change in net operating liabilities of $0.3 million, and decreased by a change in net operating assets of $0.3 million. The non-cash net income adjustments primarily consisted of $7.1 million of depreciation, $2.6 million of stock-based compensation, $0.8 million gain on equity investments and a $0.7 million change in deferred tax asset. The primary changes in working capital were an increase in net accounts receivable of $1.5 million, offset by an increase in income taxes payable of $1.4 million and a decrease in inventory of $1.0 million. Included in our operating cash flows for the period is the receipt of $0.4 million in Provider Relief Funds.

Net Cash Used in Investing Activities

Net cash used in investing activities during the six months ended June 30, 2023 was $36.1 million, primarily due to the net cash paid for the acquisition of HMP of $27.1 million. Net cash used in investing activities during the period also consisted of $10.8 million of purchases of property and equipment, partially offset by $1.8 million of sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients. Cash purchases of property and equipment represents a $0.2 million, or 2.1%, decrease year over year.

Net cash used in investing activities during the six months ended June 30, 2022 was $10.5 million, consisting of $11.0 million of purchases of property and equipment, partially offset by $0.6 million of sales proceeds from the disposal of property and equipment. Purchases of property and equipment were primarily related to medical equipment rented to our patients.

Page 36
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Net Cash Provided by Financing Activities

Net cash provided by financing activities during the six months ended June 30, 2023 was $11.3 million. For the six months ended June 30, 2023, proceeds from the 2022 Term Loan Facility (as defined below) were $5.0 million and proceeds from the 2022 Revolving Credit Facility (as defined below) were $8.0 million, which were used to partially fund the cash acquisition of HMP. Principal payments on acquired revolving and term loans were $2.4 million during the six months ended June 30, 2023. The Company acquired and cancelled 66,734 common shares at a cost of $0.5 million to satisfy employee income tax withholding associated with RSUs vestings while proceeds from the exercise of options during the six months ended June 30, 2023 were $1.2 million.

Net cash used in financing activities during the six months ended June 30, 2022 was $8.1 million. For the six months ended June 30, 2022, the Company repurchased and canceled 1,350,567 common shares at a cost of $7.0 million pursuant to the Share Repurchase Program authorized by the Board of Directors on March 7, 2022 (the "2022 Share Repurchase Program"). The Company also acquired and cancelled 23,742 common shares at a cost of $0.1 million to satisfy employee income tax withholding associated with RSUs vesting during the six months ended June 30, 2022. Net cash used in financing activities during the six months ended June 30, 2022 also included $0.9 million in principal payments on the Term Note (as defined below).

Senior Credit Facilities

On November 29, 2022, the Company refinanced its existing borrowings under the prior Commercial Business Loan Agreement with Hancock Whitney Bank and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.

The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions. Outstanding borrowings under the 2022 Term Loan Facility and 2022 Revolving Credit Facility were $5 million and $8 million, respectively, as of June 30, 2023.

The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.

The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, will restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:

•Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.

•Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.

The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2023.


Page 37
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Use of Funds

Our principal uses of cash are funding the purchase of rental assets and other capital purchases, funding of business combinations, operations, and other working capital requirements. The following table presents our material contractual obligations and commitments to make future payments as of June 30, 2023:
Within 12 MonthsBeyond 12 Months
Debt Obligations, including interest$4,374 $16,000 
Lease Obligations$377 $257 
Total $4,751$16,257

Except for the funding of potential business combinations and investments, we anticipate that our operating cash flows will satisfy our material cash requirements for the 12 months after June 30, 2023. In addition to our operating cash flows, we may need to raise additional funds to support our contractual obligations and investing activities beyond such 12 month period, and such funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, our operations and ability to execute our business strategy could be adversely affected. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. Any additional equity financing may be dilutive to our stockholders.

Retirement Plan

The Company maintains a 401(k) retirement plan for employees to which eligible employees can contribute a percentage of their pre-tax compensation. Matching employer contributions to the 401(k) plan totaled $325,000 and $351,000 for the three months ended June 30, 2023 and 2022, respectively, and $735,000 and $622,000 for the six months ended June 30, 2023 and 2022, respectively.

Off balance sheet arrangements

The Company has no material undisclosed off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its results of operations or financial condition.

Accounting and Disclosure Matters

Critical Accounting Principles and Estimates

We are required to disclose “critical accounting estimates” which are estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty and that have had or are reasonably likely to have a material impact on our financial condition or results of operations.

We follow financial accounting and reporting policies that are in accordance with accounting principles generally accepted in the United States. The more significant of these policies are summarized in Note 2 to our consolidated financial statements included in Part II, Item 8 of the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Not all significant accounting policies require management to make difficult, subjective or complex judgments. However, the policy noted below could be deemed to meet the SEC’s definition of a critical accounting estimate.


Page 38
VIEMED HEALTHCARE, INC.
MANAGEMENT'S DISCUSSION AND ANALYSIS
(Tabular amounts expressed in thousands of US Dollars, except per share amounts)
June 30, 2023 and 2022
Allowance for Doubtful Accounts

The Company estimates that a certain portion of receivables from customers may not be collected and maintains an allowance for doubtful accounts. The Company evaluates the net realizable value of accounts receivable as of the date of Consolidated Balance Sheets. Specifically, we consider historical realization data, including current and historical cash collections, accounts receivable aging trends, other operating trends and relevant business conditions. Because of continuing changes in the healthcare industry and third-party reimbursement, it is possible that the estimates could change, which could have a material impact on the operations and cash flows. If circumstances related to certain customers change or actual results differ from expectations, our estimate of the recoverability of receivables could fluctuate from that provided for in our consolidated financial statements. A change in estimate could impact bad debt expense and accounts receivable. The continued volatility in market conditions and evolving shifts in credit trends are difficult to predict causing variability and volatility that may have a material impact on our allowance for doubtful accounts in future periods. Our allowance for doubtful accounts was $11.0 million and $9.4 million as of June 30, 2023 and 2022, respectively, and based on our analysis, we believe the reserve is adequate for any exposure to credit losses.

Recently Issued Accounting Pronouncements

See Note 2 – Summary of Significant Accounting Policies of our Condensed Consolidated Financial Statements for a description of recently issued accounting pronouncements, including the expected dates of adoption and estimated effects on our results of operations, financial positions and cash flows.

Page 39
VIEMED HEALTHCARE, INC.
June 30, 2023 and 2022
Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not Applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company's management, including its Chief Executive Officer and Chief Financial Officer, completed an evaluation of the effectiveness of the Company's disclosure controls and procedures pursuant to Rule 13a-15 of the Exchange Act. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded:

i.that the Company's disclosure controls and procedures are designed to ensure (a) that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and (b) that such information is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure; and

ii.that the Company's disclosure controls and procedures are effective.

Notwithstanding the foregoing, there can be no assurance that the Company's disclosures controls and procedures will detect or uncover all failures of persons within the Company and its consolidated subsidiaries to disclose material information otherwise required to be set forth in the Company's periodic reports. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures.

Changes in Internal Control Over Financial Reporting

There have been no changes in the Company's internal control over financial reporting during the three months ended June 30, 2023 that have materially affected, or that are reasonably likely to materially affect, the Company's internal control over financial reporting.
Page 40
VIEMED HEALTHCARE, INC.
June 30, 2023 and 2022
PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may be subject to various ongoing or threatened legal actions and other proceedings, including those that arise in the ordinary course of business, which may include employment matters, breach of contract disputes, as well as governmental and regulatory matters. Please read Note 9—Commitments and Contingencies to our condensed consolidated financial statements for more information. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time.

Item 1A. Risk Factors

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 2, 2023, which could materially affect our business, financial condition or future results. Except as set forth below, there have been no material changes in our risk factors from those disclosed in that Annual Report.

Our strategic growth plan, which involves the acquisition of other businesses, may not succeed.

The Company's strategic growth plan calls for significant growth in its business over the next several years through an increase in its density in select markets where it is established as well as the expansion of its geographic footprint into new markets. This growth would place (and has placed) significant demands on the Company’s management team, systems, internal controls and financial and professional resources. As a result, the Company could be required to incur (and has incurred) expenses for hiring additional qualified personnel, retaining professionals to assist in developing the appropriate control systems and expanding the Company’s information technology infrastructure. If the Company is unable to effectively manage growth, its financial results could be adversely impacted.

The Company’s strategic growth plan contemplates continued growth from future acquisitions of home medical equipment and service providers. The Company may face increased competition for attractive acquisition candidates, which may limit the number of acquisition opportunities available to the Company or lead to the payment of higher prices for its acquisitions. Without successful acquisitions, the Company’s future growth rate could decline. In addition, the Company cannot guarantee that any future acquisitions, if consummated, will result in further growth.

The integration of acquisitions requires significant attention from management, may impose substantial demands on the Company’s operations or other projects and may impose challenges on us including, but not limited to, consistencies in business standards, procedures, policies and business cultures. There can be no assurance that any future acquisitions, if consummated, will result in further growth. Specific integration risks relating to the acquisition of other businesses by the Company may include: difficulties related to combining previously separate businesses into a single unit, including patient transitions, product and service offerings, distribution and operational capabilities and business cultures;availability of financing to the extent needed to fund acquisitions;customer loss and other general business disruption; managing the integration process while completing other independent acquisitions or dispositions;diversion of management’s attention from day-to-day operations; assumption of liabilities of an acquired business, including unforeseen or contingent liabilities or liabilities in excess of the amounts estimated; failure to realize anticipated benefits and synergies, such as cost savings and revenue enhancements; potentially substantial costs and expenses associated with acquisitions and dispositions; and failure to retain and motivate key employees difficulties in establishing and applying the Company’s internal control over financial reporting and disclosure controls and procedures to an acquired business.




Page 41
VIEMED HEALTHCARE, INC.
June 30, 2023 and 2022
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

Not applicable.

Company Repurchases of Equity Securities

The following table sets forth certain information with respect to repurchases of our common shares during the three months ended June 30, 2023.
PeriodTotal number of shares (or units) purchasedAverage price paid per share
Total number of shares purchased as part of publicly announced plans or programs (1)
Maximum number of shares that may yet be purchased under the plans or programs
Apr 1- Apr 30, 2023—$——189,851
May 1- May 31, 2023—$——189,851
Jun 1- Jun 30, 2023—$——189,851
Total—$——189,851

(1)On March 7, 2022, the Company's Board of Directors authorized and approved a share repurchase program on Nasdaq. Under the terms of the 2022 Share Repurchase Program, the Company may repurchase up to 1,984,014 of its common shares from time to time through open market purchases, block purchases or otherwise in accordance with applicable securities laws, including Rule 10b-18 of the Exchange Act. The 2022 Share Repurchase Program does not have an expiration date and may be suspended or discontinued at any time.

Dividends

We have not declared or paid any cash or stock dividends on our common shares since our inception and do not anticipate declaring or paying any cash or stock dividends in the foreseeable future. Our subsidiaries are restricted from making distributions or dividend payments to us by the 2022 Senior Credit Facilities, subject to certain exceptions.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.


Page 42
VIEMED HEALTHCARE, INC.
June 30, 2023 and 2022
Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibit Index below.
Exhibit NumberExhibit Title
#2.1
#2.2
#2.3
#2.4
#2.5
3.1
3.2
*31.1
*31.2
**32.1
**32.2
*101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*101.SCHInline XBRL Taxonomy Extension Schema Document.
*101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
*101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
*101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
*101.DEFInline XBRL Taxonomy Extension Definition Document.
*104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
* Filed herewith.
** Furnished in accordance with Item 601(b)(32)(ii) of Regulation S-K.
# Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will furnish supplementally a copy of any omitted schedule or similar attachment to the Securities and Exchange Commission upon request.
Page 43
VIEMED HEALTHCARE, INC.
June 30, 2023 and 2022
SIGNATURES

Pursuant to the requirements of the Securities Exchange of Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
VIEMED HEALTHCARE, INC.
(Registrant)
By:/s/ Casey Hoyt
Casey Hoyt
Chief Executive Officer
By:/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer
Date: August 9, 2023

Page 44
 EX-31.1 2 q22023exhibit311.htm EX-31.1 Document

Certification of Principal Executive Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Casey Hoyt, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023
 
/s/ Casey Hoyt
 

Casey Hoyt
Chief Executive Officer


 EX-31.2 3 q22023exhibit312.htm EX-31.2 Document

Certification of Principal Financial Officer Pursuant to Exchange Act Rule 13a-14(a)/15d-14(a) as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Trae Fitzgerald, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Viemed Healthcare, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2023
 
/s/ Trae Fitzgerald
 

Trae Fitzgerald
Chief Financial Officer



 EX-32.1 4 q22023exhibit321.htm EX-32.1 Document

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Casey Hoyt, the Chief Executive Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 9, 2023
/s/ Casey Hoyt
Casey Hoyt
Chief Executive Officer


 EX-32.2 5 q22023exhibit322.htm EX-32.2 Document

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Trae Fitzgerald, the Chief Financial Officer of Viemed Healthcare, Inc. (the “Company”), hereby certify, that, to my knowledge:
1.The Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 9, 2023
/s/ Trae Fitzgerald
Trae Fitzgerald
Chief Financial Officer


 EX-101.SCH 6 vmd-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Nature of Business and Operations link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - Nature of Business and Operations (Details) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - Summary of Significant Accounting Policies (Equity Investments) (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - Summary of Significant Accounting Policies (Interest Rate Swaps) (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - Summary of Significant Accounting Policies (CARES Act Funds Received) (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - Business Combinations - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - Property and Equipment (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - Current Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - Debt (Senior Credit Facilities) (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - Debt (Schedule of Notes Payable) (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - Fair Value Measurement (Recurring Basis) (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - Shareholders' Equity (Options, Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details) link:presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details) link:presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vmd-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vmd-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vmd-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development Research and Development Expense Changes in working capital, net of effects from acquisitions: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value 2018 Senior Credit Facility 2018 Senior Credit Facility [Member] 2018 Senior Credit Facility Investment, Name [Domain] Investment, Name [Domain] RSUs outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Debt Debt Disclosure [Text Block] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Purchase consideration funded by cash on hand Payments to Acquire Businesses, Gross Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Building Term Note Building Term Note [Member] Building Term Note [Member] Revolving Credit Facility Revolving Credit Facility [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Trade payables Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Commitments and Contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Identifiable Assets Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Term Loan Facility Term Loan Facility [Member] Term Loan Facility Income Taxes Income Tax Disclosure [Text Block] Deferred revenue Increase (Decrease) in Contract with Customer, Liability Concentration Risk [Line Items] Concentration Risk [Line Items] Property and equipment, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Proceeds from targeted distribution payment Coronavirus Aid, Relief, And Economic Security, Targeted Distribution Payment Received Coronavirus Aid, Relief, And Economic Security, Targeted Distribution Payment Received Revenue recognition Revenue [Policy Text Block] Customer [Axis] Customer [Axis] Current liabilities Liabilities, Current [Abstract] Business Acquisition [Line Items] Business Acquisition [Line Items] Weighted average grant price Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Expired / Forfeited (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Proceeds from general distribution payment Coronavirus Aid, Relief, And Economic Security, General Distribution Payment Received Coronavirus Aid, Relief, And Economic Security, General Distribution Payment Received Diluted (in dollars per share) Diluted earnings per share (in dollars per share) Earnings Per Share, Diluted Schedule of Investments [Table] Schedule of Investments [Table] PEO Total Compensation Amount PEO Total Compensation Amount Stock-based compensation - restricted stock units APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current 2019 Term Note 2019 Term Note [Member] 2019 Term Note Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Fair Value, Inputs, Level 3 Fair Value, Inputs, Level 3 [Member] Long-term lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-Current Liabilities, Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-Current Liabilities, Lease Liabilities Line of Credit Line of Credit [Member] Options outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Long-term assets Assets, Noncurrent [Abstract] Exercise of options Stock Issued During Period, Value, Stock Options Exercised Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Issued (USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Net income Net income Net income attributable to shareholders Net Income (Loss) Total current liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Derivative Contract [Domain] Derivative Contract [Domain] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name New Accounting Pronouncements or Change in Accounting Principle [Table] Accounting Standards Update and Change in Accounting Principle [Table] Entity Ex Transition Period Entity Ex Transition Period Shares repurchased under share repurchase program Stock Repurchased During Period, Value Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] SHAREHOLDERS' EQUITY Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Exercise of options (in shares) Exercised (in shares) Common stock issued pursuant to stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of revenue Cost of Goods and Services Sold Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Comprehensive income Comprehensive Income, Policy [Policy Text Block] New Accounting Pronouncements or Change in Accounting Principle [Line Items] New Accounting Pronouncements or Change in Accounting Principle [Line Items] Covenant Period [Domain] Covenant Period [Domain] Covenant Period [Domain] Number of RSUs (000's) Number of phantom share units (000's) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Fixed charge coverage ratio Debt Instrument, Fixed Charge Coverage Ratio Debt Instrument, Fixed Charge Coverage Ratio Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Exercised (USD per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Fair Value, Inputs, Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Delayed Draw Term Loan Facility Delayed Draw Term Loan Facility [Member] Delayed Draw Term Loan Facility Name Forgone Recovery, Individual Name Goodwill Goodwill Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Accrued liabilities Increase (Decrease) in Accrued Liabilities Maximum shares in Plan (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Omnibus Plan Omnibus Plan [Member] Omnibus Plan Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Prepaid expenses and other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Selling, general, and administrative Selling, General and Administrative Expenses [Member] Accounts Receivable Accounts Receivable [Member] Aggregate Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] Measurement Frequency [Axis] Measurement Frequency [Axis] Operating lease liabilities, less current portion Operating Lease, Liability, Noncurrent Restricted Stock Units Restricted Stock Units (RSUs) [Member] Trade payables Increase (Decrease) in Accounts Payable, Trade Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Issued Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Depreciation Depreciation Income Statement Location [Axis] Income Statement Location [Axis] Schedule of Notes Payable Schedule of Long-Term Debt Instruments [Table Text Block] Shares redeemed to pay income tax Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Stock options and other dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Schedule of Equity Method Investments Equity Method Investments [Table Text Block] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Revenue Total revenues Revenues Product and Service [Domain] Product and Service [Domain] Principal payments on term notes Repayments of Other Long-Term Debt Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventory Increase (Decrease) in Inventories Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Recalculated principal overpayment request Gain Contingency, Unrecorded Amount Acquisition related costs expensed Business Combination, Acquisition Related Costs Accrued trade payables Accrued Trade Payables, Current Accrued Trade Payables, Current Award Type [Axis] Award Type [Axis] Issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Plan Name [Domain] Plan Name [Domain] Document Quarterly Report Document Quarterly Report Income tax receivable Income Taxes Receivable, Current Supplemental disclosures of non-cash transactions Noncash Investing and Financing Items [Abstract] Unrecognized pre-tax compensation expense, restricted stock units Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Accounts payable Capital Expenditures Incurred but Not yet Paid Government grant received Coronavirus Aid, Relief, and Economic Security, Government Grant Received Coronavirus Aid, Relief, and Economic Security, Government Grant Received Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Property and equipment, gross Property, Plant and Equipment, Gross Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Trading Arrangement: Trading Arrangement [Axis] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity File Number Entity File Number Schedule of Restricted Stock Units Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Operating lease liabilities, current portion Operating Lease, Liability, Current Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Cash settlement Share-Based Payment Arrangement, Cash Used to Settle Award Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Recently adopted accounting pronouncements and Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Income tax payable/receivable Increase (Decrease) in Income Taxes Payable Furniture and equipment Furniture And Equipment [Member] Furniture And Equipment [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash and cash equivalents at beginning of year Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Issued (in shares) Common Stock, Shares, Issued Estimate of uncollectible receivables Business Combination, Acquired Receivables, Estimated Uncollectible Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Cash paid or payable Business Combination, Consideration Transferred Gross profit Gross Profit Deferred revenue Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Total Assets, Fair Value Disclosure Long-term debt Long-Term Debt Stock-based compensation Share-Based Payment Arrangement [Policy Text Block] Selling, general and administrative Selling, General and Administrative Expense Options Employee Stock Option [Member] Weighted-average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Notes Payable Notes Payable to Banks [Member] Tabular List, Table Tabular List [Table Text Block] Vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Entity Address, Address Line One Entity Address, Address Line One CARES Act Funds Received CARES Act Funds Received [Policy Text Block] CARES Act Funds Received Inventory Inventory, Policy [Policy Text Block] Principles of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average exercise price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Business Acquisition [Axis] Business Acquisition [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Balance, beginning of year Balance, end of period Accounts Receivable, Allowance for Credit Loss, Current Customer Concentration Customer Concentration Risk [Member] Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Schedule of Investments [Line Items] Schedule of Investments [Line Items] Title of 12(b) Security Title of 12(b) Security Discrete income tax benefit Discrete Income Tax Expense (Benefit) Discrete Income Tax Expense (Benefit) Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Money market mutual funds Cash and Cash Equivalents, Fair Value Disclosure Medicare revenues Medicare [Member] Medicare [Member] Business Combinations Business Combination Disclosure [Text Block] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Beginning balance (USD per share) Ending balance (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Solvet Services LLC Solvet Services LLC [Member] Solvet Services LLC Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fixed interest rate (percent) Derivative, Fixed Interest Rate Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Revenue Accounting under Topic 842 Revenue Recognition, Leases [Policy Text Block] Accounts Receivable, Allowance for Doubtful Accounts Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Equity investments Equity Method Investments Inventory Inventory, Net Statistical Measurement [Axis] Statistical Measurement [Axis] Land Land [Member] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Other long-term assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Total Shareholder Return Amount Total Shareholder Return Amount Shares repurchased under the share repurchase program Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Depreciation Depreciation, Nonproduction Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Current portion of lease liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Shares issued for vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Name Outstanding Recovery, Individual Name Revenue Accounting under Topic 606 Revenue from Contract with Customer [Policy Text Block] Principal amount Debt Instrument, Face Amount Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets Assets, Current [Abstract] Valuation of Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Medical equipment Equipment, Medical [Member] Equipment, Medical [Member] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Interest rate swaps Derivatives, Policy [Policy Text Block] Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities [Abstract] Outstanding (in shares) Shareholders' equity, beginning balance (in shares) Shareholders' equity, ending balance (in shares) Shares outstanding (in shares) Common Stock, Shares, Outstanding Other equity investments Other Investments PEO PEO [Member] Non-cash change in debt from the reclassification of debt issuance costs Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction Income from debt investment Debt Securities, Gain (Loss) Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt Total long-term assets Assets, Noncurrent Class of Stock [Domain] Class of Stock [Domain] Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Customer [Domain] Customer [Domain] Number of options (000's) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Interest Rate Interest Rate Swap [Member] Repayments of lease liabilities Lease, Payments Lease, Payments Debt Instrument [Axis] Debt Instrument [Axis] Shares redeemed to pay income tax Stock Repurchased and Retired During Period, Value Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Credit Facility [Axis] Credit Facility [Axis] TOTAL LIABILITIES Liabilities Service revenues Service [Member] Schedule of Phantom Share Units Share-Based Payment Arrangement, Activity [Table Text Block] Nature of Business and Operations Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Shareholders' Equity Shareholders' Equity and Share-Based Payments [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency [Domain] Measurement Frequency [Domain] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] All Executive Categories All Executive Categories [Member] Long-term liabilities Liabilities, Noncurrent [Abstract] Accrued bonuses payable Accrued Bonuses, Current Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Plan Name [Axis] Plan Name [Axis] Debt Disclosure [Abstract] Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Net income per share Earnings Per Share [Abstract] Debt investment Debt Securities, Noncurrent Debt Investment Marketable Securities, Policy [Policy Text Block] Common stock - No par value: unlimited authorized; 38,400,422 and 38,049,739 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Segment Reporting Segment Reporting, Policy [Policy Text Block] Total current assets Assets, Current Schedules of Revenue by Customer Schedules of Concentration of Risk, by Risk Factor [Table Text Block] All Individuals All Individuals [Member] Supplemental disclosures of cash flow information Supplemental Cash Flow Information [Abstract] Other (income) expense, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Purchase obligation Purchase Obligation Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Percent of issued and outstanding shares Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding Shares repurchased under share repurchase program (in shares) Stock Repurchased During Period, Shares Trade payables Accounts Payable, Trade, Current PEO Name PEO Name Concentration risk, percentage Concentration Risk, Percentage Base Rate Base Rate [Member] Equity investments Balance, end of period Investments Issued (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Buildings Building [Member] Accounts receivable Accounts Receivable [Policy Text Block] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Aggregate intrinsic value, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Class of Stock [Axis] Class of Stock [Axis] Stock-based compensation - options APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accrued other liabilities Other Accrued Liabilities, Current Current portion of phantom share liability Current accrued liabilities Deferred Compensation Share-Based Arrangements, Liability, Current Other durable medical equipment rentals Other Durable Medical Equipment Rentals [Member] Other Durable Medical Equipment Rentals [Member] Stated interest rate (percent) Debt Instrument, Interest Rate, Stated Percentage Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Business Combination and Asset Acquisition [Abstract] TOTAL SHAREHOLDERS' EQUITY Shareholders' equity, beginning balance Shareholders' equity, ending balance Equity, Attributable to Parent Fair value of accounts receivables acquired Business Combination, Acquired Receivable, Fair Value COVID-19 response sales and services COVID-19 Response Sales [Member] COVID-19 Response Sales [Member] Lease assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases Assets Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Net income before taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Accrued commissions payable Accrued Sales Commission, Current Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Home Medical Products Inc Home Medical Products Inc [Member] Home Medical Products Inc TOTAL LIABILITIES Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Fair Value, Inputs, Level 2 Fair Value, Inputs, Level 2 [Member] Value of share equivalents Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract] Medicaid revenues Medicaid [Member] Medicaid [Member] Entity Emerging Growth Company Entity Emerging Growth Company Covenant Period [Axis] Covenant Period [Axis] Covenant Period Financing costs and commitment fees Debt Issuance Costs, Net Identifiable intangibles, net Intangible Assets, Net (Excluding Goodwill) Proceeds from term notes Proceeds from Issuance of Other Long-Term Debt Net assets (liabilities) acquired Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Identifiable intangibles, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Document Period Focus Document Fiscal Period Focus Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Title Trading Arrangement, Individual Title Beginning balance (USD per share) Ending balance (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Investment in equity investments Payments to Acquire Other Productive Assets Common Stock Common Stock [Member] 5 Year Revolving Credit Facility 5 Year Revolving Credit Facility [Member] 5 Year Revolving Credit Facility Individual: Individual [Axis] City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Equity method investment, ownership percentage Equity Method Investment, Ownership Percentage Document Fiscal Year Focus Document Fiscal Year Focus Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract] Minimum Minimum [Member] Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property and equipment, net of accumulated depreciation and amortization Property, Plant and Equipment, Net Distributions of earnings received from equity method investments Proceeds from Equity Method Investment, Distribution Schedule of Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Equipment Financing Obligations Equipment Financing Obligation [Member] Equipment Financing Obligation Shares redeemed to pay income tax Payment, Tax Withholding, Share-Based Payment Arrangement LIABILITIES Liabilities [Abstract] Cash paid (received) during the period for income taxes, net of refunds Income Taxes Paid, Net Identifiable Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax asset Deferred Income Tax Assets, Net Expired / Forfeited Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] 2022 Senior Credit Facilities 2022 Senior Credit Facilities [Member] 2022 Senior Credit Facilities Business acquisition, percentage of voting interests acquired Business Acquisition, Percentage of Voting Interests Acquired Retained earnings Retained Earnings [Member] Current debt Current portion of notes payable Long-Term Debt, Current Maturities Schedule of Stock-based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY Liabilities and Equity 2022 Senior Credit Facilities Closing Date Of March 31 2025 2022 Senior Credit Facilities Closing Date Of March 31 2025 [Member] 2022 Senior Credit Facilities Closing Date Of March 31 2025 Non-operating income and expenses Nonoperating Income (Expense) [Abstract] Other long-term assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Basic (in dollars per share) Basic earnings per share (in dollars per share) Earnings Per Share, Basic Change in unrealized gain/loss on derivative instruments, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized pre-tax stock option expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Outstanding deposit Deposits Assets Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Basis of Consolidation Consolidation, Policy [Policy Text Block] Total long-term liabilities Liabilities, Noncurrent Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Termination Date Trading Arrangement Termination Date Available for sale debt instrument Debt Securities, Available-for-Sale Payments on revolving credit facilities Repayments of Lines of Credit Current Liabilities Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Short-term debt Short-Term Debt Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Derivative Instrument [Axis] Derivative Instrument [Axis] Phantom Share Units Phantom Share Units (PSUs) [Member] Outstanding balance Long-Term Debt, Gross Adjustments for: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] All Trading Arrangements All Trading Arrangements [Member] All Adjustments to Compensation All Adjustments to Compensation [Member] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount TOTAL ASSETS Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets Provision for uncollectible accounts Accounts Receivable, Credit Loss Expense (Reversal) Depreciation Cost, Depreciation Expired / Forfeited (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Shares issued for vesting of restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Deferred income tax (benefit) expense Deferred Income Tax Expense (Benefit) Proceeds from exercise of options Proceeds from Stock Options Exercised Accrued liabilities Accounts Payable and Accrued Liabilities, Noncurrent Consideration funded by borrowings Business Combination, Consideration Transferred, Liabilities Incurred Loss (gain) on disposal of property and equipment Loss (gain) on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property Change in inventory reserve Inventory, LIFO Reserve, Period Charge Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Income taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Aggregate Intrinsic Value Beginning balance Ending balance Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Expired / Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Equity investments Equity Method Investments [Policy Text Block] Insider Trading Arrangements [Line Items] Share price (USD per share) Share Price Aggregate intrinsic value Aggregate intrinsic value, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Equipment and supply sales Equipment Sales [Member] Equipment Sales [Member] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Purchase price payable Business Combination, Consideration, Payable, Current Business Combination, Consideration, Payable, Current Adjustment to Compensation, Amount Adjustment to Compensation Amount Proceeds from sale of property and equipment Proceeds from Sale of Property, Plant, and Equipment Document Period End Date Document Period End Date Proceeds from revolving credit facilities Proceeds from Lines of Credit Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Less: Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Total liability Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent Revenue Revenue from Contract with Customer Benchmark [Member] Schedule of Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Weighted average exercise price (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Finance lease liabilities, less current portion Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Stock-based compensation Stock-based compensation, expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Provision for income taxes Income Tax Expense (Benefit) Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms Total leverage ratio Debt Instrument, Total Leverage Ratio Debt Instrument, Total Leverage Ratio Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Amounts charged off Accounts Receivable, Allowance for Credit Loss, Writeoff Finance lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Accrued vacation and payroll Employee-related Liabilities, Current Fair Value Measurement Fair Value Disclosures [Text Block] Long-term accrued liabilities Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent Name Trading Arrangement, Individual Name Other comprehensive income (loss) Change in accumulated other comprehensive loss, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Revenue by Source Disaggregation of Revenue [Table Text Block] Revenue from sales and services under Topic 606 Revenue from Contract with Customer, Excluding Assessed Tax Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Money Market Funds Money Market Funds [Member] 2022 Senior Credit Facilities Closing Date Of December 31 2024 2022 Senior Credit Facilities Closing Date Of December 31 2024 [Member] 2022 Senior Credit Facilities Closing Date Of December 31 2024 Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash paid for acquisition of HMP, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Shares redeemed to pay income tax (in shares) Shares redeemed to pay income tax (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Cash paid during the period for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Credit Facility [Domain] Credit Facility [Domain] Basis spread on variable rate (percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Damages sought Loss Contingency, Damages Sought, Value Long-term debt Net long-term notes payable Long-Term Debt, Excluding Current Maturities Leasehold improvements Leasehold Improvements [Member] Accrued liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities Diluted (in shares) Diluted weighted-average number of shares (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Interest income (expense), net Interest Income (Expense), Nonoperating, Net Total Medicare and Medicaid Medicare And Medicaid [Member] Medicare And Medicaid [Member] Operating expenses Operating Expenses [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid-in Capital [Member] Denominator calculation from basic to diluted: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Vehicles Vehicles [Member] Income from equity method investments Equity Securities, FV-NI, Realized Gain (Loss) TOTAL ASSETS Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Necessary claims reviewed and payable (percent) Loss Contingency, Percent Of Necessary Claims Reviewed And Payable Loss Contingency, Percent Of Necessary Claims Reviewed And Payable Income from equity method investments Income (Loss) from Equity Method Investments Cover [Abstract] Cover [Abstract] Number of states in which entity provides DME and health care solutions Number of States in which Entity Operates Fair Value, Recurring Fair Value, Recurring [Member] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Schedule of Current Liabilities Other Current Liabilities [Table Text Block] Vested (USD per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Non-NEOs Non-NEOs [Member] Expired / Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Ventilator rentals, non-invasive and invasive Ventilator Rental [Member] Ventilator Rental [Member] Fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities [Abstract] Current debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt Non-PEO NEO Non-PEO NEO [Member] Equity Component [Domain] Equity Component [Domain] Finance lease liabilities, current portion Finance Lease, Liability, Current Adjustment to Compensation: Adjustment to Compensation [Axis] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Debt Instrument [Line Items] Debt Instrument [Line Items] Basic (in shares) Basic weighted-average number of common shares (in shares) Weighted Average Number of Shares Outstanding, Basic Gross contractual amount Business Combination, Acquired Receivables, Gross Contractual Amount Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type [Domain] Concentration Risk Type [Domain] Income from operations Operating Income (Loss) Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Number of patients Loss Contingency, Number Of Non-Invasive Ventilation At Home Patients Loss Contingency, Number Of Non-Invasive Ventilation At Home Patients Other comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Revenue from rentals under Topic 842 Operating Lease, Lease Income Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Concentration Risk [Table] Concentration Risk [Table] Property and equipment Property, Plant and Equipment, Policy [Policy Text Block] Weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative, gain on derivative Derivative, Gain on Derivative EX-101.PRE 10 vmd-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover - shares
 6 Months Ended
Jun. 30, 2023
Jul. 20, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-38973  
Entity Registrant Name Viemed Healthcare, Inc.  
Entity Incorporation, State or Country Code Z4  
Entity Address, Address Line One 625 E. Kaliste Saloom Rd.  
Entity Address, City or Town Lafayette  
Entity Address, State or Province LA  
Entity Address, Postal Zip Code 70508  
City Area Code 337  
Local Phone Number 504-3802  
Title of 12(b) Security Common Shares, no par value  
Trading Symbol VMD  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   38,400,422
Entity Central Index Key 0001729149  
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Period Focus Q2  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets    
Cash and cash equivalents $ 10,224 $ 16,914
Accounts receivable, net 17,893 15,379
Inventory 4,476 3,574
Income tax receivable 1,029 26
Prepaid expenses and other assets 2,327 3,849
Total current assets 35,949 39,742
Long-term assets    
Property and equipment, net 72,884 67,743
Finance lease right-of-use assets 538 0
Operating lease right-of-use assets 516 694
Equity investments 1,942 2,155
Debt investment 2,110 2,000
Deferred tax asset 3,844 3,119
Identifiable intangibles, net 688 0
Goodwill 29,759 0
Other long-term assets 887 1,590
Total long-term assets 113,168 77,301
TOTAL ASSETS 149,117 117,043
Current liabilities    
Trade payables 6,167 2,650
Deferred revenue 5,960 4,624
Accrued liabilities 15,509 11,092
Finance lease liabilities, current portion 375 0
Operating lease liabilities, current portion 395 495
Current debt 3,169 0
Total current liabilities 31,575 18,861
Long-term liabilities    
Accrued liabilities 637 889
Finance lease liabilities, less current portion 143 0
Operating lease liabilities, less current portion 143 199
Long-term debt 12,114 0
Total long-term liabilities 13,037 1,088
TOTAL LIABILITIES 44,612 19,949
Commitments and Contingencies 0 0
SHAREHOLDERS' EQUITY    
Common stock - No par value: unlimited authorized; 38,400,422 and 38,049,739 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively 17,850 15,123
Additional paid-in capital 13,488 12,125
Retained earnings 73,167 69,846
TOTAL SHAREHOLDERS' EQUITY 104,505 97,094
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $ 149,117 $ 117,043
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - shares
Jun. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Issued (in shares) 38,400,422 38,049,739
Outstanding (in shares) 38,400,422 38,049,739
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Statement [Abstract]        
Revenue $ 43,311 $ 33,310 $ 82,867 $ 65,565
Cost of revenue 17,205 12,920 32,757 25,432
Gross profit 26,106 20,390 50,110 40,133
Operating expenses        
Selling, general and administrative 20,563 17,536 40,325 33,312
Research and development 758 672 1,538 1,304
Stock-based compensation 1,471 1,271 2,862 2,576
Depreciation 298 243 538 480
Loss (gain) on disposal of property and equipment 117 (110) 95 (124)
Other (income) expense, net (2) (223) (83) (664)
Income from operations 2,901 1,001 4,835 3,249
Non-operating income and expenses        
Income from equity method investments 137 446 172 769
Interest income (expense), net 20 (59) 69 (123)
Net income before taxes 3,058 1,388 5,076 3,895
Provision for income taxes 728 421 1,229 1,166
Net income 2,330 967 3,847 2,729
Other comprehensive income (loss)        
Change in unrealized gain/loss on derivative instruments, net of tax 0 59 0 222
Other comprehensive income (loss) 0 59 0 222
Comprehensive income $ 2,330 $ 1,026 $ 3,847 $ 2,951
Net income per share        
Basic (in dollars per share) $ 0.06 $ 0.02 $ 0.10 $ 0.07
Diluted (in dollars per share) $ 0.06 $ 0.02 $ 0.10 $ 0.07
Weighted average number of common shares outstanding:        
Basic (in shares) 38,324,249 38,773,580 38,240,902 39,195,317
Diluted (in shares) 40,676,951 39,752,928 40,383,616 40,056,953
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2021   39,640,388      
Shareholders' equity, beginning balance at Dec. 31, 2021 $ 94,820 $ 14,014 $ 7,749 $ (278) $ 73,335
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 820   820    
Stock-based compensation - restricted stock units 485   485    
Shares issued for vesting of restricted stock units (in shares)   67,010      
Shares issued for vesting of restricted stock units 0 $ 334 (334)    
Shares redeemed to pay income tax (in shares)   (23,742)      
Shares redeemed to pay income tax (119)       (119)
Shares repurchased under share repurchase program (in shares)   (389,878)      
Shares repurchased under share repurchase program (1,887)       (1,887)
Change in accumulated other comprehensive loss, net of tax 163     163  
Net income 1,762       1,762
Shareholders' equity, ending balance (in shares) at Mar. 31, 2022   39,293,778      
Shareholders' equity, ending balance at Mar. 31, 2022 96,044 $ 14,348 8,720 (115) 73,091
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2021   39,640,388      
Shareholders' equity, beginning balance at Dec. 31, 2021 94,820 $ 14,014 7,749 (278) 73,335
Increase (Decrease) in Stockholders' Equity          
Change in accumulated other comprehensive loss, net of tax 222        
Net income 2,729        
Shareholders' equity, ending balance (in shares) at Jun. 30, 2022   38,333,089      
Shareholders' equity, ending balance at Jun. 30, 2022 93,227 $ 14,348 9,991 (56) 68,944
Shareholders' equity, beginning balance (in shares) at Mar. 31, 2022   39,293,778      
Shareholders' equity, beginning balance at Mar. 31, 2022 96,044 $ 14,348 8,720 (115) 73,091
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 757   757    
Stock-based compensation - restricted stock units 514   514    
Shares repurchased under share repurchase program (in shares)   (960,689)      
Shares repurchased under share repurchase program (5,114)       (5,114)
Change in accumulated other comprehensive loss, net of tax 59     59  
Net income 967       967
Shareholders' equity, ending balance (in shares) at Jun. 30, 2022   38,333,089      
Shareholders' equity, ending balance at Jun. 30, 2022 $ 93,227 $ 14,348 9,991 (56) 68,944
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2022 38,049,739 38,049,739      
Shareholders' equity, beginning balance at Dec. 31, 2022 $ 97,094 $ 15,123 12,125 0 69,846
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 348   348    
Stock-based compensation - restricted stock units 1,043   1,043    
Exercise of options (in shares)   108,370      
Exercise of options 544 $ 544      
Shares issued for vesting of restricted stock units (in shares)   183,036      
Shares issued for vesting of restricted stock units 0 $ 1,429 (1,429)    
Shares redeemed to pay income tax (in shares)   (64,756)      
Shares redeemed to pay income tax (505)       (505)
Net income 1,517       1,517
Shareholders' equity, ending balance (in shares) at Mar. 31, 2023   38,276,389      
Shareholders' equity, ending balance at Mar. 31, 2023 $ 100,041 $ 17,096 12,087 0 70,858
Shareholders' equity, beginning balance (in shares) at Dec. 31, 2022 38,049,739 38,049,739      
Shareholders' equity, beginning balance at Dec. 31, 2022 $ 97,094 $ 15,123 12,125 0 69,846
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 228,000        
Shares redeemed to pay income tax (in shares)   (66,734)      
Change in accumulated other comprehensive loss, net of tax $ 0        
Net income $ 3,847        
Shareholders' equity, ending balance (in shares) at Jun. 30, 2023 38,400,422 38,400,422      
Shareholders' equity, ending balance at Jun. 30, 2023 $ 104,505 $ 17,850 13,488 0 73,167
Shareholders' equity, beginning balance (in shares) at Mar. 31, 2023   38,276,389      
Shareholders' equity, beginning balance at Mar. 31, 2023 100,041 $ 17,096 12,087 0 70,858
Increase (Decrease) in Stockholders' Equity          
Stock-based compensation - options 301   301    
Stock-based compensation - restricted stock units 1,170   1,170    
Exercise of options (in shares)   119,356      
Exercise of options 684 $ 684      
Shares issued for vesting of restricted stock units (in shares)   6,655      
Shares issued for vesting of restricted stock units 0 $ 70 (70)    
Shares redeemed to pay income tax (in shares)   (1,978)      
Shares redeemed to pay income tax (21)       (21)
Change in accumulated other comprehensive loss, net of tax 0        
Net income $ 2,330       2,330
Shareholders' equity, ending balance (in shares) at Jun. 30, 2023 38,400,422 38,400,422      
Shareholders' equity, ending balance at Jun. 30, 2023 $ 104,505 $ 17,850 $ 13,488 $ 0 $ 73,167
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities    
Net income $ 3,847 $ 2,729
Adjustments for:    
Depreciation 9,968 7,136
Change in inventory reserve 0 (1,418)
Stock-based compensation expense 2,862 2,576
Distributions of earnings received from equity method investments 392 612
Income from equity method investments (172) (769)
Income from debt investment (110) 0
Loss (gain) on disposal of property and equipment 95 (124)
Deferred income tax (benefit) expense (725) 745
Changes in working capital, net of effects from acquisitions:    
Accounts receivable, net (500) (1,464)
Inventory (320) 1,022
Prepaid expenses and other assets 2,076 (634)
Trade payables (488) (243)
Deferred revenue 604 649
Accrued liabilities 1,593 (87)
Income tax payable/receivable (1,003) 1,362
Net cash provided by operating activities 18,119 12,092
Cash flows from investing activities    
Purchase of property and equipment (10,759) (10,989)
Investment in equity investments (7) (121)
Cash paid for acquisition of HMP, net of cash acquired (27,121) 0
Proceeds from sale of property and equipment 1,775 615
Net cash used in investing activities (36,112) (10,495)
Cash flows from financing activities    
Proceeds from exercise of options 1,228 0
Proceeds from term notes 5,000 0
Principal payments on term notes (1,357) (78)
Proceeds from revolving credit facilities 8,000 0
Payments on revolving credit facilities (1,005) (872)
Shares redeemed to pay income tax (526) (119)
Shares repurchased under the share repurchase program 0 (7,001)
Repayments of lease liabilities (37) (13)
Net cash provided by (used in) financing activities 11,303 (8,083)
Net decrease in cash and cash equivalents (6,690) (6,486)
Cash and cash equivalents at beginning of year 16,914 28,408
Cash and cash equivalents at end of period 10,224 21,922
Supplemental disclosures of cash flow information    
Cash paid during the period for interest 169 128
Cash paid (received) during the period for income taxes, net of refunds 3,093 (940)
Supplemental disclosures of non-cash transactions    
Non-cash change in debt from the reclassification of debt issuance costs $ (748) $ 0
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Business and Operations
 6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of Business and Operations Nature of Business and Operations
Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.

The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.

The Company’s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol "VMD" and in Canada on the Toronto Stock Exchange under the symbol "VMD.TO".
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Principles of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Basis of Consolidation

These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.

Use of Estimates

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.
Segment Reporting

The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure based on ASC 280, Segment Reporting.

Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the six months ended June 30, 2023, the Company's evaluation takes into consideration such factors as historical bad debt and billing modification experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.

The estimates and charge-offs for the allowance for doubtful accounts for each reporting period were as follows:
June 30, 2023June 30, 2022
Balance, beginning of year$8,483 $7,031 
Provision for uncollectible accounts7,579 6,300 
Amounts charged off(5,055)(3,948)
Balance, end of period$11,007 $9,383 

Included in accounts receivable at June 30, 2023 are amounts due from Medicare and Medicaid representing 35% and 6%, respectively, and 41% combined, of total outstanding receivables. As of December 31, 2022, 48% of total outstanding receivables were amounts due from Medicare and Medicaid.

Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Medicare revenues44 %46 %45 %47 %
Medicaid revenues9 %9 %9 %9 %
Total Medicare and Medicaid53 %55 %54 %56 %

Inventory

Inventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.

Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.

Equity investments

Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2.

The following table details the Company’s equity investments:
June 30, 2023December 31, 2022
Equity method investments$595 $816 
Other equity investments1,347 1,339 
Balance, end of period$1,942 $2,155 

The Company's equity method investments include a 49% equity interest in Solvet Services, LLC, an entity which provides health care support services to state and federal governments. Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with any subsequent adjustments made to the carrying amount of the investment for the Company’s proportionate share of income or loss. Distributions received from the investee reduce the Company’s carrying value of the investment. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of June 30, 2023 that would impair the carrying value of equity method investments.

Other equity investments include an equity interest in VeruStat, Inc., a remote patient monitoring entity, and an equity interest in DMEscripts, LLC, an e-prescribing platform. Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2023 on its investments in equity securities without a readily determinable fair value.

Debt Investment

The Company's debt investment is a variable rate secured convertible note issued by Healthcare DX, Inc. (d/b/a ModoHealth) on December 21, 2022, classified as an available-for-sale debt instrument. Accrued interest is due upon the 18 month maturity of the note and is included in the amortized cost basis at each reporting period. At each financial statement date until a conversion event, the debt instrument is required to be remeasured at fair value. Changes in unrealized gains and losses are included in accumulated other comprehensive income, net of tax effect, until realized.
Valuation of Goodwill

Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. During the three months ended June 30, 2023 the Company evaluated the events and changes that could indicate that goodwill might be impaired and concluded that an interim test was not necessary.

Comprehensive income

Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company's comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.

Revenue recognition

Revenue from a customer consists of sales and rentals of home medical equipment and patient medical services. Patient revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Patient revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).

For commercial payors, HME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with HME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any HME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which varies based on the type of equipment rental, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.
Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues.

The revenues from each major source are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$25,712 $22,736 $50,859 $44,254 
    Other durable medical equipment rentals8,419 4,912 15,325 9,271 
Revenue from sales and services under Topic 606
    Equipment and supply sales
6,778 3,245 11,542 6,282 
    COVID-19 response sales and services
— 183 — 2,278 
    Service revenues
2,402 2,234 5,141 3,480 
Total revenues$43,311 $33,310 $82,867 $65,565 

Revenue Accounting under Topic 842

The Company leases HME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.

Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date equipment is delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Revenue Accounting under Topic 606

The Company sells HME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the HME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.
For staffing services, performance obligations in the staffing agreements are satisfied over time when the customer simultaneously receives and consumes the benefits provided. Accordingly, revenues from staffing services are recognized on an hourly basis as services are rendered by the job site employee in both principal and agent arrangements.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on equipment sales, sleep study services, staffing services, or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of June 30, 2023.

Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.

Interest rate swaps

The Company utilized an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the 2019 Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.

The Company recognized any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.
During the year ended December 31, 2022, the Company settled its interest rate swap in connection with the refinancing of its credit facilities and recognized the realized gain of $0.2 million in Other Income.

Income taxes

The Company is subject to income taxes in numerous U.S. jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations.

Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.

CARES Act Funds Received

The Company received a general distribution payment from the Provider Relief Fund of $3.5 million in April 2020, a targeted distribution payment of $1.5 million in November 2021, and a general distribution payment of $0.4 million in January 2022. The U.S. Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. There is no US GAAP guidance for for-profit health care entities that receive government grants that are not in the form of an income tax credit, revenue from a contract with a customer or a loan. As such, for-profit entities must determine the appropriate accounting treatment by analogy to other guidance such as International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, in International Financial Reporting Standards. Under IAS 20, the Company determined that upon receipt of funds, it fully complied with the conditions attached to the grant. The Company recognized the distributions received from the Provider Relief Fund in the income statement in full during the period of receipt. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. The Company is not aware of any such modifications as of June 30, 2023

Recently adopted accounting pronouncements

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. While the adoption of ASC 326 could result in a higher allowance recorded in the future for credit losses on receivables within the scope of the standard due to the prescribed measurement principles, the impact of the adoption on the Company's consolidated financials statements was not material.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, the Company's condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting
standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about their obligations that are outstanding at the end of the reporting period. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company does not expect the update to affect the recognition, measurement, or financial statement presentation of supplier finance program obligations, but is evaluating the impact of the update on related disclosures upon adoption.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combinations
 6 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Business Combinations Business Combinations
On June 1, 2023, Viemed, Inc., a wholly-owned subsidiary of the Company, completed the acquisition of Home Medical Products, Inc., (“HMP”), which operates in Tennessee, Alabama, and Mississippi. The Company acquired 100% of the equity ownership of HMP in exchange for approximately $29.4 million in cash or cash payable, subject to customary post-closing net working capital and other adjustments. Approximately $15 million of the purchase consideration was funded by cash on hand, $8 million was funded by a borrowing on the 2022 Revolving Credit Facility, and $5 million was funded by a borrowing on the 2022 Term Loan Facility.

The results of HMP’s operations have been included in the consolidated financial statements since the date of acquisition. The Company expensed $254,000 of acquisition costs in conjunction with the acquisition for the six months ended June 30, 2023. These costs include system conversion and integrating operations charges, as well as legal and consulting expenses, and are included in selling, general, and administrative expense in the accompanying consolidated statements of income and comprehensive income.

The following table summarizes the consideration paid and estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The Company is in the process of obtaining third-party valuations of certain fixed assets and identifiable intangible assets; thus, the provisional measurements of property plant and equipment, trade names, non-compete agreements, and goodwill are subject to change. The fair value of accounts receivables acquired is $2.0 million, with the gross contractual amount being $2.9 million. The Company expects $0.9 million to be uncollectible.

Purchase Price
Cash paid or payable$29,417 
Identifiable Assets
Cash and cash equivalents921 
Accounts receivable2,014 
Inventory582 
Prepaid expenses and other assets535 
Property and equipment, net4,358 
Lease assets743 
Identifiable intangibles688 
Other long-term assets25 
TOTAL ASSETS9,866 
Identifiable Liabilities
Trade payables2,144 
Deferred revenue732 
Accrued liabilities1,195 
Current portion of lease liabilities536 
Current debt4,558 
Long-term lease liabilities207 
Long-term debt836 
TOTAL LIABILITIES10,208 
Net assets (liabilities) acquired(342)
Resulting goodwill$29,759 
Goodwill resulted from a combination of synergies and cost savings, and further expansion into Tennessee, Alabama, and Mississippi. All of the goodwill is deductible for income tax purposes. There are no contingent consideration arrangements included in the transaction.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment
 6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment.

The following table details the Company’s fixed assets:
June 30, 2023December 31, 2022
Medical equipment$103,571 $93,893 
Furniture and equipment3,115 2,792 
Land2,566 2,566 
Buildings7,129 7,043 
Leasehold improvements344 296 
Vehicles1,129 1,052 
Less: Accumulated depreciation(44,970)(39,899)
Property and equipment, net of accumulated depreciation and amortization$72,884 $67,743 
Depreciation in the amount of $4,908,000 and $3,497,000 is included in cost of revenue for the three months ended June 30, 2023 and 2022, respectively, and in the amount of $9,430,000 and $6,656,000 for the six months ended June 30, 2023 and 2022, respectively. Medical equipment purchases with a cost of $2,526,000 and $738,000 were included in accounts payable at June 30, 2023 and December 31, 2022, respectively.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.2
Current Liabilities
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Current Liabilities Current Liabilities
The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
June 30, 2023December 31, 2022
Accrued trade payables $2,735 $2,254 
Accrued commissions payable737 608 
Accrued bonuses payable4,329 3,708 
Accrued vacation and payroll2,450 1,484 
Current portion of phantom share liability 1,483 1,704 
Purchase price payable1,376 — 
Accrued other liabilities2,399 1,334 
Total accrued liabilities$15,509 $11,092 
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.2
Debt
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Debt Debt
2018 Senior Credit Facility

On February 20, 2018, the Company entered a Commercial Business Loan Agreement (the "2018 Senior Credit Facility") that provided for Term Loans and Lines of Credit with Hancock Whitney Bank. Until November 29, 2022, the Company maintained a line of credit in the amount of $10.0 million under the 2018 Senior Credit Facility. On May 30, 2019, the Company entered into a term note (“Building Term Note”) under the 2018 Senior Credit Facility in the principal amount of $4.8 million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. In connection with the Building Term Note, the Company entered into an interest rate swap transaction ("Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%. On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “2019 Term Note") under the 2018 Senior Credit Facility in the principal amount of $5.0 million and bearing an annual interest rate of 4.60%. The proceeds of the 2019 Term Note were utilized for general corporate purposes. The 2019 Term Note matured on September 19, 2022 at which time the entire unpaid balance of principal and interest was repaid in full. In connection with the entry in to the 2022 Senior Credit Facilities on November 29, 2022, the Company retired the 2018 Senior Credit Facility, and repaid all outstanding interest and principal in full.

2022 Senior Credit Facilities

On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.

The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions.

The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.

The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following:


•Consolidated Total Leverage Ratio (defined generally as total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.

•Consolidated Fixed Charge Coverage Ratio (defined generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.

The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2023.
The 2022 Senior Credit Facilities includes provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $30.0 million.

Financing costs and commitment fees related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method.

The recorded balances associated with the 2022 Senior Credit Facilities are as follows:
June 30, 2023December 31, 2022
Outstanding balance$13,000 $— 
Financing costs and commitment fees(748)— 
Less:
Current portion of notes payable(250)— 
Net long-term notes payable$12,002 $— 

Medical Equipment Financing

As a result of the acquisition of HMP, the Company assumed equipment financing obligations consisting of installment payments for medical equipment which secure the financing. The financing obligations are payable in monthly installments through 2026 and include interest at rates ranging from 0% to 7.99%. As of June 30, 2023, $3 million of the outstanding medical equipment financing obligations is presented on the condensed consolidated balance sheets as short term debt and $0.1 million is presented as long term debt, based on the scheduled repayment dates.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurement
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurement Fair Value Measurement
Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:

Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.

Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.
Assets Measured at Fair Value on a Recurring Basis

The Company measures certain assets at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.

The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:
At June 30, 2023
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$2,078 $— $— $2,078 
  Available for sale debt instrument— — 2,110 2,110 
Total$2,078 $— $2,110 $4,188 

At December 31, 2022
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$11,005 $— $— $11,005 
  Available for sale debt instrument$— $— $2,000 $2,000 
Total$11,005 $— $2,000 $13,005 

Available for Sale Debt Instrument

The fair value of the Company’s available for sale debt instrument approximates its amortized cost basis due to the short maturity and indexed interest rate terms. The fair value is classified within Level 3 in the fair value hierarchy as the Company evaluates adjustments using a combination of observable and unobservable inputs, such as operating results of the counterparty as well observable prices in transactions of debt and equity instruments of the issuing counterparty when available. As of June 30, 2023, the analysis resulted in no adjustments to the carrying value impacting unrealized gains or losses. All changes to measured fair value during the period were the result of accrued interest.

Assets Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets at fair value on a nonrecurring basis. These assets include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns.

The Company had no material adjustments of assets measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Shareholders' Equity Shareholders' Equity
Authorized share capital

The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value.

Issued and outstanding share capital

The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 38,400,422 and 38,049,739 shares were issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.

For the six months ended June 30, 2023, the Company acquired and cancelled 66,734 common shares at a cost of $0.5 million to satisfy employee income tax withholding associated with RSUs vesting. The Company’s retained earnings were reduced by the amount paid for the shares repurchased and cancelled.

Stock-based compensation

Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed 7,758,211 shares (equal to 20% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 common shares. As of June 30, 2023, the Company had outstanding options of 4,244,000 and RSUs of 1,123,000 associated with common shares under the Omnibus Plan.

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Stock-based compensation - options$301 $757 $649 $1,577 
Stock-based compensation - restricted stock units1,170 514 2,213 999 
Total$1,471 $1,271 $2,862 $2,576 

At June 30, 2023, there was approximately $889,000 of total unrecognized pre-tax stock option expense under the Company's equity compensation plans, which is expected to be recognized over a weighted-average period of 1.32 years. As of June 30, 2023, there was approximately $4,780,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.26 years.
Options

The following table summarizes stock option activity for the six months ended June 30, 2023:
Number of options
 (000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate intrinsic value(2)
Balance December 31, 20224,497 $5.26 6.9 years$11,356 
Issued— — 
Exercised(228)5.51 
Expired / Forfeited(25)6.47 
Balance June 30, 20234,244 $5.24 6.4 years$19,290 
(1)For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.
(2)The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing share price of the Company's common stock on the last trading day of the period ($9.78).

The aggregate intrinsic value of options outstanding was $19,290,197 and options exercisable were $16,579,787 at June 30, 2023. For the six months ended June 30, 2023, 228,000 common shares were issued pursuant to the exercise of stock options.

At June 30, 2023, the Company had 3,415,000 exercisable stock options outstanding with a weighted average exercise price of $4.93 and a weighted average remaining contractual life of 6.0 years. At December 31, 2022, the Company had 2,841,000 exercisable stock options outstanding with a weighted average exercise price of $4.53 and a weighted average remaining contractual life of 6.1 years.

The fair value of the stock options has been charged to the Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the six months ended June 30, 2023.

Restricted stock units

The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a one or three-year period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.

The following table summarizes RSU activity for the six months ended June 30, 2023:
Number of RSUs (000's)Weighted average grant priceWeighted average remaining contractual life
Aggregate intrinsic value(1)
Balance December 31, 2022629 $5.62 0.88 years$4,755 
Issued702 7.87 
Vested(190)5.56 
Expired / Forfeited(18)6.70 
Balance June 30, 20231,123 $7.02 1.26 years$10,986 
(1)The aggregate intrinsic value of time-based RSUs outstanding was based on the Company's closing stock price on the last trading day of the period ($9.78).

During the six months ended June 30, 2023, the Company issued 702,206 RSUs with a vesting term of three years and a fair value of $5.6 million. During the three months ended June 30, 2023, the Company issued no RSUs.
Phantom share units

The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period.

The following table summarizes phantom share unit activity for the six months ended June 30, 2023:
Number of phantom share units (000's)
Value of share equivalents(1)
Balance December 31, 2022513 $3,878 
Issued176 1,401 
Vested(239)(578)
Expired / Forfeited(20)(196)
Balance June 30, 2023430 $4,200 
(1)The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s stock at that time, the value of issued share equivalents is based on the market price of the Company’s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $9.78 on June 30, 2023.

The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at June 30, 2023 is $2,120,000, with $1,483,000 of this amount included in current accrued liabilities and the remaining portion of $637,000 included in long-term accrued liabilities.

The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense (benefit) associated with the phantom share units for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Selling, general, and administrative$687 $538 $1,837 $949 

The Company paid cash settlements of $2,309,000 and $1,389,000 during the six months ended June 30, 2023 and 2022, respectively, pertaining to vestings of cash-settled phantom share units.
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies
 6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters.

Legal Proceedings

As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the “Purchase Order”) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment. The Company ultimately prepaid $1.4 million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the “State Court”) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (“Reconventional Demand”) with the State Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties completed discovery on July 17, 2023. The Company filed a Motion for Summary Judgment on June 9, 2023. The Court has set an August 28, 2023 hearing on that motion and has set a date for a non-jury trial on October 30, 2023.

The Company continues to believe that it has valid legal and equitable grounds to recover its outstanding prepayment as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. The Company has determined that a loss related to the Reconventional Demand is not probable, and thus has not accrued a liability related to this claim. Although a loss may be reasonably possible, the Company does not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of June 30, 2023, outstanding funds in the amount of $0.9 million related to undelivered respiratory equipment are included within other long-term assets.
Governmental and Regulatory Matters

From time to time the Company is involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure or exclusion from participation in government healthcare programs.

In May of 2021, a final report and recommendation (“Report”) was issued by the OIG regarding an audit by OIG of claims relating to 100 of the Company’s non-invasive ventilation at home (“NIVH”) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believed that the Report ignored each patient’s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applied clinical guidelines that were contrary to CMS’s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. In November 2021, the Company filed Reconsideration Appeals with CMS's designated Qualified Independent Contractor ("QIC"). Based on its review, the QIC determined that approximately 77% of the claims it reviewed were medically necessary and properly payable under Medicare rules and regulations, overturning OIG’s and the MACs' initial recommendations and determinations. As a result of the QIC's reconsideration findings, reduced and recalculated principal overpayment requests totaling $1.1 million were issued by the MACs. In order to limit the assessment of interest during the appeals period, the Company remitted the associated funds to the MACs. In December 2022, an Administrative Law Judge overturned all of the remaining appealed claims and instructed the MACs to refund all funds previously remitted by the Company. Accordingly, the funds remitted to the MACs are recorded in Prepaid expenses and other assets at December 31, 2022 and were received during the six months ended June 30, 2023.
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes
 6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
For the six months ended June 30, 2023, the Company recorded income tax expense of $1.2 million, which includes a discrete tax benefit of $0.1 million associated with stock-based compensation arrangements. Excluding the impact of the discrete taxes, the effective rate for the six months ended June 30, 2023 is 28.6%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year.

At June 30, 2023 and 2022, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2019.

The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per ShareIncome per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year. Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate.
The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Numerator - basic and diluted:
Net income attributable to shareholders$2,330 $967 $3,847 $2,729 
Denominator:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 
Basic earnings per share$0.06 $0.02 $0.10 $0.07 
Diluted earnings per share$0.06 $0.02 $0.10 $0.07 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Stock options and other dilutive securities2,352,702 979,348 2,142,714 861,636 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 

Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.2
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Pay vs Performance Disclosure            
Net income attributable to shareholders $ 2,330 $ 1,517 $ 967 $ 1,762 $ 3,847 $ 2,729
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Principles of Presentation
Principles of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
Basis of Consolidation Basis of ConsolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated.
Use of Estimates Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates.
Segment Reporting
Segment Reporting

The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure based on ASC 280, Segment Reporting.
Accounts receivable
Accounts receivable

Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.

The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.

For the six months ended June 30, 2023, the Company's evaluation takes into consideration such factors as historical bad debt and billing modification experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.
Inventory InventoryInventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value.
Property and equipment
Property and equipment

Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives.
Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable.
Equity investments
Equity investments

Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2.
The Company's equity method investments include a 49% equity interest in Solvet Services, LLC, an entity which provides health care support services to state and federal governments. Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with any subsequent adjustments made to the carrying amount of the investment for the Company’s proportionate share of income or loss. Distributions received from the investee reduce the Company’s carrying value of the investment. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of June 30, 2023 that would impair the carrying value of equity method investments.

Other equity investments include an equity interest in VeruStat, Inc., a remote patient monitoring entity, and an equity interest in DMEscripts, LLC, an e-prescribing platform. Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2023 on its investments in equity securities without a readily determinable fair value.
Debt Investment Debt InvestmentThe Company's debt investment is a variable rate secured convertible note issued by Healthcare DX, Inc. (d/b/a ModoHealth) on December 21, 2022, classified as an available-for-sale debt instrument. Accrued interest is due upon the 18 month maturity of the note and is included in the amortized cost basis at each reporting period. At each financial statement date until a conversion event, the debt instrument is required to be remeasured at fair value. Changes in unrealized gains and losses are included in accumulated other comprehensive income, net of tax effect, until realized.
Valuation of Goodwill
Valuation of Goodwill

Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. During the three months ended June 30, 2023 the Company evaluated the events and changes that could indicate that goodwill might be impaired and concluded that an interim test was not necessary.
Comprehensive income Comprehensive incomeComprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company's comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity.
Revenue recognition
Revenue recognition

Revenue from a customer consists of sales and rentals of home medical equipment and patient medical services. Patient revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Patient revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services.

The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare & Medicaid Services (“CMS”).

For commercial payors, HME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.

The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with HME rentals, the Company recognizes revenue in accordance with FASB ASC 842, “Leases,” (Topic 842). For any HME sales and services, the Company recognizes revenue under FASB ASU 2014-09, “Revenue from Contracts with Customers,” (Topic 606) and related amendments.

The Company recognizes equipment rental revenue over the non-cancelable lease term, which varies based on the type of equipment rental, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term.
Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues.
Revenue Accounting under Topic 842
Revenue Accounting under Topic 842

The Company leases HME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.

Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date equipment is delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.
Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.
Revenue Accounting under Topic 606
Revenue Accounting under Topic 606

The Company sells HME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.

The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the HME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.
For staffing services, performance obligations in the staffing agreements are satisfied over time when the customer simultaneously receives and consumes the benefits provided. Accordingly, revenues from staffing services are recognized on an hourly basis as services are rendered by the job site employee in both principal and agent arrangements.

The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.

Returns and refunds are not accepted on equipment sales, sleep study services, staffing services, or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of June 30, 2023.
Stock-based compensation
Stock-based compensation

The Company accounts for its stock-based compensation in accordance with ASC 718, "Compensation—Stock Compensation", which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award.

For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.
Interest rate swaps
Interest rate swaps

The Company utilized an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the 2019 Term Note (as defined below). 

For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.

The Company recognized any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.
During the year ended December 31, 2022, the Company settled its interest rate swap in connection with the refinancing of its credit facilities and recognized the realized gain of $0.2 million in Other Income.
Income taxes
Income taxes

The Company is subject to income taxes in numerous U.S. jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations.

Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.
CARES Act Funds Received
CARES Act Funds Received

The Company received a general distribution payment from the Provider Relief Fund of $3.5 million in April 2020, a targeted distribution payment of $1.5 million in November 2021, and a general distribution payment of $0.4 million in January 2022. The U.S. Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. There is no US GAAP guidance for for-profit health care entities that receive government grants that are not in the form of an income tax credit, revenue from a contract with a customer or a loan. As such, for-profit entities must determine the appropriate accounting treatment by analogy to other guidance such as International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, in International Financial Reporting Standards. Under IAS 20, the Company determined that upon receipt of funds, it fully complied with the conditions attached to the grant. The Company recognized the distributions received from the Provider Relief Fund in the income statement in full during the period of receipt. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. The Company is not aware of any such modifications as of June 30, 2023
Recently adopted accounting pronouncements and Recently issued accounting pronouncements
Recently adopted accounting pronouncements

On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. While the adoption of ASC 326 could result in a higher allowance recorded in the future for credit losses on receivables within the scope of the standard due to the prescribed measurement principles, the impact of the adoption on the Company's consolidated financials statements was not material.

Recently issued accounting pronouncements

The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, the Company's condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting
standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.

In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about their obligations that are outstanding at the end of the reporting period. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company does not expect the update to affect the recognition, measurement, or financial statement presentation of supplier finance program obligations, but is evaluating the impact of the update on related disclosures upon adoption.
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Tables)
 6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
Accounts Receivable, Allowance for Doubtful Accounts
The estimates and charge-offs for the allowance for doubtful accounts for each reporting period were as follows:
June 30, 2023June 30, 2022
Balance, beginning of year$8,483 $7,031 
Provision for uncollectible accounts7,579 6,300 
Amounts charged off(5,055)(3,948)
Balance, end of period$11,007 $9,383 
Schedules of Revenue by Customer
Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and six months ended June 30, 2023 and 2022 were as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Medicare revenues44 %46 %45 %47 %
Medicaid revenues9 %9 %9 %9 %
Total Medicare and Medicaid53 %55 %54 %56 %
Schedule of Equity Method Investments
The following table details the Company’s equity investments:
June 30, 2023December 31, 2022
Equity method investments$595 $816 
Other equity investments1,347 1,339 
Balance, end of period$1,942 $2,155 
Schedule of Revenue by Source
The revenues from each major source are summarized in the following table:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Revenue from rentals under Topic 842
    Ventilator rentals, non-invasive and invasive$25,712 $22,736 $50,859 $44,254 
    Other durable medical equipment rentals8,419 4,912 15,325 9,271 
Revenue from sales and services under Topic 606
    Equipment and supply sales
6,778 3,245 11,542 6,282 
    COVID-19 response sales and services
— 183 — 2,278 
    Service revenues
2,402 2,234 5,141 3,480 
Total revenues$43,311 $33,310 $82,867 $65,565 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combinations (Tables)
 6 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The following table summarizes the consideration paid and estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The Company is in the process of obtaining third-party valuations of certain fixed assets and identifiable intangible assets; thus, the provisional measurements of property plant and equipment, trade names, non-compete agreements, and goodwill are subject to change. The fair value of accounts receivables acquired is $2.0 million, with the gross contractual amount being $2.9 million. The Company expects $0.9 million to be uncollectible.

Purchase Price
Cash paid or payable$29,417 
Identifiable Assets
Cash and cash equivalents921 
Accounts receivable2,014 
Inventory582 
Prepaid expenses and other assets535 
Property and equipment, net4,358 
Lease assets743 
Identifiable intangibles688 
Other long-term assets25 
TOTAL ASSETS9,866 
Identifiable Liabilities
Trade payables2,144 
Deferred revenue732 
Accrued liabilities1,195 
Current portion of lease liabilities536 
Current debt4,558 
Long-term lease liabilities207 
Long-term debt836 
TOTAL LIABILITIES10,208 
Net assets (liabilities) acquired(342)
Resulting goodwill$29,759 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Tables)
 6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
The following table details the Company’s fixed assets:
June 30, 2023December 31, 2022
Medical equipment$103,571 $93,893 
Furniture and equipment3,115 2,792 
Land2,566 2,566 
Buildings7,129 7,043 
Leasehold improvements344 296 
Vehicles1,129 1,052 
Less: Accumulated depreciation(44,970)(39,899)
Property and equipment, net of accumulated depreciation and amortization$72,884 $67,743 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.2
Current Liabilities (Tables)
 6 Months Ended
Jun. 30, 2023
Payables and Accruals [Abstract]  
Schedule of Current Liabilities
The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:
June 30, 2023December 31, 2022
Accrued trade payables $2,735 $2,254 
Accrued commissions payable737 608 
Accrued bonuses payable4,329 3,708 
Accrued vacation and payroll2,450 1,484 
Current portion of phantom share liability 1,483 1,704 
Purchase price payable1,376 — 
Accrued other liabilities2,399 1,334 
Total accrued liabilities$15,509 $11,092 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.2
Debt (Tables)
 6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Notes Payable
The recorded balances associated with the 2022 Senior Credit Facilities are as follows:
June 30, 2023December 31, 2022
Outstanding balance$13,000 $— 
Financing costs and commitment fees(748)— 
Less:
Current portion of notes payable(250)— 
Net long-term notes payable$12,002 $— 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurement (Tables)
 6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured on Recurring Basis
The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:
At June 30, 2023
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$2,078 $— $— $2,078 
  Available for sale debt instrument— — 2,110 2,110 
Total$2,078 $— $2,110 $4,188 

At December 31, 2022
(In thousands)Level 1Level 2Level 3Total
Recurring Fair Value Measurements:
  Money market mutual funds$11,005 $— $— $11,005 
  Available for sale debt instrument$— $— $2,000 $2,000 
Total$11,005 $— $2,000 $13,005 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Tables)
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense
The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Stock-based compensation - options$301 $757 $649 $1,577 
Stock-based compensation - restricted stock units1,170 514 2,213 999 
Total$1,471 $1,271 $2,862 $2,576 
The following table summarizes expense (benefit) associated with the phantom share units for the three and six months ended June 30, 2023 and 2022 (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Selling, general, and administrative$687 $538 $1,837 $949 
Schedule of Option Activity
The following table summarizes stock option activity for the six months ended June 30, 2023:
Number of options
 (000's)
Weighted average exercise price(1)
Weighted average remaining contractual life
Aggregate intrinsic value(2)
Balance December 31, 20224,497 $5.26 6.9 years$11,356 
Issued— — 
Exercised(228)5.51 
Expired / Forfeited(25)6.47 
Balance June 30, 20234,244 $5.24 6.4 years$19,290 
(1)For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.
(2)The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing share price of the Company's common stock on the last trading day of the period ($9.78).
Schedule of Restricted Stock Units
The following table summarizes RSU activity for the six months ended June 30, 2023:
Number of RSUs (000's)Weighted average grant priceWeighted average remaining contractual life
Aggregate intrinsic value(1)
Balance December 31, 2022629 $5.62 0.88 years$4,755 
Issued702 7.87 
Vested(190)5.56 
Expired / Forfeited(18)6.70 
Balance June 30, 20231,123 $7.02 1.26 years$10,986 
(1)The aggregate intrinsic value of time-based RSUs outstanding was based on the Company's closing stock price on the last trading day of the period ($9.78).
Schedule of Phantom Share Units
The following table summarizes phantom share unit activity for the six months ended June 30, 2023:
Number of phantom share units (000's)
Value of share equivalents(1)
Balance December 31, 2022513 $3,878 
Issued176 1,401 
Vested(239)(578)
Expired / Forfeited(20)(196)
Balance June 30, 2023430 $4,200 
(1)The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s stock at that time, the value of issued share equivalents is based on the market price of the Company’s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $9.78 on June 30, 2023.
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share (Tables)
 6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share
The following reflects the earnings and share data used in the basic and diluted earnings per share computations:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Numerator - basic and diluted:
Net income attributable to shareholders$2,330 $967 $3,847 $2,729 
Denominator:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 
Basic earnings per share$0.06 $0.02 $0.10 $0.07 
Diluted earnings per share$0.06 $0.02 $0.10 $0.07 
Denominator calculation from basic to diluted:
Basic weighted-average number of common shares38,324,249 38,773,580 38,240,902 39,195,317 
Stock options and other dilutive securities2,352,702 979,348 2,142,714 861,636 
Diluted weighted-average number of shares40,676,951 39,752,928 40,383,616 40,056,953 
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.2
Nature of Business and Operations (Details)
Jun. 30, 2023
state
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Number of states in which entity provides DME and health care solutions 50
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Accounts Receivable, Allowance for Credit Loss [Roll Forward]    
Balance, beginning of year $ 8,483 $ 7,031
Provision for uncollectible accounts 7,579 6,300
Amounts charged off (5,055) (3,948)
Balance, end of period $ 11,007 $ 9,383
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Customer Percentages) (Details) - Customer Concentration
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Total Medicare and Medicaid | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     41.00%   48.00%
Total Medicare and Medicaid | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 53.00% 55.00% 54.00% 56.00%  
Medicare revenues | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     35.00%    
Medicare revenues | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 44.00% 46.00% 45.00% 47.00%  
Medicaid revenues | Accounts Receivable          
Concentration Risk [Line Items]          
Concentration risk, percentage     6.00%    
Medicaid revenues | Revenue          
Concentration Risk [Line Items]          
Concentration risk, percentage 9.00% 9.00% 9.00% 9.00%  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Equity Investments) (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Equity investments $ 595 $ 816
Other equity investments 1,347 1,339
Balance, end of period $ 1,942 $ 2,155
Solvet Services LLC    
Schedule of Investments [Line Items]    
Equity method investment, ownership percentage 49.00%  
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Revenue Recognition) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total revenues $ 43,311 $ 33,310 $ 82,867 $ 65,565
Ventilator rentals, non-invasive and invasive        
Disaggregation of Revenue [Line Items]        
Revenue from rentals under Topic 842 25,712 22,736 50,859 44,254
Other durable medical equipment rentals        
Disaggregation of Revenue [Line Items]        
Revenue from rentals under Topic 842 8,419 4,912 15,325 9,271
Equipment and supply sales        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 6,778 3,245 11,542 6,282
COVID-19 response sales and services        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 0 183 0 2,278
Service revenues        
Disaggregation of Revenue [Line Items]        
Revenue from sales and services under Topic 606 $ 2,402 $ 2,234 $ 5,141 $ 3,480
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (Interest Rate Swaps) (Details)
$ in Millions
 12 Months Ended
Dec. 31, 2022
USD ($)
Interest Rate  
New Accounting Pronouncements or Change in Accounting Principle [Line Items]  
Derivative, gain on derivative $ 0.2
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Summary of Significant Accounting Policies (CARES Act Funds Received) (Details) - USD ($)
$ in Millions
 1 Months Ended
Jan. 31, 2022
Nov. 30, 2021
Apr. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]      
Government grant received     $ 3.5
Proceeds from targeted distribution payment   $ 1.5  
Proceeds from general distribution payment $ 0.4    
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combinations - Narrative (Details) - Home Medical Products Inc - USD ($)
$ in Thousands
 6 Months Ended
Jun. 01, 2023
Jun. 30, 2023
Business Acquisition [Line Items]    
Business acquisition, percentage of voting interests acquired 100.00%  
Cash paid or payable $ 29,417  
Purchase consideration funded by cash on hand 15,000  
Acquisition related costs expensed   $ 254
Fair value of accounts receivables acquired 2,000  
Gross contractual amount 2,900  
Estimate of uncollectible receivables 900  
Revolving Credit Facility | Line of Credit | 5 Year Revolving Credit Facility    
Business Acquisition [Line Items]    
Consideration funded by borrowings 8,000  
Term Loan Facility | Line of Credit | Delayed Draw Term Loan Facility    
Business Acquisition [Line Items]    
Consideration funded by borrowings $ 5,000  
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details) - USD ($)
$ in Thousands
Jun. 01, 2023
Jun. 30, 2023
Dec. 31, 2022
Identifiable Liabilities      
Goodwill   $ 29,759 $ 0
Home Medical Products Inc      
Business Acquisition [Line Items]      
Cash paid or payable $ 29,417    
Identifiable Assets      
Cash and cash equivalents 921    
Accounts receivable 2,014    
Inventory 582    
Prepaid expenses and other assets 535    
Property and equipment, net 4,358    
Lease assets 743    
Identifiable intangibles, net 688    
Other long-term assets 25    
TOTAL ASSETS 9,866    
Identifiable Liabilities      
Trade payables 2,144    
Deferred revenue 732    
Accrued liabilities 1,195    
Current portion of lease liabilities 536    
Current debt 4,558    
Long-term lease liabilities 207    
Long-term debt 836    
TOTAL LIABILITIES 10,208    
Net assets (liabilities) acquired (342)    
Goodwill $ 29,759    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Schedule of Fixed Assets) (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]    
Less: Accumulated depreciation $ (44,970) $ (39,899)
Property and equipment, net of accumulated depreciation and amortization 72,884 67,743
Medical equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 103,571 93,893
Furniture and equipment    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 3,115 2,792
Land    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 2,566 2,566
Buildings    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 7,129 7,043
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross 344 296
Vehicles    
Property, Plant and Equipment [Line Items]    
Property and equipment, gross $ 1,129 $ 1,052
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.2
Property and Equipment (Narrative) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Depreciation $ 4,908 $ 3,497 $ 9,430 $ 6,656  
Medical equipment          
Property, Plant and Equipment [Line Items]          
Accounts payable     $ 2,526   $ 738
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.2
Current Liabilities (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Accrued trade payables $ 2,735 $ 2,254
Accrued commissions payable 737 608
Accrued bonuses payable 4,329 3,708
Accrued vacation and payroll 2,450 1,484
Current portion of phantom share liability 1,483 1,704
Purchase price payable 1,376 0
Accrued other liabilities 2,399 1,334
Total accrued liabilities $ 15,509 $ 11,092
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.2
Debt (Senior Credit Facilities) (Details)
 6 Months Ended
Nov. 29, 2022
USD ($)
Jun. 30, 2023
USD ($)
Jun. 01, 2023
Sep. 19, 2019
USD ($)
May 30, 2019
USD ($)
Building Term Note | Notes Payable          
Debt Instrument [Line Items]          
Principal amount         $ 4,800,000
Building Term Note | Notes Payable | Interest Rate          
Debt Instrument [Line Items]          
Fixed interest rate (percent)         4.68%
2019 Term Note | Notes Payable          
Debt Instrument [Line Items]          
Principal amount       $ 5,000,000  
Stated interest rate (percent)       4.60%  
Equipment Financing Obligations          
Debt Instrument [Line Items]          
Short-term debt   $ 3,000,000      
Long-term debt   $ 100,000      
Equipment Financing Obligations | Minimum          
Debt Instrument [Line Items]          
Stated interest rate (percent)     0.00%    
Equipment Financing Obligations | Maximum          
Debt Instrument [Line Items]          
Stated interest rate (percent)     7.99%    
Line of Credit | 2018 Senior Credit Facility          
Debt Instrument [Line Items]          
Maximum borrowing capacity $ 10,000,000        
Revolving Credit Facility | 2019 Term Note | Line of Credit          
Debt Instrument [Line Items]          
Fixed charge coverage ratio   1.25      
Revolving Credit Facility | 2022 Senior Credit Facilities          
Debt Instrument [Line Items]          
Maximum borrowing capacity   $ 30,000,000      
Revolving Credit Facility | 2022 Senior Credit Facilities | Line of Credit          
Debt Instrument [Line Items]          
Maximum borrowing capacity 30,000,000        
Revolving Credit Facility | 2022 Senior Credit Facilities | Line of Credit | 2022 Senior Credit Facilities Closing Date Of December 31 2024          
Debt Instrument [Line Items]          
Total leverage ratio   2.75      
Revolving Credit Facility | 2022 Senior Credit Facilities | Line of Credit | 2022 Senior Credit Facilities Closing Date Of March 31 2025          
Debt Instrument [Line Items]          
Total leverage ratio   2.50      
Revolving Credit Facility | 2022 Senior Credit Facilities | Notes Payable          
Debt Instrument [Line Items]          
Maximum borrowing capacity $ 30,000,000        
Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | 2022 Senior Credit Facilities | Line of Credit | Minimum          
Debt Instrument [Line Items]          
Basis spread on variable rate (percent) 2.625%        
Revolving Credit Facility | Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | 2022 Senior Credit Facilities | Line of Credit | Maximum          
Debt Instrument [Line Items]          
Basis spread on variable rate (percent) 3.375%        
Revolving Credit Facility | Base Rate | 2022 Senior Credit Facilities | Line of Credit | Minimum          
Debt Instrument [Line Items]          
Basis spread on variable rate (percent) 1.625%        
Revolving Credit Facility | Base Rate | 2022 Senior Credit Facilities | Line of Credit | Maximum          
Debt Instrument [Line Items]          
Basis spread on variable rate (percent) 2.375%        
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.2
Debt (Schedule of Notes Payable) (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Debt Instrument [Line Items]    
Current portion of notes payable $ (3,169) $ 0
Net long-term notes payable 12,114 0
Notes Payable    
Debt Instrument [Line Items]    
Outstanding balance 13,000 0
Financing costs and commitment fees (748) 0
Current portion of notes payable (250) 0
Net long-term notes payable $ 12,002 $ 0
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.2
Fair Value Measurement (Recurring Basis) (Details) - Fair Value, Recurring - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Available for sale debt instrument $ 2,110 $ 2,000
Total 4,188 13,005
Money Market Funds    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 2,078 11,005
Fair Value, Inputs, Level 1    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Available for sale debt instrument 0 0
Total 2,078 11,005
Fair Value, Inputs, Level 1 | Money Market Funds    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 2,078 11,005
Fair Value, Inputs, Level 2    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Available for sale debt instrument 0 0
Total 0 0
Fair Value, Inputs, Level 2 | Money Market Funds    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds 0 0
Fair Value, Inputs, Level 3    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Available for sale debt instrument 2,110 2,000
Total 2,110 2,000
Fair Value, Inputs, Level 3 | Money Market Funds    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Money market mutual funds $ 0 $ 0
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Issued and Outstanding Share Capital) (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Mar. 31, 2022
Jun. 30, 2023
Dec. 31, 2022
Jun. 30, 2022
Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Issued (in shares) 38,400,422     38,400,422 38,049,739    
Shares outstanding (in shares) 38,400,422     38,400,422 38,049,739    
Common Stock              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares outstanding (in shares) 38,400,422 38,276,389 39,293,778 38,400,422 38,049,739 38,333,089 39,640,388
Shares redeemed to pay income tax (in shares) 1,978 64,756 23,742 66,734      
Shares redeemed to pay income tax       $ 0.5      
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Stock-based Compensation) (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 11, 2020
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Options outstanding (in shares)   4,244,000   4,244,000   4,497,000
Stock-based compensation, expense   $ 1,471 $ 1,271 $ 2,862 $ 2,576  
Unrecognized pre-tax stock option expense   889   $ 889    
Weighted-average period of recognition       1 year 3 months 25 days    
Omnibus Plan            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Maximum shares in Plan (in shares) 7,758,211          
Percent of issued and outstanding shares 20.00%          
Omnibus Plan | Common Stock            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Maximum shares in Plan (in shares) 2,600,000          
Options            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
Stock-based compensation, expense   $ 301 757 $ 649 1,577  
Restricted Stock Units            
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]            
RSUs outstanding (in shares)   1,123,000   1,123,000   629,000
Stock-based compensation, expense   $ 1,170 $ 514 $ 2,213 $ 999  
Weighted-average period of recognition       1 year 3 months 3 days    
Unrecognized pre-tax compensation expense, restricted stock units   $ 4,780   $ 4,780    
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Options, Stock Option Activity) (Details)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
USD ($)
$ / shares
shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Number of options (000's)    
Beginning balance (in shares) | shares 4,497,000  
Issued (in shares) | shares 0  
Exercised (in shares) | shares (228,000)  
Expired / Forfeited (in shares) | shares (25,000)  
Ending balance (in shares) | shares 4,244,000 4,497,000
Weighted average exercise price    
Beginning balance (USD per share) $ 5.26  
Issued (USD per share) 0  
Exercised (USD per share) 5.51  
Expired / Forfeited (USD per share) 6.47  
Ending balance (USD per share) $ 5.24 $ 5.26
Weighted average remaining contractual life    
Weighted average remaining contractual life 6 years 4 months 24 days 6 years 10 months 24 days
Aggregate Intrinsic Value    
Aggregate intrinsic value | $ $ 19,290,197 $ 11,356,000
Share price (USD per share) $ 9.78  
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Options, Narrative) (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Aggregate intrinsic value, outstanding $ 19,290,197 $ 11,356,000
Aggregate intrinsic value, exercisable $ 16,579,787  
Common stock issued pursuant to stock options (in shares) 228,000  
Exercisable (in shares) 3,415,000 2,841,000
Weighted average exercise price (USD per share) $ 4.93 $ 4.53
Weighted average remaining contractual term 6 years 6 years 1 month 6 days
Issued (in shares) 0  
Common Stock    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Common stock issued pursuant to stock options (in shares) 228,000  
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Restricted Stock Units) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2023
Dec. 31, 2022
Aggregate Intrinsic Value      
Share price (USD per share) $ 9.78 $ 9.78  
Restricted Stock Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   3 years  
Number of RSUs (000's)      
Beginning balance (in shares)   629,000  
Issued (in shares) 0 702,206  
Vested (in shares)   (190,000)  
Expired / Forfeited (in shares)   (18,000)  
Ending balance (in shares) 1,123,000 1,123,000 629,000
Weighted average grant price      
Beginning balance (USD per share)   $ 5.62  
Issued (USD per share)   7.87  
Vested (USD per share)   5.56  
Expired / Forfeited (USD per share)   6.70  
Ending balance (USD per share) $ 7.02 $ 7.02 $ 5.62
Weighted average remaining contractual life      
Weighted average remaining contractual life   1 year 3 months 3 days 10 months 17 days
Aggregate Intrinsic Value      
Aggregate Intrinsic Value $ 10,986 $ 10,986 $ 4,755
Fair value   $ 5,600  
Restricted Stock Units | Minimum      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   1 year  
Phantom Share Units      
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]      
Vesting period   3 years  
Number of RSUs (000's)      
Beginning balance (in shares)   513,000  
Issued (in shares)   176,000  
Vested (in shares)   (239,000)  
Expired / Forfeited (in shares)   (20,000)  
Ending balance (in shares) 430,000 430,000 513,000
Aggregate Intrinsic Value      
Aggregate Intrinsic Value $ 4,200 $ 4,200 $ 3,878
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Shareholders' Equity (Phantom Share Units) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Value of share equivalents          
Share price (USD per share) $ 9.78   $ 9.78    
Current accrued liabilities $ 1,483   $ 1,483   $ 1,704
Stock-based compensation $ 1,471 $ 1,271 $ 2,862 $ 2,576  
Phantom Share Units          
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]          
Vesting period     3 years    
Number of phantom share units (000's)          
Beginning balance (in shares)     513    
Issued (in shares)     176    
Vested (in shares)     (239)    
Expired / Forfeited (in shares)     (20)    
Ending balance (in shares) 430   430    
Value of share equivalents          
Beginning balance     $ 3,878    
Issued     1,401    
Vested     (578)    
Expired / Forfeited     (196)    
Ending balance $ 4,200   4,200    
Total liability 2,120   2,120    
Current accrued liabilities 1,483   1,483    
Long-term accrued liabilities 637   637    
Cash settlement     2,309 1,389  
Phantom Share Units | Selling, general, and administrative          
Value of share equivalents          
Stock-based compensation $ 687 $ 538 $ 1,837 $ 949  
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Commitments and Contingencies (Details)
$ in Millions
Dec. 28, 2020
USD ($)
Jun. 30, 2023
USD ($)
Nov. 30, 2021
USD ($)
May 31, 2021
patient
Mar. 31, 2020
USD ($)
Commitments and Contingencies Disclosure [Abstract]          
Purchase obligation         $ 1.4
Damages sought $ 4.7        
Outstanding deposit   $ 0.9      
Number of patients | patient       100  
Necessary claims reviewed and payable (percent)     77.00%    
Recalculated principal overpayment request     $ 1.1    
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.2
Income Taxes (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 728 $ 421 $ 1,229 $ 1,166
Discrete income tax benefit     $ 100  
Effective tax rate     28.60%  
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]            
Net income attributable to shareholders $ 2,330 $ 1,517 $ 967 $ 1,762 $ 3,847 $ 2,729
Denominator:            
Basic weighted-average number of common shares (in shares) 38,324,249   38,773,580   38,240,902 39,195,317
Diluted weighted-average number of shares (in shares) 40,676,951   39,752,928   40,383,616 40,056,953
Basic earnings per share (in dollars per share) $ 0.06   $ 0.02   $ 0.10 $ 0.07
Diluted earnings per share (in dollars per share) $ 0.06   $ 0.02   $ 0.10 $ 0.07
Denominator calculation from basic to diluted:            
Basic weighted-average number of common shares (in shares) 38,324,249   38,773,580   38,240,902 39,195,317
Stock options and other dilutive securities (in shares) 2,352,702   979,348   2,142,714 861,636
Diluted weighted-average number of shares (in shares) 40,676,951   39,752,928   40,383,616 40,056,953
XML 62 vmd-20230630_htm.xml IDEA: XBRL DOCUMENT 0001729149 2023-01-01 2023-06-30 0001729149 2023-07-20 0001729149 2023-06-30 0001729149 2022-12-31 0001729149 2023-04-01 2023-06-30 0001729149 2022-04-01 2022-06-30 0001729149 2022-01-01 2022-06-30 0001729149 us-gaap:CommonStockMember 2021-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001729149 us-gaap:RetainedEarningsMember 2021-12-31 0001729149 2021-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001729149 2022-01-01 2022-03-31 0001729149 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001729149 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001729149 us-gaap:CommonStockMember 2022-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001729149 us-gaap:RetainedEarningsMember 2022-03-31 0001729149 2022-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001729149 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001729149 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001729149 us-gaap:CommonStockMember 2022-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001729149 us-gaap:RetainedEarningsMember 2022-06-30 0001729149 2022-06-30 0001729149 us-gaap:CommonStockMember 2022-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001729149 us-gaap:RetainedEarningsMember 2022-12-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001729149 2023-01-01 2023-03-31 0001729149 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001729149 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001729149 us-gaap:CommonStockMember 2023-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001729149 us-gaap:RetainedEarningsMember 2023-03-31 0001729149 2023-03-31 0001729149 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001729149 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001729149 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001729149 us-gaap:CommonStockMember 2023-06-30 0001729149 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001729149 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001729149 us-gaap:RetainedEarningsMember 2023-06-30 0001729149 vmd:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicareMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-04-01 2023-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-04-01 2022-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001729149 vmd:MedicareAndMedicaidMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001729149 vmd:SolvetServicesLLCMember 2023-06-30 0001729149 vmd:VentilatorRentalMember 2023-04-01 2023-06-30 0001729149 vmd:VentilatorRentalMember 2022-04-01 2022-06-30 0001729149 vmd:VentilatorRentalMember 2023-01-01 2023-06-30 0001729149 vmd:VentilatorRentalMember 2022-01-01 2022-06-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2023-04-01 2023-06-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2022-04-01 2022-06-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2023-01-01 2023-06-30 0001729149 vmd:OtherDurableMedicalEquipmentRentalsMember 2022-01-01 2022-06-30 0001729149 vmd:EquipmentSalesMember 2023-04-01 2023-06-30 0001729149 vmd:EquipmentSalesMember 2022-04-01 2022-06-30 0001729149 vmd:EquipmentSalesMember 2023-01-01 2023-06-30 0001729149 vmd:EquipmentSalesMember 2022-01-01 2022-06-30 0001729149 vmd:COVID19ResponseSalesMember 2023-04-01 2023-06-30 0001729149 vmd:COVID19ResponseSalesMember 2022-04-01 2022-06-30 0001729149 vmd:COVID19ResponseSalesMember 2023-01-01 2023-06-30 0001729149 vmd:COVID19ResponseSalesMember 2022-01-01 2022-06-30 0001729149 us-gaap:ServiceMember 2023-04-01 2023-06-30 0001729149 us-gaap:ServiceMember 2022-04-01 2022-06-30 0001729149 us-gaap:ServiceMember 2023-01-01 2023-06-30 0001729149 us-gaap:ServiceMember 2022-01-01 2022-06-30 0001729149 us-gaap:InterestRateSwapMember 2022-01-01 2022-12-31 0001729149 2020-04-01 2020-04-30 0001729149 2021-11-01 2021-11-30 0001729149 2022-01-01 2022-01-31 0001729149 vmd:HomeMedicalProductsIncMember 2023-06-01 0001729149 vmd:HomeMedicalProductsIncMember 2023-06-01 2023-06-01 0001729149 vmd:HomeMedicalProductsIncMember us-gaap:RevolvingCreditFacilityMember vmd:A5YearRevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2023-06-01 2023-06-01 0001729149 vmd:HomeMedicalProductsIncMember vmd:TermLoanFacilityMember vmd:DelayedDrawTermLoanFacilityMember us-gaap:LineOfCreditMember 2023-06-01 2023-06-01 0001729149 vmd:HomeMedicalProductsIncMember 2023-01-01 2023-06-30 0001729149 vmd:EquipmentMedicalMember 2023-06-30 0001729149 vmd:EquipmentMedicalMember 2022-12-31 0001729149 vmd:FurnitureAndEquipmentMember 2023-06-30 0001729149 vmd:FurnitureAndEquipmentMember 2022-12-31 0001729149 us-gaap:LandMember 2023-06-30 0001729149 us-gaap:LandMember 2022-12-31 0001729149 us-gaap:BuildingMember 2023-06-30 0001729149 us-gaap:BuildingMember 2022-12-31 0001729149 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001729149 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001729149 us-gaap:VehiclesMember 2023-06-30 0001729149 us-gaap:VehiclesMember 2022-12-31 0001729149 vmd:EquipmentMedicalMember 2023-01-01 2023-06-30 0001729149 vmd:EquipmentMedicalMember 2022-01-01 2022-12-31 0001729149 us-gaap:LineOfCreditMember vmd:A2018SeniorCreditFacilityMember 2022-11-29 0001729149 vmd:BuildingTermNoteMember us-gaap:NotesPayableToBanksMember 2019-05-30 0001729149 vmd:BuildingTermNoteMember us-gaap:InterestRateSwapMember us-gaap:NotesPayableToBanksMember 2019-05-30 0001729149 vmd:A2019TermNoteMember us-gaap:NotesPayableToBanksMember 2019-09-19 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember 2022-11-29 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:NotesPayableToBanksMember 2022-11-29 0001729149 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-11-29 2022-11-29 0001729149 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-11-29 2022-11-29 0001729149 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-11-29 2022-11-29 0001729149 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-11-29 2022-11-29 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember vmd:A2022SeniorCreditFacilitiesClosingDateOfDecember312024Member 2023-01-01 2023-06-30 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember us-gaap:LineOfCreditMember vmd:A2022SeniorCreditFacilitiesClosingDateOfMarch312025Member 2023-01-01 2023-06-30 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2019TermNoteMember us-gaap:LineOfCreditMember 2023-01-01 2023-06-30 0001729149 us-gaap:RevolvingCreditFacilityMember vmd:A2022SeniorCreditFacilitiesMember 2023-06-30 0001729149 us-gaap:NotesPayableToBanksMember 2023-06-30 0001729149 us-gaap:NotesPayableToBanksMember 2022-12-31 0001729149 srt:MinimumMember vmd:EquipmentFinancingObligationMember 2023-06-01 0001729149 srt:MaximumMember vmd:EquipmentFinancingObligationMember 2023-06-01 0001729149 vmd:EquipmentFinancingObligationMember 2023-06-30 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001729149 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001729149 vmd:OmnibusPlanMember 2020-06-11 0001729149 vmd:OmnibusPlanMember 2020-06-11 2020-06-11 0001729149 vmd:OmnibusPlanMember us-gaap:CommonStockMember 2020-06-11 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2023-06-30 0001729149 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0001729149 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001729149 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001729149 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001729149 2022-01-01 2022-12-31 0001729149 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001729149 srt:MinimumMember us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-06-30 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001729149 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-12-31 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2023-01-01 2023-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2022-12-31 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2023-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-04-01 2022-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-06-30 0001729149 us-gaap:PhantomShareUnitsPSUsMember 2022-01-01 2022-06-30 0001729149 2020-03-31 0001729149 2020-12-28 2020-12-28 0001729149 2021-05-31 0001729149 2021-11-30 shares iso4217:USD iso4217:USD shares vmd:state pure vmd:patient 0001729149 false 2023 Q2 --12-31 P1Y P3Y 10-Q true 2023-06-30 false 001-38973 Viemed Healthcare, Inc. Z4 625 E. Kaliste Saloom Rd. Lafayette LA 70508 337 504-3802 Common Shares, no par value VMD NASDAQ Yes Yes Accelerated Filer true true false false false 38400422 10224000 16914000 17893000 15379000 4476000 3574000 1029000 26000 2327000 3849000 35949000 39742000 72884000 67743000 538000 0 516000 694000 1942000 2155000 2110000 2000000 3844000 3119000 688000 0 29759000 0 887000 1590000 113168000 77301000 149117000 117043000 6167000 2650000 5960000 4624000 15509000 11092000 375000 0 395000 495000 3169000 0 31575000 18861000 637000 889000 143000 0 143000 199000 12114000 0 13037000 1088000 44612000 19949000 0 0 38400422 38400422 38049739 38049739 17850000 15123000 13488000 12125000 73167000 69846000 104505000 97094000 149117000 117043000 43311000 33310000 82867000 65565000 17205000 12920000 32757000 25432000 26106000 20390000 50110000 40133000 20563000 17536000 40325000 33312000 758000 672000 1538000 1304000 1471000 1271000 2862000 2576000 298000 243000 538000 480000 -117000 110000 -95000 124000 2000 223000 83000 664000 2901000 1001000 4835000 3249000 137000 446000 172000 769000 20000 -59000 69000 -123000 3058000 1388000 5076000 3895000 728000 421000 1229000 1166000 2330000 967000 3847000 2729000 0 59000 0 222000 0 59000 0 222000 2330000 1026000 3847000 2951000 0.06 0.02 0.10 0.07 0.06 0.02 0.10 0.07 38324249 38773580 38240902 39195317 40676951 39752928 40383616 40056953 39640388 14014000 7749000 -278000 73335000 94820000 820000 820000 485000 485000 67010 334000 -334000 0 23742 119000 119000 389878 1887000 1887000 163000 163000 1762000 1762000 39293778 14348000 8720000 -115000 73091000 96044000 757000 757000 514000 514000 960689 5114000 5114000 59000 59000 967000 967000 38333089 14348000 9991000 -56000 68944000 93227000 38049739 15123000 12125000 0 69846000 97094000 348000 348000 1043000 1043000 108370 544000 544000 183036 1429000 -1429000 0 64756 505000 505000 1517000 1517000 38276389 17096000 12087000 0 70858000 100041000 301000 301000 1170000 1170000 119356 684000 684000 6655 70000 -70000 0 1978 21000 21000 2330000 2330000 38400422 17850000 13488000 0 73167000 104505000 3847000 2729000 9968000 7136000 0 -1418000 2862000 2576000 392000 612000 172000 769000 110000 0 -95000 124000 -725000 745000 500000 1464000 320000 -1022000 -2076000 634000 -488000 -243000 604000 649000 1593000 -87000 -1003000 1362000 18119000 12092000 10759000 10989000 7000 121000 27121000 0 1775000 615000 -36112000 -10495000 1228000 0 5000000 0 1357000 78000 8000000 0 1005000 872000 526000 119000 0 7001000 37000 13000 11303000 -8083000 -6690000 -6486000 16914000 28408000 10224000 21922000 169000 128000 3093000 -940000 748000 0 Nature of Business and Operations<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:107%">Viemed Healthcare, Inc. (the "Company"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute respiratory healthcare services in the United States. The Company’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. The Company currently serves patients in 50 states of the United States. The Company was incorporated under the Business Corporations Act (British Columbia) on December 14, 2016. The Company's registered and records office is located at Suite 2800, Park Place, 666 Burrard Street, Vancouver, British Columbia V6C 2Z7 and its corporate office is located at 625 E. Kaliste Saloom Road, Lafayette, Louisiana 70508.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an "emerging growth company," as defined in the Jumpstart Our Business Startups Act (the "JOBS Act") and a "smaller reporting company" under Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), and, as such, has elected to comply with certain reduced U.S. public company reporting requirements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s common shares are traded in the U.S. on the Nasdaq Capital Market under the symbol "VMD" and in Canada on the Toronto Stock Exchange under the symbol "VMD.TO".</span></div> 50 Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Principles of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Basis of Consolidation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">These consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure based on ASC 280, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, the Company's evaluation takes into consideration such factors as historical bad debt and billing modification experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.</span></div><div style="margin-bottom:0.1pt"><span><br/></span></div><div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and charge-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"><tr><td style="width:1.0%"></td><td style="width:46.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for uncollectible accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts charged off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,007</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,383</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Included in accounts receivable at June 30, 2023 are amounts due from Medicare and Medicaid representing 35% and 6%, respectively, and 41% combined, of total outstanding receivables. As of December 31, 2022, 48% of total outstanding receivables were amounts due from Medicare and Medicaid. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and six months ended June 30, 2023 and 2022 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Inventory</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity investments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s equity investments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:47.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,942</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's equity method investments include a 49% equity interest in Solvet Services, LLC, an entity which provides health care support services to state and federal governments. Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with any subsequent adjustments made to the carrying amount of the investment for the Company’s proportionate share of income or loss. Distributions received from the investee reduce the Company’s carrying value of the investment. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of June 30, 2023 that would impair the carrying value of equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other equity investments include an equity interest in VeruStat, Inc., a remote patient monitoring entity, and an equity interest in DMEscripts, LLC, an e-prescribing platform. Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2023 on its investments in equity securities without a readily determinable fair value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Debt Investment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's debt investment is a variable rate secured convertible note issued by Healthcare DX, Inc. (d/b/a ModoHealth) on December 21, 2022, classified as an available-for-sale debt instrument. Accrued interest is due upon the 18 month maturity of the note and is included in the amortized cost basis at each reporting period. At each financial statement date until a conversion event, the debt instrument is required to be remeasured at fair value. Changes in unrealized gains and losses are included in accumulated other comprehensive income, net of tax effect, until realized. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. During the three months ended June 30, 2023 the Company evaluated the events and changes that could indicate that goodwill might be impaired and concluded that an interim test was not necessary.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive income</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Comprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company's comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of sales and rentals of home medical equipment and patient medical services. Patient revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Patient revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (“CMS”). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, HME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with HME rentals, the Company recognizes revenue in accordance with FASB ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Leases,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any HME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Revenue from Contracts with Customers,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which varies based on the type of equipment rental, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues.</span></div><div style="margin-bottom:0.1pt;padding-left:27pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals under Topic 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services under Topic 606</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,310</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82,867</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases HME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date equipment is delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells HME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the HME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For staffing services, performance obligations in the staffing agreements are satisfied over time when the customer simultaneously receives and consumes the benefits provided. Accordingly, revenues from staffing services are recognized on an hourly basis as services are rendered by the job site employee in both principal and agent arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services, staffing services, or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of June 30, 2023.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation—Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilized an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the 2019 Term Note (as defined below). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognized any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, the Company settled its interest rate swap in connection with the refinancing of its credit facilities and recognized the realized gain of $0.2 million in Other Income. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous U.S. jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.</span></div><div style="padding-right:45pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Funds Received</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received a general distribution payment from the Provider Relief Fund of $3.5 million in April 2020, a targeted distribution payment of $1.5 million in November 2021, and a general distribution payment of $0.4 million in January 2022. The U.S. Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. There is no US GAAP guidance for for-profit health care entities that receive government grants that are not in the form of an income tax credit, revenue from a contract with a customer or a loan. As such, for-profit entities must determine the appropriate accounting treatment by analogy to other guidance such as International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, in International Financial Reporting Standards. Under IAS 20, the Company determined that upon receipt of funds, it fully complied with the conditions attached to the grant. The Company recognized the distributions received from the Provider Relief Fund in the income statement in full during the period of receipt. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. The Company is not aware of any such modifications as of June 30, 2023</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. While the adoption of ASC 326 could result in a higher allowance recorded in the future for credit losses on receivables within the scope of the standard due to the prescribed measurement principles, the impact of the adoption on the Company's consolidated financials statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, the Company's condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about their obligations that are outstanding at the end of the reporting period. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company does not expect the update to affect the recognition, measurement, or financial statement presentation of supplier finance program obligations, but is evaluating the impact of the update on related disclosures upon adoption.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Principles of Presentation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The accompanying condensed consolidated financial statements are unaudited, but reflect all adjustments consisting of normal recurring accruals, which, in the opinion of management, are necessary to present fairly the Company's Condensed Consolidated Balance Sheets, Condensed Consolidated Statements of Income and Comprehensive Income, Condensed Consolidated Statements of Changes in Shareholders’ Equity and Condensed Consolidated Statements of Cash Flows for the interim periods presented. The Company's fiscal year ends on December 31. The Condensed Consolidated Balance Sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto and the report of the Company's independent registered public accounting firm included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The nature of the Company's business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</span></div> Basis of ConsolidationThese consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions have been eliminated. Use of EstimatesThe preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Management bases these estimates and assumptions upon historical experience, existing and known circumstances, authoritative accounting pronouncements and other factors that management believes to be reasonable. Significant areas requiring the use of management estimates relate to revenue recognition, accounts receivable and the related allowance for doubtful accounts, income tax provisions, and fair value of financial instruments. Actual results could differ from these estimates. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s chief operating decision-makers ("CODMs") are its Chief Executive Officer and Chief Operating Officer, who make resource allocation decisions and assess performance based on financial information presented on an aggregate basis. There are no segment managers who are held accountable by the chief operating decision-makers, or anyone else, for any planning, strategy and key decision-making regarding operations. The corporate office is responsible for contract negotiation with vendors and payors, corporate compliance with healthcare laws and regulations, and revenue cycle management, among other corporate supporting functions. Accordingly, the Company has a single reportable segment and operating segment structure based on ASC 280, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Accounts receivable</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable are regularly reviewed for collectability and an allowance is recorded to cover the estimated bad debts and billing modifications. The accounts receivable are presented on the Condensed Consolidated Balance Sheets net of the allowance for doubtful accounts. It is possible that the estimates of the allowance for doubtful accounts could change, which could have a material impact on our operations and cash flows.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company writes off receivables when the likelihood for collection is remote, and when the Company believes collection efforts have been fully exhausted and it does not intend to devote additional resources in attempting to collect. The write-offs are charged against the allowance for doubtful accounts.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, the Company's evaluation takes into consideration such factors as historical bad debt and billing modification experience, national and local economic trends and conditions, industry and regulatory conditions, other collection indicators and information about disaggregated receivables. The complexity of many third-party billing arrangements, patient qualification for medical necessity of equipment and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded.</span></div> <div style="margin-bottom:0.1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The estimates and charge-offs for the allowance for doubtful accounts for each reporting period were as follows:</span></div><div style="margin-bottom:0.1pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.568%"><tr><td style="width:1.0%"></td><td style="width:46.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.304%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,483 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,031 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for uncollectible accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts charged off</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,055)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,948)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,007</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">9,383</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8483000 7031000 7579000 6300000 5055000 3948000 11007000 9383000 0.35 0.06 0.41 0.48 <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenues from Medicare and Medicaid as percentages of the Company's traditional revenue streams, excluding COVID-19 response sales and services, for the three and six months ended June 30, 2023 and 2022 were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare revenues</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Medicare and Medicaid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">53</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">55</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">54</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">56</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr></table></div> 0.44 0.46 0.45 0.47 0.09 0.09 0.09 0.09 0.53 0.55 0.54 0.56 InventoryInventory represents non-serialized supplies that consist of equipment parts, consumables, and associated product supplies and is expensed at the time of sale or use. The Company values inventory at the lower of cost or net realizable value. Obsolete and unserviceable inventories are valued at estimated net realizable value. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Property and equipment</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment is presented on the Condensed Consolidated Balance Sheets at historic cost less accumulated depreciation. Major renewals and improvements that extend the useful life of assets are capitalized to the respective property accounts, while maintenance and repairs, which do not extend the useful life of the respective assets, are expensed as incurred. Management has estimated the useful lives of equipment leased to customers. Depreciation is computed using the straight-line method over the estimated useful lives of the respective assets. Property and equipment are amortized on a straight-line basis over their estimated useful lives. </span></div>Depreciation of medical equipment commences at the date of service, which represents the date that the asset has been delivered to a patient and is put in use and continues through the useful life of the asset. Property and equipment with definite useful lives are tested for impairment whenever events or changes in circumstances indicate that their carrying amount may not be recoverable. <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Equity investments</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Equity investments on the Condensed Consolidated Balance Sheets are comprised of an investment accounted for under the equity method and equity investments without readily determinable fair values accounted for under the measurement alternative described in ASC 321-10-35-2.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's equity method investments include a 49% equity interest in Solvet Services, LLC, an entity which provides health care support services to state and federal governments. Investments accounted for under the equity method are investments in unconsolidated entities over whose operating and financial policies the Company has the ability to exercise significant influence but not control. Equity method investments are initially measured at cost in the Condensed Consolidated Balance Sheets with any subsequent adjustments made to the carrying amount of the investment for the Company’s proportionate share of income or loss. Distributions received from the investee reduce the Company’s carrying value of the investment. The Company has recognized its share of income or loss on the gain (loss) from equity method investments within non-operating expenses in the Condensed Consolidated Statements of Income. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. No events or changes have occurred as of June 30, 2023 that would impair the carrying value of equity method investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other equity investments include an equity interest in VeruStat, Inc., a remote patient monitoring entity, and an equity interest in DMEscripts, LLC, an e-prescribing platform. Other equity investments are investments without a readily determinable fair value which do not qualify for the practical expedient in ASC 820. For these investments, the Company has elected the measurement alternative which measures the investment at cost, less any impairment. ASU 2019-04 clarifies that if an entity identifies observable price changes in orderly transactions for the identical or a similar investment of the same issuer, it must measure its equity investment at fair value in accordance with ASC 820 as of the date that the observable transaction occurred. The Company was not aware of any impairment or observable price change adjustments that needed to be made as of June 30, 2023 on its investments in equity securities without a readily determinable fair value.</span></div> <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s equity investments:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.172%"><tr><td style="width:1.0%"></td><td style="width:47.645%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity method investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">816 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other equity investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,347 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,942</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,155</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 595000 816000 1347000 1339000 1942000 2155000 0.49 Debt InvestmentThe Company's debt investment is a variable rate secured convertible note issued by Healthcare DX, Inc. (d/b/a ModoHealth) on December 21, 2022, classified as an available-for-sale debt instrument. Accrued interest is due upon the 18 month maturity of the note and is included in the amortized cost basis at each reporting period. At each financial statement date until a conversion event, the debt instrument is required to be remeasured at fair value. Changes in unrealized gains and losses are included in accumulated other comprehensive income, net of tax effect, until realized. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Goodwill</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Goodwill resulting from business combinations is not amortized, rather, it is assessed for impairment annually and upon the occurrence of a triggering event or change in circumstances indicating a possible impairment. Such triggering events potentially warranting an annual or interim goodwill impairment assessment include, among other factors, declines in historical or projected revenue, operating income or cash flows, and sustained decreases in the Company’s stock price or market capitalization. Such changes in circumstance can include, among others, changes in the legal environment, reimbursement environment, operating performance, and/or future prospects. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each year. The impairment assessment can be performed on either a quantitative or qualitative basis. The Company first assesses qualitative factors to determine whether it is necessary to perform a quantitative goodwill impairment analysis. If determined necessary, the Company applies the quantitative impairment test to identify and measure the amount of impairment, if any. Fair value determinations require considerable judgment and are sensitive to changes in underlying assumptions and factors, such as estimates of a reporting unit's fair value and judgment about impairment triggering events. As a result, there can be no assurance that the estimates and assumptions made for purposes of the annual or interim goodwill impairment test will prove to be accurate predictions of the future. During the three months ended June 30, 2023 the Company evaluated the events and changes that could indicate that goodwill might be impaired and concluded that an interim test was not necessary.</span></div> Comprehensive incomeComprehensive income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. The Company's comprehensive income represents net income adjusted for unrealized gains and losses on derivative instruments, net of tax. Accumulated other comprehensive loss is presented on the accompanying Condensed Consolidated Balance Sheets as a component of shareholders' equity. <div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue recognition</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue from a customer consists of sales and rentals of home medical equipment and patient medical services. Patient revenues are billed to and collections received from Medicare, Medicaid, third-party insurers, co-insurance and patient-pay. Patient revenue is recognized net of contractual adjustments and bad debt based on contractual arrangements with third-party payors, an evaluation of expected collections resulting from the analysis of current and past due accounts, past collection experience in relation to amounts billed and other relevant information. Contractual adjustments result from the differences between the rates charged for services and reimbursement rates paid by government-sponsored healthcare programs and insurance companies for such services. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company's contracts with customers often include multiple products and services, and the Company evaluates these arrangements to determine the unit of accounting for revenue recognition purposes based on whether the product or service is distinct from other products or services in the arrangement and should be accounted for as a separate performance obligation. A product or service is distinct if the customer can benefit from it on its own or together with other readily available resources and the Company's ability to transfer the goods or services is separately identifiable from other promises in the contractual arrangement with the customer (e.g. patient). Revenue is then allocated to each separately identifiable good or service based on the standalone price of the items underlying the performance obligations. Most of the Company’s products fall in the Medicare Fee-for-Service (“FFS”) program which is a payment model where services are unbundled and paid for separately. These services are paid based on a Medicare determined price that is publicly available on the website for the Centers for Medicare &amp; Medicaid Services (“CMS”). </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For commercial payors, HME companies must negotiate in-network pricing separately, though in general, the Company’s payors tend to benchmark their contract rates and coverage policies closely to those of Medicare.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company considers performance obligations for sales and rentals to be met when the customer receives the equipment, and revenue for rentals is recognized over time, over the respective rental period. For revenue associated with HME rentals, the Company recognizes revenue in accordance with FASB ASC 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Leases,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 842). For any HME sales and services, the Company recognizes revenue under FASB ASU 2014-09, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">“Revenue from Contracts with Customers,”</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> (Topic 606) and related amendments. </span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes equipment rental revenue over the non-cancelable lease term, which varies based on the type of equipment rental, less estimated adjustments, in accordance with Topic 842. The Company has separate contracts with each patient that are not subject to a master lease agreement with any third-party payor. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div>Revenues associated with external staffing services are accrued on an hourly basis and are recorded based on the determination of whether the Company is acting as a principal or an agent. In arrangements in which the Company manages customers' supplemental workforce needs utilizing its own network of healthcare professionals, the Company is determined to be a principal and includes the contractual gross billings in revenues with a corresponding increase to cost of revenues for worksite employee payroll costs associated with these services. Alternatively, when the Company acts as agent in the performance of workforce management, revenue is recorded based on contractually agreed upon fees or commissions with no associated cost of revenues. <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The revenues from each major source are summarized in the following table:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.127%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from rentals under Topic 842</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Ventilator rentals, non-invasive and invasive</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,712 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44,254 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    Other durable medical equipment rentals</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,419 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,912 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,271 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Revenue from sales and services under Topic 606</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">   </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> Equipment and supply sales</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,778 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,282 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">    COVID-19 response sales and services</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Service revenues</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,234 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,480 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total revenues</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">43,311</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">33,310</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">82,867</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">65,565</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 25712000 22736000 50859000 44254000 8419000 4912000 15325000 9271000 6778000 3245000 11542000 6282000 0 183000 0 2278000 2402000 2234000 5141000 3480000 43311000 33310000 82867000 65565000 <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 842</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company leases HME such as non-invasive and invasive ventilators, positive airway pressure ("PAP") machines, percussion vests, oxygen concentrator units and other small respiratory equipment to customers for a fixed monthly amount on a month-to-month basis. The customer generally has the right to cancel the lease at any time during the rental period. The Company accounts for these rentals as operating leases.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under FASB ASC Topic 842, the Company recognizes rental revenue on operating leases on a straight-line basis over the contractual lease term which varies based on the type of equipment rental. The lease term begins on the date equipment is delivered to patients, and revenues are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private commercial payors, and Medicaid. Certain customer co-payments are included in revenue when considered probable of payment, which is generally when paid.</span></div>Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial. <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Revenue Accounting under Topic 606</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company sells HME, replacement parts and supplies to customers and recognizes revenue based on contractual payment rates as determined by the payors at the point in time where control of the good or service is transferred through delivery to the customer. The customer and, if applicable, the payors are generally charged at the time that the product is sold. For sales of equipment previously placed in service, proceeds associated with these sales are recorded to gain (loss) on disposal of property and equipment.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company also provides sleep study services to customers and recognizes revenue when the sleep study results are complete, satisfying the performance obligation. In response to the COVID-19 pandemic, the Company began offering contact and vaccine tracing services, which revenues are recognized in the period in which the service has been provided. The transaction price on equipment sales, sleep studies and contact and vaccine tracing is the amount that the Company expects to receive in exchange for the goods and services provided. Due to the nature of the HME business, gross charges are retail charges and generally do not reflect what the Company is ultimately paid. As such, the transaction price is constrained for the difference between the gross charge and what is estimated to be collected from payors and from patients. The transaction price therefore is predominantly based on contractual payment rates as determined by the payors. The payment terms and conditions of customer contracts vary by customer type and the products and services offered.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For staffing services, performance obligations in the staffing agreements are satisfied over time when the customer simultaneously receives and consumes the benefits provided. Accordingly, revenues from staffing services are recognized on an hourly basis as services are rendered by the job site employee in both principal and agent arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company determines its estimates of contractual allowances and discounts based upon contractual agreements, its policies and historical experience. While the rates are fixed for the product or service with the customer and the payors, such amounts typically include co-payments, co-insurance and deductibles, which vary in amounts, and are due from the patient. The Company includes in the transaction price only the amount that the Company expects to be entitled, which is substantially all of the payor billings at contractual rates. The transaction price is initially constrained by the amount of customer co-payments, which are included in the transaction price when considered probable of payment and included in revenue if the product or service has already been provided to the customer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application or claim denial.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Returns and refunds are not accepted on equipment sales, sleep study services, staffing services, or contact and vaccine tracing services. The Company does not offer warranties to customers in excess of the manufacturer’s warranty. Any taxes due upon sale of the products or services are not recognized as revenue. The Company does not have any partially or unfilled performance obligations related to contracts with customers and as such, the Company has no contract liabilities as of June 30, 2023.</span></div> <div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for its stock-based compensation in accordance with ASC 718</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">, "Compensation—Stock Compensation"</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Stock–based compensation costs for stock options are determined at the grant date using the Black-Scholes option pricing model. Stock-based compensation costs for restricted stock units ("RSUs") are determined at the grant date based on the closing stock price. The expense of such stock-based compensation awards is recognized using the graded vesting attribution method over the vesting period and the offsetting credit is recorded as an increase in additional paid-in capital. Forfeitures are recorded as incurred. Any excess tax benefit or deficiency is recognized as a component of income taxes and within operating cash flows upon vesting of the share-based award. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the Company’s phantom share units settled in cash, the Company computes the fair value of the phantom share units using the closing price of the Company's stock at the end of each period and records a liability based on the percentage of requisite service.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Interest rate swaps</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company utilized an interest rate swap contract to reduce exposure to fluctuations in variable interest rates for future interest payments on the 2019 Term Note (as defined below). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For determining the fair value of the interest rate swap contract, the Company uses significant other observable market data or assumptions (Level 2 inputs) that market participants would use in pricing similar assets or liabilities, including assumptions about counterparty risk. These fair value estimates reflect an income approach based on the terms of the interest rate swap contract and inputs corroborated by observable market data including interest rate curves. The Company presents a positive ending period fair value of the interest rate swap contract in other long-term assets, as a component of long-term assets, and a negative ending period fair value of the interest rate swap contract in accrued liabilities, as a component of long-term liabilities on the Condensed Consolidated Balance Sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognized any differences between the variable interest rate payments and the fixed interest rate settlements from its swap counterparty as an adjustment to interest expense over the life of the swap. If determined to be an effective cash flow hedge, the Company will record the changes in the estimated fair value of the swaps to accumulated other comprehensive income or loss on the Condensed Consolidated Balance Sheets. To the extent that interest rate swaps are determined to be ineffective, the Company would recognize the changes in the estimated fair value of swaps in interest and other non-operating expenses, net in its Condensed Consolidated Statements of Income.</span></div>During the year ended December 31, 2022, the Company settled its interest rate swap in connection with the refinancing of its credit facilities and recognized the realized gain of $0.2 million in Other Income. 200000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Income taxes</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is subject to income taxes in numerous U.S. jurisdictions. Significant judgment is required in determining the provision for income taxes. The Company's income tax provisions reflect management’s interpretation of country and state tax laws. There are many transactions and calculations for which the ultimate tax determination is uncertain during the ordinary course of business and may remain uncertain for several years after their occurrence. The Company recognizes assets and liabilities for taxation when it is probable that the Company will receive refunds from or pay taxes to the relevant tax authority. Where the final determination of tax assets and liabilities is different from the amounts that were initially recorded, such differences will impact the current and deferred income taxes provision in the period in which such a determination is made. Changes in tax law or changes in the way tax law is interpreted may also impact the Company's effective tax rate as well as the Company's business and operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred income tax assets and liabilities are recognized for the future income tax consequences attributable to temporary differences between the financial statement carrying value of assets and liabilities and their respective income tax bases. Deferred income tax assets or liabilities are measured using enacted income tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be settled. The calculation of current and deferred income taxes requires management to make estimates and assumptions and to exercise a certain amount of judgment concerning the carrying value of assets and liabilities. The current and deferred income tax assets and liabilities are also impacted by expectations about future operating results and the timing of reversal of temporary differences as well as possible audits of tax filings by regulatory agencies. Changes or differences in these estimates or assumptions may result in changes to the current and deferred tax assets and liabilities on the Condensed Consolidated Balance Sheets and a charge to or recovery of income tax expense.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">CARES Act Funds Received</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company received a general distribution payment from the Provider Relief Fund of $3.5 million in April 2020, a targeted distribution payment of $1.5 million in November 2021, and a general distribution payment of $0.4 million in January 2022. The U.S. Department of Health and Human Services ("HHS") has stated that Provider Relief Fund payments are not loans and will not need to be repaid. However, as a condition to the receipt of funds, the Company and any other providers must agree to a detailed set of terms and conditions. CMS has indicated that the terms and conditions may be subject to ongoing changes and reporting. There is no US GAAP guidance for for-profit health care entities that receive government grants that are not in the form of an income tax credit, revenue from a contract with a customer or a loan. As such, for-profit entities must determine the appropriate accounting treatment by analogy to other guidance such as International Accounting Standards (IAS) 20, Accounting for Government Grants and Disclosure of Government Assistance, in International Financial Reporting Standards. Under IAS 20, the Company determined that upon receipt of funds, it fully complied with the conditions attached to the grant. The Company recognized the distributions received from the Provider Relief Fund in the income statement in full during the period of receipt. To the extent that reporting requirements and terms and conditions are modified, it may affect the Company's ability to comply and may require the return of funds. The Company is not aware of any such modifications as of June 30, 2023</span></div> 3500000 1500000 400000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently adopted accounting pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On January 1, 2023, the Company adopted ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments. The standard replaces the current incurred loss impairment model that recognizes losses when a probable threshold is met with a requirement to recognize lifetime expected credit losses immediately when a financial asset is originated or purchased. Further, the FASB issued ASU 2019-04 and ASU 2019-05 to provide additional guidance on the credit losses standard. While the adoption of ASC 326 could result in a higher allowance recorded in the future for credit losses on receivables within the scope of the standard due to the prescribed measurement principles, the impact of the adoption on the Company's consolidated financials statements was not material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company is an “emerging growth company” as defined by the JOBS Act. The JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, for complying with new or revised accounting standards. In other words, an emerging growth company can selectively delay the adoption of all accounting standards until those standards would otherwise apply to private companies. The Company has elected to utilize this exemption and, as a result, the Company's condensed consolidated financial statements may not be comparable to the financial statements of issuers that are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. To date, however, the Company has not delayed the adoption of any accounting </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">standards except as noted below. Section 107 of the JOBS Act provides that the Company can elect to opt out of the extended transition period at any time, which election is irrevocable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In September 2022, the FASB issued ASU No. 2022-04, Liabilities — Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations, which requires entities that use supplier finance programs in connection with the purchase of goods and services to disclose the key terms of the programs and information about their obligations that are outstanding at the end of the reporting period. The amendments in this update are effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for the amendment on rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company does not expect the update to affect the recognition, measurement, or financial statement presentation of supplier finance program obligations, but is evaluating the impact of the update on related disclosures upon adoption.</span></div> Business Combinations<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On June 1, 2023, Viemed, Inc., a wholly-owned subsidiary of the Company, completed the acquisition of Home Medical Products, Inc., (“HMP”), which operates in Tennessee, Alabama, and Mississippi. The Company acquired 100% of the equity ownership of HMP in exchange for approximately $29.4 million in cash or cash payable, subject to customary post-closing net working capital and other adjustments. Approximately $15 million of the purchase consideration was funded by cash on hand, $8 million was funded by a borrowing on the 2022 Revolving Credit Facility, and $5 million was funded by a borrowing on the 2022 Term Loan Facility.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The results of HMP’s operations have been included in the consolidated financial statements since the date of acquisition. The Company expensed $254,000 of acquisition costs in conjunction with the acquisition for the six months ended June 30, 2023. These costs include system conversion and integrating operations charges, as well as legal and consulting expenses, and are included in selling, general, and administrative expense in the accompanying consolidated statements of income and comprehensive income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid and estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The Company is in the process of obtaining third-party valuations of certain fixed assets and identifiable intangible assets; thus, the provisional measurements of property plant and equipment, trade names, non-compete agreements, and goodwill are subject to change. The fair value of accounts receivables acquired is $2.0 million, with the gross contractual amount being $2.9 million. The Company expects $0.9 million to be uncollectible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.057%"><tr><td style="width:1.0%"></td><td style="width:83.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid or payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Identifiable Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Identifiable Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets (liabilities) acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Resulting goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,759 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>Goodwill resulted from a combination of synergies and cost savings, and further expansion into Tennessee, Alabama, and Mississippi. All of the goodwill is deductible for income tax purposes. There are no contingent consideration arrangements included in the transaction. 1 29400000 15000000 8000000 5000000 254000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes the consideration paid and estimated fair values of the assets acquired and liabilities assumed at the acquisition date. The Company is in the process of obtaining third-party valuations of certain fixed assets and identifiable intangible assets; thus, the provisional measurements of property plant and equipment, trade names, non-compete agreements, and goodwill are subject to change. The fair value of accounts receivables acquired is $2.0 million, with the gross contractual amount being $2.9 million. The Company expects $0.9 million to be uncollectible.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.057%"><tr><td style="width:1.0%"></td><td style="width:83.528%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.272%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Purchase Price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid or payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,417 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Identifiable Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,014 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">535 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,358 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">743 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identifiable intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">688 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,866 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Identifiable Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,195 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">536 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,208 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net assets (liabilities) acquired</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(342)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Resulting goodwill</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,759 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 2000000 2900000 900000 29417000 921000 2014000 582000 535000 4358000 743000 688000 25000 9866000 2144000 732000 1195000 536000 4558000 207000 836000 10208000 -342000 29759000 Property and Equipment<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s fixed assets consist of its medical equipment held for rental, furniture and equipment, real property and related improvements, and vehicles and other various small equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s fixed assets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,571 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,899)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72,884</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">67,743</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation in the amount of $4,908,000 and $3,497,000 is included in cost of revenue for the three months ended June 30, 2023 and 2022, respectively, and in the amount of $9,430,000 and $6,656,000 for the six months ended June 30, 2023 and 2022, respectively. Medical equipment purchases with a cost of $2,526,000 and $738,000 were included in accounts payable at June 30, 2023 and December 31, 2022, respectively. <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table details the Company’s fixed assets:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.287%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,571 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93,893 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,792 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,566 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Buildings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,043 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">344 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vehicles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,970)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39,899)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:100%">Property and equipment, net of accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">72,884</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">67,743</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 103571000 93893000 3115000 2792000 2566000 2566000 7129000 7043000 344000 296000 1129000 1052000 44970000 39899000 72884000 67743000 4908000 3497000 9430000 6656000 2526000 738000 Current Liabilities<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"></td><td style="width:56.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s short-term accrued liabilities are included within current liabilities and consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.798%"><tr><td style="width:1.0%"></td><td style="width:56.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.880%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued trade payables </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,254 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued commissions payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">737 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued bonuses payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued vacation and payroll</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,450 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,484 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of phantom share liability </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase price payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,376 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,334 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">15,509</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,092</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2735000 2254000 737000 608000 4329000 3708000 2450000 1484000 1483000 1704000 1376000 0 2399000 1334000 15509000 11092000 Debt<div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2018 Senior Credit Facility </span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On February 20, 2018, the Company entered a Commercial Business Loan Agreement (the "2018 Senior Credit Facility") that provided for Term Loans and Lines of Credit with Hancock Whitney Bank. Until November 29, 2022, the Company maintained a line of credit in the amount of $10.0 million under the 2018 Senior Credit Facility. On May 30, 2019, the Company entered into a term note (“Building Term Note”) under the 2018 Senior Credit Facility in the principal amount of $4.8 million. The proceeds of the Building Term Note were used to purchase the Company's corporate headquarters. In connection with the Building Term Note, the Company entered into an interest rate swap transaction ("Interest Rate Swap Transaction") with Hancock Whitney Bank effectively fixing the interest rate for the Building Term Note at 4.68%. On September 19, 2019, the Company entered into an additional loan agreement providing for a term note (the “2019 Term Note") under the 2018 Senior Credit Facility in the principal amount of $5.0 million and bearing an annual interest rate of 4.60%. The proceeds of the 2019 Term Note were utilized for general corporate purposes. The 2019 Term Note matured on September 19, 2022 at which time the entire unpaid balance of principal and interest was repaid in full. In connection with the entry in to the 2022 Senior Credit Facilities on November 29, 2022, the Company retired the 2018 Senior Credit Facility, and repaid all outstanding interest and principal in full. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2022 Senior Credit Facilities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On November 29, 2022, the Company refinanced its existing borrowings under the 2018 Senior Credit Facility and entered into a new credit agreement (the "2022 Senior Credit Facilities") with the lenders from time to time party thereto, and Regions Bank, as administrative agent (the "Administrative Agent") and collateral agent, that provides for an up to $30.0 million revolving credit facility (the "2022 Revolving Credit Facility") and an up to $30.0 million delayed draw term loan facility (the "2022 Term Loan Facility"), both maturing in November 2027.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The proceeds of the 2022 Revolving Credit Facility may be used to refinance existing indebtedness, for working capital purposes, capital expenditures and other general corporate purposes (including permitted acquisitions), and to pay transaction fees, costs and expenses related to the 2022 Senior Credit Facilities. The proceeds of the 2022 Term Loan Facility and any additional term loans established in accordance with the 2022 Senior Credit Facilities may be used to finance permitted acquisitions and to pay transaction fees, costs and expenses related to such acquisitions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The interest rates per annum applicable to the 2022 Senior Credit Facilities are Term SOFR (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 2.625% to 3.375%, or, at the option of the Company, a Base Rate (as defined in the 2022 Senior Credit Facilities) plus an applicable margin, which ranges from 1.625% to 2.375%.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2022 Senior Credit Facilities require the Company to comply with certain affirmative, as well as certain negative covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company to incur indebtedness, grant liens, make investments, engage in acquisitions, mergers or consolidations and pay dividends and other restricted payments. The 2022 Senior Credit Facilities also include certain financial covenants, which generally include, but are not limited to the following</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Consolidated Total Leverage Ratio (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">defined generally as </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">total indebtedness to adjusted EBITDA) of not greater than (i) for any fiscal quarter ending during the period from the closing date to and including December 31, 2024, 2.75 to 1.0 and (ii) for any fiscal quarter ending on and after March 31, 2025, 2.50 to 1.0, subject to certain adjustments following a material acquisition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">•</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">Consolidated Fixed Charge Coverage Ratio (</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">defined</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> generally as (a) adjusted EBITDA minus capital expenditures minus cash taxes to (b) the sum of scheduled principal payments plus cash interest expense plus restricted payments) of not less than 1.25:1.0.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company was in compliance with all covenants under the 2022 Senior Credit Facilities in effect at June 30, 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The 2022 Senior Credit Facilities includes provisions permitting the Company from time to time to, subject to certain terms and conditions, increase the aggregate amount of commitments under the 2022 Revolving Credit Facility and/or establish one or more additional term loans under the 2022 Term Loan Facility, in each case, with additional commitments from existing lenders or new commitments from financial institutions acceptable to the Administrative Agent in its reasonable discretion; provided, that, (a) the aggregate principal amount of any increases in the 2022 Revolving Credit Facility, and (b) the aggregate principal amount of all additional term loans under the 2022 Term Loan Facility established after the closing date will not exceed $30.0 million.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financing costs and commitment fees related to the 2022 Senior Credit Facilities are capitalized and amortized over the term of the loans using the effective interest method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The recorded balances associated with the 2022 Senior Credit Facilities are as follows:</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:61.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing costs and commitment fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Medical Equipment Financing</span></div><div style="padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As a result of the acquisition of HMP, the Company assumed equipment financing obligations consisting of installment payments for medical equipment which secure the financing. The financing obligations are payable in monthly installments through 2026 and include interest at rates ranging from 0% to 7.99%. As of June 30, 2023, $3 million of the outstanding medical equipment financing obligations is presented on the condensed consolidated balance sheets as short term debt and $0.1 million is presented as long term debt, based on the scheduled repayment dates.</span></div> 10000000 4800000 0.0468 5000000 0.0460 30000000 30000000 0.02625 0.03375 0.01625 0.02375 2.75 2.50 1.25 30000000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The recorded balances associated with the 2022 Senior Credit Facilities are as follows:</span></div><div style="margin-top:5pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.281%"><tr><td style="width:1.0%"></td><td style="width:61.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.813%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing costs and commitment fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(748)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(250)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net long-term notes payable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">12,002</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13000000 0 748000 0 250000 0 12002000 0 0 0.0799 3000000 100000 Fair Value Measurement<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Under ASC Topic 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (i.e., an exit price). ASC Topic 820 establishes a hierarchy for inputs to valuation techniques used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. There are three levels to the hierarchy based on the reliability of inputs, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 2 - Inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets and liabilities in markets that are not active.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Level 3 - Unobservable inputs for the asset or liability. The degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:0.1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain assets at fair value on a recurring basis. There were no transfers between fair value measurement levels during any presented period.</span></div><div style="margin-bottom:0.1pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Available for sale debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,078</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Available for sale debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Available for Sale Debt Instrument</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of the Company’s available for sale debt instrument approximates its amortized cost basis due to the short maturity and indexed interest rate terms. The fair value is classified within Level 3 in the fair value hierarchy as the Company evaluates adjustments using a combination of observable and unobservable inputs, such as operating results of the counterparty as well observable prices in transactions of debt and equity instruments of the issuing counterparty when available. As of June 30, 2023, the analysis resulted in no adjustments to the carrying value impacting unrealized gains or losses. All changes to measured fair value during the period were the result of accrued interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Assets Measured at Fair Value on a Nonrecurring Basis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company measures certain assets at fair value on a nonrecurring basis. These assets include equity method investments and other equity investments. Equity method investments are evaluated for impairment whenever events or changes in circumstances indicate that the carrying value of the investments may exceed the fair value. The Company's other equity investments are holdings in privately-held companies without a readily determinable market value. The Company remeasures equity securities without readily determinable fair value at fair value when an orderly transaction is identified for an identical or similar investment of the same issuer in accordance with the measurement alternative under Topic 820. ASU 2019-04 states that the measurement alternative is a nonrecurring fair value measurement. Accordingly, other equity investments without readily determinable fair value are classified within Level 3 in the fair value hierarchy because the Company estimates the value using a combination of observable and unobservable inputs, including valuation ascribed to the issuing company in subsequent financing rounds, volatility in the results of operations of the issuers and rights and obligations of the holdings the Company owns.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company had no material adjustments of assets measured at fair value on a nonrecurring basis during any of the periods presented. There were no transfers between fair value measurement levels during any presented period.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following tables summarize the Company's assets measured at fair value on a recurring basis as of June 30, 2023 and December 31, 2022:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Available for sale debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,078</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,110</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,188</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.129%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">At December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Recurring Fair Value Measurements:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Money market mutual funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,005 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">  Available for sale debt instrument</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">—</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,000</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">13,005</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2078000 0 0 2078000 0 0 2110000 2110000 2078000 0 2110000 4188000 11005000 0 0 11005000 0 0 2000000 2000000 11005000 0 2000000 13005000 Shareholders' Equity<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Authorized share capital</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company’s authorized share capital consists of an unlimited number of common shares, with no stated par value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Issued and outstanding share capital</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has only one class of stock outstanding, common shares. The authorized stock consists of an unlimited number of common shares with no stated par value, of which 38,400,422 and 38,049,739 shares were issued and outstanding as of June 30, 2023 and December 31, 2022, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, the Company acquired and cancelled 66,734 common shares at a cost of $0.5 million to satisfy employee income tax withholding associated with RSUs vesting. The Company’s retained earnings were reduced by the amount paid for the shares repurchased and cancelled.</span></div><div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"><span><br/></span></div><div style="padding-left:49.5pt;padding-right:6.75pt;text-align:justify;text-indent:-49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effective June 11, 2020 (the "Effective Date"), the Company’s shareholders approved the Company's 2020 Long Term Incentive Plan (the "Omnibus Plan"). Upon approval of the Omnibus Plan, no future awards are available to be made under the Company's previous RSU and Option Plans (collectively, the "Former Plan"), and the common shares that were not settled or awarded under the Former Plan as of the Effective Date are available for awards under the Omnibus Plan. The maximum number of common shares that are available for awards under the Omnibus Plan and under any other security-based compensation arrangements adopted by the Company, including the Former Plan, may not exceed 7,758,211 shares (equal to 20% of the issued and outstanding common shares of the Company on the Effective Date). The maximum amount of the foregoing common shares that may be awarded under the Omnibus Plan as “incentive stock options” is 2,600,000 common shares. As of June 30, 2023, the Company had outstanding options of 4,244,000 and RSUs of 1,123,000 associated with common shares under the Omnibus Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,862</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:31.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At June 30, 2023, there was approximately $889,000 of total unrecognized pre-tax stock option expense under the Company's equity compensation plans, which is expected to be recognized over a weighted-average period of 1.32 years. As of June 30, 2023, there was approximately $4,780,000 of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.26 years.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/> (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,290</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing share price of the Company's common stock on the last trading day of the period ($9.78).</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding was $19,290,197 and options exercisable were $16,579,787 at June 30, 2023. For the six months ended June 30, 2023, 228,000 common shares were issued pursuant to the exercise of stock options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At June 30, 2023, the Company had 3,415,000 exercisable stock options outstanding with a weighted average exercise price of $4.93 and a weighted average remaining contractual life of 6.0 years. At December 31, 2022, the Company had 2,841,000 exercisable stock options outstanding with a weighted average exercise price of $4.53 and a weighted average remaining contractual life of 6.1 years.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The fair value of the stock options has been charged to the Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, using the grant date fair value based on the Black-Scholes option pricing model. The assumptions used to determine the grant date fair value of stock options include exercise price, risk-free interest rates, expected volatility, and average life of an option. The risk-free interest rates are based on the rates available at the time of the grant for zero-coupon U.S. government issues with a remaining term equal to the option’s expected life. The average life of an option is based on both historical and projected exercise and lapsing data. Expected volatility is based on implied volatilities from traded options on the Company's common shares and historical volatility of the Company's common shares over the expected life of the option. There were no issuances of options during the six months ended June 30, 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accounts for RSUs using fair value. The fair value of the RSUs has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and credited to additional paid-in capital over the vesting period, based on the stock price on the date of grant. RSUs vest generally over a <span style="-sec-ix-hidden:f-635">one</span> or <span style="-sec-ix-hidden:f-636">three</span>-year period. The Company accounts for forfeitures on RSUs under ASU 2016-09 and recognizes forfeitures in the period in which they occur.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.88 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.02</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.26 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based RSUs outstanding was based on the Company's closing stock price on the last trading day of the period ($9.78).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023, the Company issued 702,206 RSUs with a vesting term of three years and a fair value of $5.6 million. During the three months ended June 30, 2023, the Company issued no RSUs.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Phantom share units</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company has a phantom share unit plan, which it uses for grants to directors, officers, and employees. Phantom share units granted under the plan are non-assignable and are settled in cash at vesting based on the fair value of the Company's common stock on the vesting date. Phantom share units vest annually over a three-year period. The cash-settled phantom share units are accounted for as liability awards and are re-measured at fair value each reporting period until they become vested with accrued liability and related expense being recognized over the requisite service period. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of phantom share units (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of share equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s stock at that time, the value of issued share equivalents is based on the market price of the Company’s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $9.78 on June 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change in fair value of the phantom share units has been charged to the Condensed Consolidated Statements of Income and Comprehensive Income and recorded as a liability included in accrued liabilities and long-term accrued liabilities. The total liability associated with phantom share units at June 30, 2023 is $2,120,000, with $1,483,000 of this amount included in current accrued liabilities and the remaining portion of $637,000 included in long-term accrued liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The impact associated with the fair value re-measurement of phantom share units is recorded in selling, general and administrative expenses within the unaudited Condensed Consolidated Statements of Income and Comprehensive Income. The following table summarizes expense (benefit) associated with the phantom share units for the three and six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company paid cash settlements of $2,309,000 and $1,389,000 during the six months ended June 30, 2023 and 2022, respectively, pertaining to vestings of cash-settled phantom share units.</span></div> 38400422 38400422 38049739 38049739 66734 500000 7758211 0.20 2600000 4244000 1123000 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.118%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">757 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation - restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,213 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">999 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,471</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,271</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,862</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,576</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table summarizes expense (benefit) associated with the phantom share units for the three and six months ended June 30, 2023 and 2022 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.405%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.705%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general, and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">687 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">538 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,837 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">949 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 301000 757000 649000 1577000 1170000 514000 2213000 999000 1471000 1271000 2862000 2576000 889000 P1Y3M25D 4780000 P1Y3M3D <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of options<br/> (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average exercise price</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,497</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.26</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.9 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">11,356</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.51 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,244</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.24</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6.4 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">19,290</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For presentation purposes, stock options issued with a Canadian dollar exercise price have been translated to U.S. dollars based on the prevailing exchange rate on the date of grant.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing share price of the Company's common stock on the last trading day of the period ($9.78).</span></div> 4497000 5.26 P6Y10M24D 11356000 0 0 228000 228000 5.51 25000 6.47 4244000 5.24 P6Y4M24D 19290000 9.78 19290197 16579787 228000 3415000 4.93 P6Y 2841000 4.53 P6Y1M6D 0 <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes RSU activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.122%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of RSUs (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average grant price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted average remaining contractual life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate intrinsic value</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">629</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5.62</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">0.88 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,755</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">702 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.56 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.70 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,123</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">7.02</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1.26 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">10,986</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate intrinsic value of time-based RSUs outstanding was based on the Company's closing stock price on the last trading day of the period ($9.78).</span></div> 629000 5.62 P0Y10M17D 4755000 702000 7.87 190000 5.56 18000 6.70 1123000 7.02 P1Y3M3D 10986000 9.78 702206 P3Y 5600000 0 P3Y <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following table summarizes phantom share unit activity for the six months ended June 30, 2023:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.371%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.299%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of phantom share units (000's)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of share equivalents</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">513</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,878 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,401 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(578)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired / Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(196)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">430</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,200</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">The value of outstanding share equivalents at the beginning of the period is based on the market price of the Company’s stock at that time, the value of issued share equivalents is based on the market price of the Company’s stock at issuance, the value of vested share equivalents is based on the cash paid at the time of vesting, and the values of expired/forfeited share equivalents and outstanding share equivalents at the end of the period are based on the market price of the Company's stock at the end of the period. The market price of the Company's stock was $9.78 on June 30, 2023.</span></div> 513000 3878000 176000 1401000 239000 578000 20000 196000 430000 4200000 9.78 2120000 1483000 637000 687000 538000 1837000 949000 2309000 1389000 Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company accrues estimates for resolution of any legal and other contingencies when losses are probable and reasonably estimable in accordance with ASC 450, Contingencies (“ASC 450”). No less than quarterly, the Company reviews the status of each significant matter underlying a legal proceeding or claim and assess our potential financial exposure. The Company accrues a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to the Company at the time the judgment is made, which may prove to be incomplete or inaccurate or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Furthermore, the outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As previously disclosed, the Company (through its subsidiary Sleep Management LLC) submitted a purchase order (the “Purchase Order”) in March 2020 to Vyaire Medical, Inc. d/b/a CareFusion Respiratory Technologies (“Vyaire”) for respiratory equipment. The Company ultimately prepaid $1.4 million towards the delivery of such respiratory equipment. Vyaire was unable or unwilling to deliver the vast majority of the respiratory equipment referenced in the Purchase Order, and also refused to refund the prepayment amount (less the amounts paid for equipment actually received). On July 29, 2020, the Company (through its subsidiary Sleep Management LLC) filed a lawsuit against Vyaire in the United States District Court for the Western District of Louisiana (the “Court”). This lawsuit was dismissed on December 8, 2020 in connection with the commencement of the lawsuit filed by the Company (through its subsidiary Sleep Management) on November 5, 2020, against Vyaire in the 15th Judicial District Court for the Parish of Lafayette, Louisiana (the “State Court”) seeking damages for breach of contract and seeking a declaratory judgment that the Company is not required to pay any further funds to Vyaire. On December 28, 2020, Vyaire filed its Answer, Affirmative Defenses, and Reconventional Demand (“Reconventional Demand”) with the State Court alleging breach of contract and seeking damages of $4.7 million, purportedly for the improper cancellation of the Purchase Order. The Company filed its Answer to the Reconventional Demand on February 12, 2021 and the parties completed discovery on July 17, 2023. The Company filed a Motion for Summary Judgment on June 9, 2023. The Court has set an August 28, 2023 hearing on that motion and has set a date for a non-jury trial on October 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company continues to believe that it has valid legal and equitable grounds to recover its outstanding prepayment as a result of Vyaire’s failure to deliver the vast majority of the respiratory equipment referenced in the Purchase Order. The Company has determined that a loss related to the Reconventional Demand is not probable, and thus has not accrued a liability related to this claim. Although a loss may be reasonably possible, the Company does not have sufficient information to determine the amount or range of reasonably possible loss with respect to the Reconventional Demand given that the dispute is in the early stages of the legal process. As of June 30, 2023, outstanding funds in the amount of $0.9 million related to undelivered respiratory equipment are included within other long-term assets.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Governmental and Regulatory Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">From time to time the Company is involved in various external governmental investigations, audits and reviews. Reviews, audits and investigations of this sort can lead to government actions, which can result in the assessment of recoupment of reimbursement, civil or criminal fines or penalties, or other sanctions, including restrictions or changes in the way the Company conducts business, loss of licensure or exclusion from participation in government healthcare programs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">In May of 2021, a final report and recommendation (“Report”) was issued by the OIG regarding an audit by OIG of claims relating to 100 of the Company’s non-invasive ventilation at home (“NIVH”) patients. The OIG asserted that most of the sampled Medicare claims submitted for the monthly rental of non-invasive ventilators did not comply with Medicare requirements. The Company firmly believed that the Report ignored each patient’s diagnosis and supporting documentation of that diagnosis from treating and prescribing physicians and applied clinical guidelines that were contrary to CMS’s accepted standard of care. In late June of 2021, the Company received initial request letters from DME Medicare Administrative Contractors ("MACs") referencing the Report and requesting repayment of purported overpayments. The Company responded to each initial request by submitting a rebuttal and by filing a redetermination appeal as prescribed by the initial request letters and by statute. In September 2021, the MACs informed the Company of unfavorable decisions with respect to the redetermination appeals. In November 2021, the Company filed Reconsideration Appeals with CMS's designated Qualified Independent Contractor ("QIC"). Based on its review, the QIC determined that approximately 77% of the claims it reviewed were medically necessary and properly payable under Medicare rules and regulations, overturning OIG’s and the MACs' initial recommendations and determinations. As a result of the QIC's reconsideration findings, reduced and recalculated principal overpayment requests totaling $1.1 million were issued by the MACs. In order to limit the assessment of interest during the appeals period, the Company remitted the associated funds to the MACs. In December 2022, an Administrative Law Judge overturned all of the remaining appealed claims and instructed the MACs to refund all funds previously remitted by the Company. Accordingly, the funds remitted to the MACs are recorded in Prepaid expenses and other assets at December 31, 2022 and were received during the six months ended June 30, 2023.</span></div> 1400000 4700000 900000 100 0.77 1100000 Income Taxes<div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023, the Company recorded income tax expense of $1.2 million, which includes a discrete tax benefit of $0.1 million associated with stock-based compensation arrangements. Excluding the impact of the discrete taxes, the effective rate for the six months ended June 30, 2023 is 28.6%. The effective rate differs from the amount computed by applying the statutory federal and state income tax rates to ordinary income before the provision for income taxes due to permanent non-deductible differences. The Company's effective tax rate is based on forecasted annual results which may fluctuate significantly through the rest of the year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">At June 30, 2023 and 2022, the Company had no amounts recorded for uncertain tax positions and does not expect any material changes in uncertain tax benefits during the next 12 months. The Company recognizes interest and penalties related to income tax matters in income tax expense. The Company is subject to U.S. federal income tax as well as income tax in various states. The Company is generally not subject to examination by taxing authorities for years prior to 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations.</span></div> 1200000 -100000 0.286 Earnings Per Share<span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income per common share is calculated using earnings for the year divided by the weighted average number of shares outstanding during the year</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Using the treasury stock method, diluted income per share amounts are calculated giving effect to the potential dilution that would occur if securities or other contracts to issue common shares were exercised or converted to common shares by assuming the proceeds received from the exercise of stock options and the vesting of RSUs are used to purchase common shares at the prevailing market rate. </span><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,847 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,324,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,773,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,240,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,195,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,676,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,752,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,383,616 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,056,953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,324,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,773,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,240,902 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,195,317 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,352,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,676,951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,752,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,383,616 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,056,953 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Anti-dilutive shares excluded from the calculation consisted of dilutive employee stock options and RSUs that were de minimis in all periods presented.</span></div> <div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The following reflects the earnings and share data used in the basic and diluted earnings per share computations:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.124%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.836%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator - basic and diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to shareholders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,330 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,847 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,729 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,324,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,773,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,240,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,195,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,676,951 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,752,928 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,383,616 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,056,953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.06 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.02 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.07 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator calculation from basic to diluted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic weighted-average number of common shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,324,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,773,580 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,240,902 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,195,317 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options and other dilutive securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,352,702 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">979,348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,142,714 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">861,636 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted-average number of shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,676,951 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,752,928 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,383,616 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,056,953 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2330000 967000 3847000 2729000 38324249 38773580 38240902 39195317 40676951 39752928 40383616 40056953 0.06 0.02 0.10 0.07 0.06 0.02 0.10 0.07 38324249 38773580 38240902 39195317 2352702 979348 2142714 861636 40676951 39752928 40383616 40056953 EXCEL 63 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 64 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 65 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 66 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 176 289 1 false 53 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.viemed.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - Nature of Business and Operations Sheet http://www.viemed.com/role/NatureofBusinessandOperations Nature of Business and Operations Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Business Combinations Sheet http://www.viemed.com/role/BusinessCombinations Business Combinations Notes 9 false false R10.htm 0000010 - Disclosure - Property and Equipment Sheet http://www.viemed.com/role/PropertyandEquipment Property and Equipment Notes 10 false false R11.htm 0000011 - Disclosure - Current Liabilities Sheet http://www.viemed.com/role/CurrentLiabilities Current Liabilities Notes 11 false false R12.htm 0000012 - Disclosure - Debt Sheet http://www.viemed.com/role/Debt Debt Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurement Sheet http://www.viemed.com/role/FairValueMeasurement Fair Value Measurement Notes 13 false false R14.htm 0000014 - Disclosure - Shareholders' Equity Sheet http://www.viemed.com/role/ShareholdersEquity Shareholders' Equity Notes 14 false false R15.htm 0000015 - Disclosure - Commitments and Contingencies Sheet http://www.viemed.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 15 false false R16.htm 0000016 - Disclosure - Income Taxes Sheet http://www.viemed.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 0000017 - Disclosure - Earnings Per Share Sheet http://www.viemed.com/role/EarningsPerShare Earnings Per Share Notes 17 false false R18.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 18 false false R19.htm 9954701 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.viemed.com/role/SummaryofSignificantAccountingPolicies 19 false false R20.htm 9954702 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.viemed.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 9954703 - Disclosure - Business Combinations (Tables) Sheet http://www.viemed.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.viemed.com/role/BusinessCombinations 21 false false R22.htm 9954704 - Disclosure - Property and Equipment (Tables) Sheet http://www.viemed.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.viemed.com/role/PropertyandEquipment 22 false false R23.htm 9954705 - Disclosure - Current Liabilities (Tables) Sheet http://www.viemed.com/role/CurrentLiabilitiesTables Current Liabilities (Tables) Tables http://www.viemed.com/role/CurrentLiabilities 23 false false R24.htm 9954706 - Disclosure - Debt (Tables) Sheet http://www.viemed.com/role/DebtTables Debt (Tables) Tables http://www.viemed.com/role/Debt 24 false false R25.htm 9954707 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.viemed.com/role/FairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.viemed.com/role/FairValueMeasurement 25 false false R26.htm 9954708 - Disclosure - Shareholders' Equity (Tables) Sheet http://www.viemed.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://www.viemed.com/role/ShareholdersEquity 26 false false R27.htm 9954709 - Disclosure - Earnings Per Share (Tables) Sheet http://www.viemed.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.viemed.com/role/EarningsPerShare 27 false false R28.htm 9954710 - Disclosure - Nature of Business and Operations (Details) Sheet http://www.viemed.com/role/NatureofBusinessandOperationsDetails Nature of Business and Operations (Details) Details http://www.viemed.com/role/NatureofBusinessandOperations 28 false false R29.htm 9954711 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 29 false false R30.htm 9954712 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails Summary of Significant Accounting Policies (Customer Percentages) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 30 false false R31.htm 9954713 - Disclosure - Summary of Significant Accounting Policies (Equity Investments) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails Summary of Significant Accounting Policies (Equity Investments) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 31 false false R32.htm 9954714 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails Summary of Significant Accounting Policies (Revenue Recognition) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 32 false false R33.htm 9954715 - Disclosure - Summary of Significant Accounting Policies (Interest Rate Swaps) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails Summary of Significant Accounting Policies (Interest Rate Swaps) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 33 false false R34.htm 9954716 - Disclosure - Summary of Significant Accounting Policies (CARES Act Funds Received) (Details) Sheet http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCARESActFundsReceivedDetails Summary of Significant Accounting Policies (CARES Act Funds Received) (Details) Details http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables 34 false false R35.htm 9954717 - Disclosure - Business Combinations - Narrative (Details) Sheet http://www.viemed.com/role/BusinessCombinationsNarrativeDetails Business Combinations - Narrative (Details) Details 35 false false R36.htm 9954718 - Disclosure - Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details) Sheet http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details) Details 36 false false R37.htm 9954719 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details) Sheet http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails Property and Equipment (Schedule of Fixed Assets) (Details) Details http://www.viemed.com/role/PropertyandEquipmentTables 37 false false R38.htm 9954720 - Disclosure - Property and Equipment (Narrative) (Details) Sheet http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment (Narrative) (Details) Details http://www.viemed.com/role/PropertyandEquipmentTables 38 false false R39.htm 9954721 - Disclosure - Current Liabilities (Details) Sheet http://www.viemed.com/role/CurrentLiabilitiesDetails Current Liabilities (Details) Details http://www.viemed.com/role/CurrentLiabilitiesTables 39 false false R40.htm 9954722 - Disclosure - Debt (Senior Credit Facilities) (Details) Sheet http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails Debt (Senior Credit Facilities) (Details) Details http://www.viemed.com/role/DebtTables 40 false false R41.htm 9954723 - Disclosure - Debt (Schedule of Notes Payable) (Details) Notes http://www.viemed.com/role/DebtScheduleofNotesPayableDetails Debt (Schedule of Notes Payable) (Details) Details http://www.viemed.com/role/DebtTables 41 false false R42.htm 9954724 - Disclosure - Fair Value Measurement (Recurring Basis) (Details) Sheet http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails Fair Value Measurement (Recurring Basis) (Details) Details http://www.viemed.com/role/FairValueMeasurementTables 42 false false R43.htm 9954725 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails Shareholders' Equity (Issued and Outstanding Share Capital) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 43 false false R44.htm 9954726 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails Shareholders' Equity (Stock-based Compensation) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 44 false false R45.htm 9954727 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails Shareholders' Equity (Options, Stock Option Activity) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 45 false false R46.htm 9954728 - Disclosure - Shareholders' Equity (Options, Narrative) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails Shareholders' Equity (Options, Narrative) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 46 false false R47.htm 9954729 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails Shareholders' Equity (Restricted Stock Units) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 47 false false R48.htm 9954730 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details) Sheet http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails Shareholders' Equity (Phantom Share Units) (Details) Details http://www.viemed.com/role/ShareholdersEquityTables 48 false false R49.htm 9954731 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.viemed.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.viemed.com/role/CommitmentsandContingencies 49 false false R50.htm 9954732 - Disclosure - Income Taxes (Details) Sheet http://www.viemed.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.viemed.com/role/IncomeTaxes 50 false false R51.htm 9954733 - Disclosure - Earnings Per Share (Details) Sheet http://www.viemed.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.viemed.com/role/EarningsPerShareTables 51 false false All Reports Book All Reports [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 10-Q should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. vmd-20230630.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - vmd-20230630.htm 4 vmd-20230630.htm q22023exhibit311.htm q22023exhibit312.htm q22023exhibit321.htm q22023exhibit322.htm vmd-20230630.xsd vmd-20230630_cal.xml vmd-20230630_def.xml vmd-20230630_lab.xml vmd-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 69 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "vmd-20230630.htm": { "axisCustom": 1, "axisStandard": 21, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 669, "http://xbrl.sec.gov/dei/2023": 30 }, "contextCount": 176, "dts": { "calculationLink": { "local": [ "vmd-20230630_cal.xml" ] }, "definitionLink": { "local": [ "vmd-20230630_def.xml" ] }, "inline": { "local": [ "vmd-20230630.htm" ] }, "labelLink": { "local": [ "vmd-20230630_lab.xml" ] }, "presentationLink": { "local": [ "vmd-20230630_pre.xml" ] }, "schema": { "local": [ "vmd-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] } }, "elementCount": 544, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 2, "http://xbrl.sec.gov/dei/2023": 5, "total": 7 }, "keyCustom": 20, "keyStandard": 269, "memberCustom": 22, "memberStandard": 29, "nsprefix": "vmd", "nsuri": "http://www.viemed.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://www.viemed.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Property and Equipment", "menuCat": "Notes", "order": "10", "role": "http://www.viemed.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Current Liabilities", "menuCat": "Notes", "order": "11", "role": "http://www.viemed.com/role/CurrentLiabilities", "shortName": "Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Debt", "menuCat": "Notes", "order": "12", "role": "http://www.viemed.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Fair Value Measurement", "menuCat": "Notes", "order": "13", "role": "http://www.viemed.com/role/FairValueMeasurement", "shortName": "Fair Value Measurement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Shareholders' Equity", "menuCat": "Notes", "order": "14", "role": "http://www.viemed.com/role/ShareholdersEquity", "shortName": "Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "15", "role": "http://www.viemed.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Income Taxes", "menuCat": "Notes", "order": "16", "role": "http://www.viemed.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Earnings Per Share", "menuCat": "Notes", "order": "17", "role": "http://www.viemed.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "menuCat": "Notes", "order": "18", "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "shortName": "Pay vs Performance Disclosure", "subGroupType": "", "uniqueAnchor": null }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "19", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "20", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - Business Combinations (Tables)", "menuCat": "Tables", "order": "21", "role": "http://www.viemed.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - Property and Equipment (Tables)", "menuCat": "Tables", "order": "22", "role": "http://www.viemed.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - Current Liabilities (Tables)", "menuCat": "Tables", "order": "23", "role": "http://www.viemed.com/role/CurrentLiabilitiesTables", "shortName": "Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - Debt (Tables)", "menuCat": "Tables", "order": "24", "role": "http://www.viemed.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - Fair Value Measurement (Tables)", "menuCat": "Tables", "order": "25", "role": "http://www.viemed.com/role/FairValueMeasurementTables", "shortName": "Fair Value Measurement (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - Shareholders' Equity (Tables)", "menuCat": "Tables", "order": "26", "role": "http://www.viemed.com/role/ShareholdersEquityTables", "shortName": "Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - Earnings Per Share (Tables)", "menuCat": "Tables", "order": "27", "role": "http://www.viemed.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - Nature of Business and Operations (Details)", "menuCat": "Details", "order": "28", "role": "http://www.viemed.com/role/NatureofBusinessandOperationsDetails", "shortName": "Nature of Business and Operations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfStatesInWhichEntityOperates", "reportCount": 1, "unique": true, "unitRef": "state", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-4", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)", "menuCat": "Details", "order": "29", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails", "shortName": "Summary of Significant Accounting Policies (Accounts Receivable, Allowance for Doubtful Accounts) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-4", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-54", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Summary of Significant Accounting Policies (Customer Percentages) (Details)", "menuCat": "Details", "order": "30", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails", "shortName": "Summary of Significant Accounting Policies (Customer Percentages) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-54", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - Summary of Significant Accounting Policies (Equity Investments) (Details)", "menuCat": "Details", "order": "31", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails", "shortName": "Summary of Significant Accounting Policies (Equity Investments) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:EquityMethodInvestmentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - Summary of Significant Accounting Policies (Revenue Recognition) (Details)", "menuCat": "Details", "order": "32", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails", "shortName": "Summary of Significant Accounting Policies (Revenue Recognition) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-69", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OperatingLeaseLeaseIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-89", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainOnDerivative", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - Summary of Significant Accounting Policies (Interest Rate Swaps) (Details)", "menuCat": "Details", "order": "33", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails", "shortName": "Summary of Significant Accounting Policies (Interest Rate Swaps) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-89", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeGainOnDerivative", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "vmd:CARESActFundsReceivedPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-90", "decimals": "-5", "first": true, "lang": "en-US", "name": "vmd:CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - Summary of Significant Accounting Policies (CARES Act Funds Received) (Details)", "menuCat": "Details", "order": "34", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCARESActFundsReceivedDetails", "shortName": "Summary of Significant Accounting Policies (CARES Act Funds Received) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "vmd:CARESActFundsReceivedPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-90", "decimals": "-5", "first": true, "lang": "en-US", "name": "vmd:CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-93", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - Business Combinations - Narrative (Details)", "menuCat": "Details", "order": "35", "role": "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "shortName": "Business Combinations - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-93", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details)", "menuCat": "Details", "order": "36", "role": "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails", "shortName": "Business Combinations - Summarizes the Consideration Paid and Estimated Fair Values of the Assets Acquired and Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-93", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - Property and Equipment (Schedule of Fixed Assets) (Details)", "menuCat": "Details", "order": "37", "role": "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails", "shortName": "Property and Equipment (Schedule of Fixed Assets) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - Property and Equipment (Narrative) (Details)", "menuCat": "Details", "order": "38", "role": "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSoldDepreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:AccruedTradePayablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - Current Liabilities (Details)", "menuCat": "Details", "order": "39", "role": "http://www.viemed.com/role/CurrentLiabilitiesDetails", "shortName": "Current Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OtherCurrentLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "vmd:AccruedTradePayablesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "4", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-113", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - Debt (Senior Credit Facilities) (Details)", "menuCat": "Details", "order": "40", "role": "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "shortName": "Debt (Senior Credit Facilities) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-113", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - Debt (Schedule of Notes Payable) (Details)", "menuCat": "Details", "order": "41", "role": "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "shortName": "Debt (Schedule of Notes Payable) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtInstrumentsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-126", "decimals": "-3", "lang": "en-US", "name": "us-gaap:DebtInstrumentCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-138", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - Fair Value Measurement (Recurring Basis) (Details)", "menuCat": "Details", "order": "42", "role": "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails", "shortName": "Fair Value Measurement (Recurring Basis) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-138", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - Shareholders' Equity (Issued and Outstanding Share Capital) (Details)", "menuCat": "Details", "order": "43", "role": "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "shortName": "Shareholders' Equity (Issued and Outstanding Share Capital) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-147", "decimals": "-5", "lang": "en-US", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - Shareholders' Equity (Stock-based Compensation) (Details)", "menuCat": "Details", "order": "44", "role": "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "shortName": "Shareholders' Equity (Stock-based Compensation) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-4", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - Shareholders' Equity (Options, Stock Option Activity) (Details)", "menuCat": "Details", "order": "45", "role": "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails", "shortName": "Shareholders' Equity (Options, Stock Option Activity) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - Shareholders' Equity (Options, Narrative) (Details)", "menuCat": "Details", "order": "46", "role": "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "shortName": "Shareholders' Equity (Options, Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "0", "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - Shareholders' Equity (Restricted Stock Units) (Details)", "menuCat": "Details", "order": "47", "role": "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "shortName": "Shareholders' Equity (Restricted Stock Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-158", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-3", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954730 - Disclosure - Shareholders' Equity (Phantom Share Units) (Details)", "menuCat": "Details", "order": "48", "role": "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "shortName": "Shareholders' Equity (Phantom Share Units) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-165", "decimals": "-3", "lang": "en-US", "name": "vmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-173", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954731 - Disclosure - Commitments and Contingencies (Details)", "menuCat": "Details", "order": "49", "role": "http://www.viemed.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-173", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:PurchaseObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-8", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "menuCat": "Statements", "order": "5", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-14", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954732 - Disclosure - Income Taxes (Details)", "menuCat": "Details", "order": "50", "role": "http://www.viemed.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": "-5", "lang": "en-US", "name": "vmd:DiscreteIncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954733 - Disclosure - Earnings Per Share (Details)", "menuCat": "Details", "order": "51", "role": "http://www.viemed.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-5", "decimals": "0", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": "-3", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Nature of Business and Operations", "menuCat": "Notes", "order": "7", "role": "http://www.viemed.com/role/NatureofBusinessandOperations", "shortName": "Nature of Business and Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Business Combinations", "menuCat": "Notes", "order": "9", "role": "http://www.viemed.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "vmd-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 53, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r785" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r818" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r858" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r857" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r783" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r782" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r784" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.viemed.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "ecd_Additional402vDisclosureTextBlock": { "auth_ref": [ "r819" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "localname": "Additional402vDisclosureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToCompAmt": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "localname": "AdjToCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AdjToCompAxis": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "localname": "AdjToCompAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "localname": "AdjToNonPeoNeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AdjToPeoCompFnTextBlock": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "localname": "AdjToPeoCompFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AggtErrCompAmt": { "auth_ref": [ "r790", "r801", "r811", "r836" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "localname": "AggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "auth_ref": [ "r793", "r804", "r814", "r839" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "localname": "AggtErrCompNotYetDeterminedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AllAdjToCompMember": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "localname": "AllAdjToCompMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllExecutiveCategoriesMember": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "localname": "AllExecutiveCategoriesMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllIndividualsMember": { "auth_ref": [ "r797", "r805", "r815", "r832", "r840", "r844", "r852" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "localname": "AllIndividualsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_AllTradingArrangementsMember": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "localname": "AllTradingArrangementsMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "domainItemType" }, "ecd_AwardExrcPrice": { "auth_ref": [ "r847" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "localname": "AwardExrcPrice", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "perShareItemType" }, "ecd_AwardGrantDateFairValue": { "auth_ref": [ "r848" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "localname": "AwardGrantDateFairValue", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_AwardTmgDiscLineItems": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "localname": "AwardTmgDiscLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMethodTextBlock": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "localname": "AwardTmgMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgMnpiCnsdrdFlag": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "localname": "AwardTmgMnpiCnsdrdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardTmgMnpiDiscTextBlock": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "localname": "AwardTmgMnpiDiscTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_AwardTmgPredtrmndFlag": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "localname": "AwardTmgPredtrmndFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_AwardUndrlygSecuritiesAmt": { "auth_ref": [ "r846" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "localname": "AwardUndrlygSecuritiesAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_AwardsCloseToMnpiDiscIndName": { "auth_ref": [ "r845" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "localname": "AwardsCloseToMnpiDiscIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTable": { "auth_ref": [ "r844" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "localname": "AwardsCloseToMnpiDiscTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "auth_ref": [ "r844" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "localname": "AwardsCloseToMnpiDiscTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ChangedPeerGroupFnTextBlock": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "localname": "ChangedPeerGroupFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CoSelectedMeasureAmt": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "localname": "CoSelectedMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_CoSelectedMeasureName": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "localname": "CoSelectedMeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "auth_ref": [ "r829" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "auth_ref": [ "r828" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "localname": "CompActuallyPaidVsNetIncomeTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "auth_ref": [ "r827" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "auth_ref": [ "r826" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompAnalysisTextBlock": { "auth_ref": [ "r790", "r801", "r811", "r836" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "localname": "ErrCompAnalysisTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ErrCompRecoveryTable": { "auth_ref": [ "r787", "r798", "r808", "r833" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "localname": "ErrCompRecoveryTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ExecutiveCategoryAxis": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "localname": "ExecutiveCategoryAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "auth_ref": [ "r794", "r805", "r815", "r840" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "auth_ref": [ "r794", "r805", "r815", "r840" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "auth_ref": [ "r794", "r805", "r815", "r840" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "auth_ref": [ "r794", "r805", "r815", "r840" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_ForgoneRecoveryIndName": { "auth_ref": [ "r794", "r805", "r815", "r840" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "ForgoneRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_IndividualAxis": { "auth_ref": [ "r797", "r805", "r815", "r832", "r840", "r844", "r852" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "localname": "IndividualAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_InsiderTradingArrLineItems": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "localname": "InsiderTradingArrLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTradingPoliciesProcLineItems": { "auth_ref": [ "r786", "r856" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "localname": "InsiderTradingPoliciesProcLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "auth_ref": [ "r786", "r856" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "localname": "InsiderTrdPoliciesProcAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "booleanItemType" }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "auth_ref": [ "r786", "r856" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "xbrltype": "textBlockItemType" }, "ecd_MeasureAxis": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "localname": "MeasureAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_MeasureName": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "localname": "MeasureName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_MnpiDiscTimedForCompValFlag": { "auth_ref": [ "r843" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "localname": "MnpiDiscTimedForCompValFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "booleanItemType" }, "ecd_MtrlTermsOfTrdArrTextBlock": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "localname": "MtrlTermsOfTrdArrTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "textBlockItemType" }, "ecd_NamedExecutiveOfficersFnTextBlock": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "localname": "NamedExecutiveOfficersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonGaapMeasureDescriptionTextBlock": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "localname": "NonGaapMeasureDescriptionTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_NonNeosMember": { "auth_ref": [ "r794", "r805", "r815", "r832", "r840" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "localname": "NonNeosMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "auth_ref": [ "r822" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoAvgTotalCompAmt": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "localname": "NonPeoNeoAvgTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_NonPeoNeoMember": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "localname": "NonPeoNeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_NonRule10b51ArrAdoptedFlag": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "localname": "NonRule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_NonRule10b51ArrTrmntdFlag": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "localname": "NonRule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_OtherPerfMeasureAmt": { "auth_ref": [ "r824" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "localname": "OtherPerfMeasureAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "decimalItemType" }, "ecd_OutstandingAggtErrCompAmt": { "auth_ref": [ "r792", "r803", "r813", "r838" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "localname": "OutstandingAggtErrCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryCompAmt": { "auth_ref": [ "r795", "r806", "r816", "r841" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "localname": "OutstandingRecoveryCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_OutstandingRecoveryIndName": { "auth_ref": [ "r795", "r806", "r816", "r841" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "localname": "OutstandingRecoveryIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PayVsPerformanceDisclosureLineItems": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "localname": "PayVsPerformanceDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_PeerGroupIssuersFnTextBlock": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "localname": "PeerGroupIssuersFnTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_PeerGroupTotalShareholderRtnAmt": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "localname": "PeerGroupTotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoActuallyPaidCompAmt": { "auth_ref": [ "r822" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "localname": "PeoActuallyPaidCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PeoMember": { "auth_ref": [ "r832" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "localname": "PeoMember", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "domainItemType" }, "ecd_PeoName": { "auth_ref": [ "r825" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "localname": "PeoName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "normalizedStringItemType" }, "ecd_PeoTotalCompAmt": { "auth_ref": [ "r821" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "localname": "PeoTotalCompAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_PvpTable": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "localname": "PvpTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "stringItemType" }, "ecd_PvpTableTextBlock": { "auth_ref": [ "r820" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "localname": "PvpTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "auth_ref": [ "r787", "r798", "r808", "r833" ], "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "localname": "RecoveryOfErrCompDisclosureLineItems", "nsuri": "http://xbrl.sec.gov/ecd/2023", "xbrltype": "stringItemType" }, "ecd_RestatementDateAxis": { "auth_ref": [ "r788", "r799", "r809", "r834" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "localname": "RestatementDateAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "stringItemType" }, "ecd_RestatementDeterminationDate": { "auth_ref": [ "r789", "r800", "r810", "r835" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "localname": "RestatementDeterminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "dateItemType" }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "auth_ref": [ "r796", "r807", "r817", "r842" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "localname": "RestatementDoesNotRequireRecoveryTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_Rule10b51ArrAdoptedFlag": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "localname": "Rule10b51ArrAdoptedFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_Rule10b51ArrTrmntdFlag": { "auth_ref": [ "r851" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "localname": "Rule10b51ArrTrmntdFlag", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "booleanItemType" }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "auth_ref": [ "r791", "r802", "r812", "r837" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "localname": "StkPrcOrTsrEstimationMethodTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TabularListTableTextBlock": { "auth_ref": [ "r831" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "localname": "TabularListTableTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TotalShareholderRtnAmt": { "auth_ref": [ "r823" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "localname": "TotalShareholderRtnAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "auth_ref": [ "r830" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "textBlockItemType" }, "ecd_TradingArrAxis": { "auth_ref": [ "r850" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "localname": "TradingArrAxis", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TradingArrByIndTable": { "auth_ref": [ "r852" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "localname": "TradingArrByIndTable", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrAdoptionDate": { "auth_ref": [ "r853" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "localname": "TrdArrAdoptionDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrDuration": { "auth_ref": [ "r854" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "localname": "TrdArrDuration", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "durationItemType" }, "ecd_TrdArrIndName": { "auth_ref": [ "r852" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "localname": "TrdArrIndName", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrIndTitle": { "auth_ref": [ "r852" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "localname": "TrdArrIndTitle", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_TrdArrSecuritiesAggAvailAmt": { "auth_ref": [ "r855" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "localname": "TrdArrSecuritiesAggAvailAmt", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "sharesItemType" }, "ecd_TrdArrTerminationDate": { "auth_ref": [ "r853" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "localname": "TrdArrTerminationDate", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "xbrltype": "stringItemType" }, "ecd_UndrlygSecurityMktPriceChngPct": { "auth_ref": [ "r849" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "localname": "UndrlygSecurityMktPriceChngPct", "nsuri": "http://xbrl.sec.gov/ecd/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "pureItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [ "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r272", "r754", "r907", "r951", "r952" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r313", "r314", "r315", "r316", "r381", "r525", "r561", "r599", "r600", "r654", "r673", "r677", "r678", "r711", "r728", "r729", "r744", "r751", "r764", "r768", "r905", "r942", "r943", "r944", "r945", "r946", "r947" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r313", "r314", "r315", "r316", "r381", "r525", "r561", "r599", "r600", "r654", "r673", "r677", "r678", "r711", "r728", "r729", "r744", "r751", "r764", "r768", "r905", "r942", "r943", "r944", "r945", "r946", "r947" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r272", "r754", "r907", "r951", "r952" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r270", "r528", "r555", "r556", "r557", "r558", "r559", "r560", "r732", "r752", "r767", "r862", "r900", "r901", "r907", "r951" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r270", "r528", "r555", "r556", "r557", "r558", "r559", "r560", "r732", "r752", "r767", "r862", "r900", "r901", "r907", "r951" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r313", "r314", "r315", "r316", "r374", "r381", "r410", "r411", "r412", "r524", "r525", "r561", "r599", "r600", "r654", "r673", "r677", "r678", "r711", "r728", "r729", "r744", "r751", "r764", "r768", "r771", "r895", "r905", "r943", "r944", "r945", "r946", "r947" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r313", "r314", "r315", "r316", "r374", "r381", "r410", "r411", "r412", "r524", "r525", "r561", "r599", "r600", "r654", "r673", "r677", "r678", "r711", "r728", "r729", "r744", "r751", "r764", "r768", "r771", "r895", "r905", "r943", "r944", "r945", "r946", "r947" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r284", "r285", "r286" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Current Liabilities" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesNoncurrent": { "auth_ref": [ "r29" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer), including liabilities for compensation costs, fringe benefits other than pension and postretirement obligations, rent, contractual rights and obligations, and statutory obligations.", "label": "Accounts Payable and Accrued Liabilities, Noncurrent", "terseLabel": "Accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableTradeCurrent": { "auth_ref": [ "r21", "r22" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Trade, Current", "terseLabel": "Trade payables" } } }, "localname": "AccountsPayableTradeCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r273", "r274" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedBonusesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Bonuses, Current", "terseLabel": "Accrued bonuses payable" } } }, "localname": "AccruedBonusesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedSalesCommissionCurrent": { "auth_ref": [ "r25", "r735" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Sales Commission, Current", "terseLabel": "Accrued commissions payable" } } }, "localname": "AccruedSalesCommissionCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r56", "r176", "r545" ], "calculation": { "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r4", "r13", "r33", "r468", "r471", "r520", "r564", "r565", "r868", "r869", "r870", "r881", "r882", "r883" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r106" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r417", "r418", "r419", "r586", "r881", "r882", "r883", "r938", "r954" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares redeemed to pay income tax" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for restricted stock unit under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Restricted Stock Unit, Increase for Cost Recognition", "terseLabel": "Stock-based compensation - restricted stock units" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation - options" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments for:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r414", "r424" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation", "verboseLabel": "Stock-based compensation, expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r185", "r277", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "periodEndLabel": "Balance, end of period", "periodStartLabel": "Balance, beginning of year" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]", "terseLabel": "Accounts Receivable, Allowance for Credit Loss [Roll Forward]" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableWriteOffs": { "auth_ref": [ "r300" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of direct write-downs of accounts receivable charged against the allowance.", "label": "Accounts Receivable, Allowance for Credit Loss, Writeoff", "negatedTerseLabel": "Amounts charged off" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableWriteOffs", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r142", "r179", "r212", "r250", "r264", "r268", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r458", "r460", "r494", "r539", "r621", "r766", "r781", "r903", "r904", "r940" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r171", "r188", "r212", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r458", "r460", "r494", "r766", "r903", "r904", "r940" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r82" ], "calculation": { "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r212", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r458", "r460", "r494", "r903", "r904", "r940" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total long-term assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Noncurrent [Abstract]", "terseLabel": "Long-term assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r281", "r301", "r533", "r886" ], "calculation": { "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available for sale debt instrument" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r385", "r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "stringItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Principles of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BuildingMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "label": "Building [Member]", "verboseLabel": "Buildings" } } }, "localname": "BuildingMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r451", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r65", "r67", "r451", "r762", "r763" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r451" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Business acquisition, percentage of voting interests acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesEstimatedUncollectible": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the best estimate at the acquisition date of the contractual cash flows not expected to be collected, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.", "label": "Business Combination, Acquired Receivables, Estimated Uncollectible", "terseLabel": "Estimate of uncollectible receivables" } } }, "localname": "BusinessCombinationAcquiredReceivablesEstimatedUncollectible", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesFairValue": { "auth_ref": [ "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of acquired receivable from business combination, excluding certain loans and debt securities acquired in transfer.", "label": "Business Combination, Acquired Receivable, Fair Value", "terseLabel": "Fair value of accounts receivables acquired" } } }, "localname": "BusinessCombinationAcquiredReceivablesFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquiredReceivablesGrossContractualAmount": { "auth_ref": [ "r69" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "For receivables acquired in a business combination, excluding certain loans and debt securities acquired in a transfer (as defined), this element represents the gross contractual amounts receivable, by major class of receivable, such as loans, direct finance leases (as defined), and any other class of receivables.", "label": "Business Combination, Acquired Receivables, Gross Contractual Amount", "terseLabel": "Gross contractual amount" } } }, "localname": "BusinessCombinationAcquiredReceivablesGrossContractualAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAcquisitionRelatedCosts": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.", "label": "Business Combination, Acquisition Related Costs", "terseLabel": "Acquisition related costs expensed" } } }, "localname": "BusinessCombinationAcquisitionRelatedCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r1", "r2", "r11" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Cash paid or payable" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r1", "r2", "r72", "r457" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Consideration funded by borrowings" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r137", "r452" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "terseLabel": "Trade payables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "terseLabel": "Current debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "Identifiable intangibles, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]", "terseLabel": "Identifiable Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Net assets (liabilities) acquired" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-Term Debt", "terseLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other long-term assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r68", "r71" ], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Identifiable Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r41", "r42", "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r39", "r174", "r733" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market mutual funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r39", "r120", "r209" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r3", "r120" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r164", "r182", "r183", "r184", "r212", "r236", "r237", "r239", "r241", "r248", "r249", "r287", "r317", "r319", "r320", "r321", "r324", "r325", "r355", "r356", "r357", "r358", "r359", "r494", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r609", "r630", "r648", "r721", "r722", "r723", "r724", "r725", "r859", "r876", "r884" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r92", "r540", "r608" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r128", "r311", "r312", "r727", "r896" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r769", "r770", "r771", "r773", "r774", "r775", "r778", "r881", "r882", "r938", "r953", "r954" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r105" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r14", "r105", "r609", "r627", "r954", "r955" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Shareholders' equity, ending balance (in shares)", "periodStartLabel": "Shareholders' equity, beginning balance (in shares)", "terseLabel": "Outstanding (in shares)", "verboseLabel": "Shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r105", "r541", "r766" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock - No par value: unlimited authorized; 38,400,422 and 38,049,739 issued and outstanding as of June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r34", "r193", "r195", "r201", "r534", "r550" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r46", "r48", "r84", "r85", "r272", "r726" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r46", "r48", "r84", "r85", "r272", "r574", "r726" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r46", "r48", "r84", "r85", "r272", "r726", "r861" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [ "r726" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r46", "r48", "r84", "r85", "r272" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r45", "r46", "r48", "r49", "r84", "r141", "r726" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r46", "r48", "r84", "r85", "r272", "r726" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r73", "r737" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Basis of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r361", "r362", "r373" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r115", "r528" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldDepreciation": { "auth_ref": [ "r873", "r893" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for allocation of cost of tangible asset over its useful life directly used in production of good and rendering of service.", "label": "Cost, Depreciation", "terseLabel": "Depreciation" } } }, "localname": "CostOfGoodsAndServicesSoldDepreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r47", "r272" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r129", "r211", "r326", "r332", "r333", "r334", "r335", "r336", "r337", "r342", "r349", "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r101", "r102", "r143", "r144", "r215", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r507", "r746", "r747", "r748", "r749", "r750", "r877" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate (percent)" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentCarryingAmount": { "auth_ref": [ "r20", "r144", "r353" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.", "label": "Long-Term Debt, Gross", "terseLabel": "Outstanding balance" } } }, "localname": "DebtInstrumentCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r88", "r90", "r327", "r507", "r747", "r748" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r27", "r328" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate (percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r215", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r507", "r746", "r747", "r748", "r749", "r750", "r877" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r28", "r215", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r507", "r746", "r747", "r748", "r749", "r750", "r877" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r28", "r58", "r59", "r87", "r88", "r90", "r94", "r131", "r132", "r215", "r327", "r328", "r329", "r330", "r331", "r333", "r338", "r339", "r340", "r341", "r343", "r344", "r345", "r346", "r347", "r348", "r351", "r507", "r746", "r747", "r748", "r749", "r750", "r877" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r41", "r42", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash or Partial Noncash Transaction", "negatedTerseLabel": "Non-cash change in debt from the reclassification of debt issuance costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesGainLoss": { "auth_ref": [ "r553", "r871", "r872" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity), investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).", "label": "Debt Securities, Gain (Loss)", "negatedTerseLabel": "Income from debt investment" } } }, "localname": "DebtSecuritiesGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesNoncurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.", "label": "Debt Securities, Noncurrent", "terseLabel": "Debt investment" } } }, "localname": "DebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share-Based Arrangements, Liability, Current", "terseLabel": "Current portion of phantom share liability", "verboseLabel": "Current accrued liabilities" } } }, "localname": "DeferredCompensationShareBasedArrangementsLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable after one year (or the operating cycle, if longer).", "label": "Deferred Compensation Share-Based Arrangements, Liability, Classified, Noncurrent", "terseLabel": "Long-term accrued liabilities" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements.", "label": "Deferred Compensation Share-Based Arrangements, Liability, Current and Noncurrent", "terseLabel": "Total liability" } } }, "localname": "DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFinanceCostsNet": { "auth_ref": [ "r89", "r906" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Net", "negatedTerseLabel": "Financing costs and commitment fees" } } }, "localname": "DeferredFinanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r429", "r430" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r9", "r136", "r161", "r445", "r446", "r879" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income tax (benefit) expense" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositsAssets": { "auth_ref": [ "r865" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment in the future.", "label": "Deposits Assets", "terseLabel": "Outstanding deposit" } } }, "localname": "DepositsAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r9", "r55" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationNonproduction": { "auth_ref": [ "r9", "r55" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.", "label": "Depreciation, Nonproduction", "terseLabel": "Depreciation" } } }, "localname": "DepreciationNonproduction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [ "r598", "r600", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r636", "r637", "r638", "r639", "r642", "r643", "r644", "r645", "r698", "r699", "r700", "r701", "r769", "r771" ], "lang": { "en-us": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFixedInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed interest rate related to the interest rate derivative.", "label": "Derivative, Fixed Interest Rate", "terseLabel": "Fixed interest rate (percent)" } } }, "localname": "DerivativeFixedInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DerivativeGainOnDerivative": { "auth_ref": [ "r462" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain on Derivative", "terseLabel": "Derivative, gain on derivative" } } }, "localname": "DerivativeGainOnDerivative", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r77", "r78", "r79", "r80", "r598", "r600", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r636", "r637", "r638", "r639", "r642", "r643", "r644", "r645", "r698", "r699", "r700", "r701", "r736", "r769", "r771" ], "lang": { "en-us": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesPolicyTextBlock": { "auth_ref": [ "r15", "r74", "r75", "r76", "r81", "r214" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.", "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Interest rate swaps" } } }, "localname": "DerivativesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r372", "r752", "r753", "r754", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r372", "r752", "r753", "r754", "r755", "r756", "r757", "r758" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r907" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Revenue by Source" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r202", "r224", "r225", "r226", "r227", "r228", "r234", "r236", "r239", "r240", "r241", "r245", "r483", "r484", "r535", "r551", "r740" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share (in dollars per share)", "verboseLabel": "Basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r202", "r224", "r225", "r226", "r227", "r228", "r236", "r239", "r240", "r241", "r245", "r483", "r484", "r535", "r551", "r740" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r233", "r242", "r243", "r244" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued vacation and payroll" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards": { "auth_ref": [ "r416" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate cash paid by the entity during the period to settle equity instruments granted under equity-based payment arrangements.", "label": "Share-Based Payment Arrangement, Cash Used to Settle Award", "terseLabel": "Cash settlement" } } }, "localname": "EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r415" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period of recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r936" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized pre-tax compensation expense, restricted stock units" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r936" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized pre-tax stock option expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r14", "r167", "r197", "r198", "r199", "r216", "r217", "r218", "r221", "r229", "r231", "r247", "r291", "r297", "r360", "r417", "r418", "r419", "r441", "r442", "r466", "r468", "r469", "r470", "r471", "r473", "r482", "r499", "r500", "r501", "r502", "r503", "r504", "r520", "r564", "r565", "r566", "r586", "r648" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "auth_ref": [ "r7", "r9", "r112", "r547" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities.", "label": "Proceeds from Equity Method Investment, Distribution", "terseLabel": "Distributions of earnings received from equity method investments" } } }, "localname": "EquityMethodInvestmentDividendsOrDistributions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r255", "r282", "r863", "r888" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r7", "r86", "r285" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments [Policy Text Block]", "terseLabel": "Equity investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.", "label": "Equity Method Investments [Table Text Block]", "terseLabel": "Schedule of Equity Method Investments" } } }, "localname": "EquityMethodInvestmentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "auth_ref": [ "r552", "r887" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Income from equity method investments" } } }, "localname": "EquitySecuritiesFvNiRealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r340", "r375", "r376", "r377", "r378", "r379", "r380", "r488", "r521", "r522", "r523", "r747", "r748", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r487", "r488", "r489", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r486" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r340", "r375", "r380", "r488", "r521", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Fair Value, Inputs, Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r340", "r375", "r380", "r488", "r522", "r747", "r748", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Fair Value, Inputs, Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r340", "r375", "r376", "r377", "r378", "r379", "r380", "r488", "r523", "r747", "r748", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Fair Value, Inputs, Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r16", "r83" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r340", "r375", "r376", "r377", "r378", "r379", "r380", "r521", "r522", "r523", "r747", "r748", "r759", "r760", "r761" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r486", "r491" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities, current portion" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities, less current portion" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAsset": { "auth_ref": [ "r512" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainContingencyUnrecordedAmount": { "auth_ref": [ "r902" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.", "label": "Gain Contingency, Unrecorded Amount", "terseLabel": "Recalculated principal overpayment request" } } }, "localname": "GainContingencyUnrecordedAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnDispositionOfAssets": { "auth_ref": [ "r875", "r892", "r894" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property", "negatedNetLabel": "Loss (gain) on disposal of property and equipment", "negatedTerseLabel": "Loss (gain) on disposal of property and equipment" } } }, "localname": "GainLossOnDispositionOfAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r177", "r306", "r532", "r745", "r766", "r890", "r891" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "auth_ref": [ "r305", "r307", "r745" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.", "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Valuation of Goodwill" } } }, "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r114", "r212", "r250", "r263", "r267", "r269", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r494", "r742", "r903" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r111", "r147", "r250", "r263", "r267", "r269", "r536", "r548", "r742" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net income before taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r9", "r112", "r146", "r253", "r282", "r547" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Income from equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r308", "r310", "r633" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r310", "r633" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r213", "r426", "r433", "r434", "r437", "r443", "r447", "r448", "r449", "r585" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r152", "r162", "r230", "r231", "r254", "r431", "r444", "r554" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r196", "r427", "r428", "r434", "r435", "r436", "r438", "r579" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r40" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid (received) during the period for income taxes, net of refunds" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesReceivable": { "auth_ref": [ "r91", "r866" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.", "label": "Income Taxes Receivable, Current", "terseLabel": "Income tax receivable" } } }, "localname": "IncomeTaxesReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Trade payables" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.", "label": "Increase (Decrease) in Income Taxes Payable", "terseLabel": "Income tax payable/receivable" } } }, "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r526", "r874" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in working capital, net of effects from acquisitions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r53", "r54" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Identifiable intangibles, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest income (expense), net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r205", "r207", "r208" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid during the period for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r731", "r776", "r777" ], "lang": { "en-us": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryLIFOReservePeriodCharge": { "auth_ref": [ "r125" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.", "label": "Inventory, LIFO Reserve, Period Charge", "terseLabel": "Change in inventory reserve" } } }, "localname": "InventoryLIFOReservePeriodCharge", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r187", "r734", "r766" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r153", "r173", "r186", "r302", "r303", "r304", "r527", "r738" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Investments": { "auth_ref": [ "r538" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.", "label": "Investments", "totalLabel": "Balance, end of period", "verboseLabel": "Equity investments" } } }, "localname": "Investments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LandMember": { "auth_ref": [ "r908" ], "lang": { "en-us": { "role": { "documentation": "Part of earth's surface not covered by water.", "label": "Land [Member]", "terseLabel": "Land" } } }, "localname": "LandMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r24", "r212", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r459", "r460", "r461", "r494", "r607", "r741", "r781", "r903", "r940", "r941" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "LIABILITIES" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r110", "r145", "r543", "r766", "r878", "r889", "r939" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r26", "r172", "r212", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r459", "r460", "r461", "r494", "r766", "r903", "r940", "r941" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r20", "r97", "r98", "r99", "r103", "r212", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r459", "r460", "r461", "r494", "r903", "r940", "r941" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total long-term liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Long-term liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r23" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r20", "r144", "r339", "r354", "r747", "r748", "r950" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.", "label": "Long-Term Debt", "terseLabel": "Long-term debt" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r180" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.", "label": "Long-Term Debt, Current Maturities", "negatedLabel": "Current portion of notes payable", "terseLabel": "Current debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r181" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.", "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "verboseLabel": "Net long-term notes payable" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r28", "r57" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyDamagesSoughtValue": { "auth_ref": [ "r897", "r898", "r899" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.", "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Damages sought" } } }, "localname": "LossContingencyDamagesSoughtValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r93" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Debt Investment" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r909" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r206" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r206" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r120", "r121", "r122" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r113", "r122", "r148", "r170", "r191", "r194", "r199", "r212", "r220", "r224", "r225", "r226", "r227", "r230", "r231", "r238", "r250", "r263", "r267", "r269", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r484", "r494", "r549", "r629", "r646", "r647", "r742", "r779", "r903" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "terseLabel": "Net income attributable to shareholders", "totalLabel": "Net income", "verboseLabel": "Net income" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "auth_ref": [ "r165", "r166", "r167", "r168", "r169", "r219", "r220", "r221", "r222", "r223", "r226", "r232", "r245", "r279", "r280", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r309", "r417", "r418", "r419", "r439", "r440", "r441", "r442", "r453", "r454", "r455", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r492", "r493", "r495", "r496", "r497", "r498", "r505", "r506", "r508", "r509", "r510", "r511", "r516", "r517", "r518", "r519", "r520", "r529", "r530", "r531", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r577" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "auth_ref": [ "r44", "r165", "r166", "r167", "r168", "r169", "r219", "r220", "r221", "r222", "r223", "r226", "r232", "r245", "r279", "r280", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r309", "r417", "r418", "r419", "r439", "r440", "r441", "r442", "r453", "r454", "r455", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r492", "r493", "r495", "r496", "r497", "r498", "r505", "r506", "r508", "r509", "r510", "r511", "r516", "r517", "r518", "r519", "r520", "r529", "r530", "r531", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r577" ], "lang": { "en-us": { "role": { "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.", "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]" } } }, "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesInterestRateSwapsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently adopted accounting pronouncements and Recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Supplemental disclosures of non-cash transactions" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Non-operating income and expenses" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_NotesPayableToBanksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a bank.", "label": "Notes Payable to Banks [Member]", "terseLabel": "Notes Payable" } } }, "localname": "NotesPayableToBanksMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtScheduleofNotesPayableDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfStatesInWhichEntityOperates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of states the entity operates in as of the balance sheet date.", "label": "Number of States in which Entity Operates", "terseLabel": "Number of states in which entity provides DME and health care solutions" } } }, "localname": "NumberOfStatesInWhichEntityOperates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/NatureofBusinessandOperationsDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r250", "r263", "r267", "r269", "r742" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncome": { "auth_ref": [ "r246", "r514", "r515" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.", "label": "Operating Lease, Lease Income", "terseLabel": "Revenue from rentals under Topic 842" } } }, "localname": "OperatingLeaseLeaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, less current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r512" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r96", "r139", "r575", "r576" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/NatureofBusinessandOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Accrued other liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r178" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other long-term assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "auth_ref": [ "r189", "r190" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "terseLabel": "Change in unrealized gain/loss on derivative instruments, net of tax" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r6", "r12", "r140", "r192", "r195" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Change in accumulated other comprehensive loss, net of tax", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of other current liabilities.", "label": "Other Current Liabilities [Table Text Block]", "terseLabel": "Schedule of Current Liabilities" } } }, "localname": "OtherCurrentLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherInvestments": { "auth_ref": [ "r864" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_Investments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investments classified as other.", "label": "Other Investments", "terseLabel": "Other equity investments" } } }, "localname": "OtherInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r117" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 6.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedTerseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r37" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedTerseLabel": "Shares repurchased under the share repurchase program" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r204" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedLabel": "Shares redeemed to pay income tax" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r35", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Purchase consideration funded by cash on hand" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r35" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Cash paid for acquisition of HMP, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "auth_ref": [ "r119" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other.", "label": "Payments to Acquire Other Productive Assets", "negatedTerseLabel": "Investment in equity investments" } } }, "localname": "PaymentsToAcquireOtherProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r119" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchase of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PhantomShareUnitsPSUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded as phantom share or unit.", "label": "Phantom Share Units (PSUs) [Member]", "terseLabel": "Phantom Share Units" } } }, "localname": "PhantomShareUnitsPSUsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r910", "r911", "r912", "r913", "r914", "r915", "r916", "r917", "r918", "r919", "r920", "r921", "r922", "r923", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934", "r935" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r867" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r36" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-Term Debt", "terseLabel": "Proceeds from term notes" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r36", "r877" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit facilities" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r118" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Proceeds from Sale of Property, Plant, and Equipment", "terseLabel": "Proceeds from sale of property and equipment" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r5", "r19" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r126", "r156", "r159", "r160" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r127", "r175", "r546" ], "calculation": { "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r10", "r537", "r546", "r766" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 }, "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net of accumulated depreciation and amortization" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r10", "r156", "r159", "r544" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProvisionForDoubtfulAccounts": { "auth_ref": [ "r203", "r299" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "verboseLabel": "Provision for uncollectible accounts" } } }, "localname": "ProvisionForDoubtfulAccounts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesAccountsReceivableAllowanceforDoubtfulAccountsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PurchaseObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.", "label": "Purchase Obligation", "terseLabel": "Purchase obligation" } } }, "localname": "PurchaseObligation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r38", "r877" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedTerseLabel": "Payments on revolving credit facilities" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r38" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other, maturing after one year or the operating cycle, if longer.", "label": "Repayments of Other Long-Term Debt", "negatedLabel": "Principal payments on term notes" } } }, "localname": "RepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r95", "r425", "r948" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r174" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r107", "r133", "r542", "r568", "r573", "r584", "r610", "r766" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r167", "r216", "r217", "r218", "r221", "r229", "r231", "r291", "r297", "r417", "r418", "r419", "r441", "r442", "r466", "r469", "r470", "r473", "r482", "r564", "r566", "r586", "r954" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r251", "r252", "r262", "r265", "r266", "r270", "r271", "r272", "r371", "r372", "r528" ], "calculation": { "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue from sales and services under Topic 606" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerMember": { "auth_ref": [ "r272", "r860" ], "lang": { "en-us": { "role": { "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r163", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r730" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Accounting under Topic 606" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionLeases": { "auth_ref": [ "r739" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue recognition for leases entered into by lessor.", "label": "Revenue Recognition, Leases [Policy Text Block]", "terseLabel": "Revenue Accounting under Topic 842" } } }, "localname": "RevenueRecognitionLeases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r631", "r730", "r739" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r200", "r212", "r251", "r252", "r262", "r265", "r266", "r270", "r271", "r272", "r287", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r494", "r536", "r903" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 }, "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenue", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.", "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility" } } }, "localname": "RevolvingCreditFacilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Accounts Receivable, Allowance for Doubtful Accounts" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r65", "r67", "r451" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDebtInstrumentsTextBlock": { "auth_ref": [ "r28", "r58", "r59", "r87", "r88", "r90", "r94", "r131", "r132", "r747", "r749", "r880" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Notes Payable" } } }, "localname": "ScheduleOfDebtInstrumentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r885" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r487", "r488" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/FairValueMeasurementTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInvestmentsLineItems": { "auth_ref": [ "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule of Investments [Line Items]", "terseLabel": "Schedule of Investments [Line Items]" } } }, "localname": "ScheduleOfInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInvestmentsTable": { "auth_ref": [ "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r694", "r695", "r696", "r697", "r702", "r703", "r704", "r706", "r707", "r708", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investments owned by investment company.", "label": "Schedule of Investments [Table]", "terseLabel": "Schedule of Investments [Table]" } } }, "localname": "ScheduleOfInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r17", "r18", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "terseLabel": "Schedule of Phantom Share Units" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r383", "r384", "r385", "r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "auth_ref": [ "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Units" } } }, "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r17", "r18", "r61" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r45", "r46", "r48", "r49", "r84", "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Revenue by Customer" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r937" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r256", "r257", "r258", "r259", "r260", "r261", "r271", "r743" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r116" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general, and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r752" ], "lang": { "en-us": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service revenues" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r8" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r765" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Expired / Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r402" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Expired / Forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Issued (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "RSUs outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of RSUs (000's)", "verboseLabel": "Number of phantom share units (000's)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r397", "r398" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (USD per share)", "periodStartLabel": "Beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r401" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Value of share equivalents" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [ "r383", "r384", "r385", "r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Maximum shares in Plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r916" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Expired / Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r916" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Expired / Forfeited (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Issued (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value", "verboseLabel": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Options outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options (000's)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r389", "r390" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (USD per share)", "periodStartLabel": "Beginning balance (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r385", "r386", "r387", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r394" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r393" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Issued (USD per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r382", "r388", "r407", "r408", "r409", "r410", "r413", "r420", "r421", "r422", "r423" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (USD per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails", "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails", "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "negatedTerseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r60" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r135" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "auth_ref": [ "r130", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "terseLabel": "Shareholders' Equity" } } }, "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares redeemed to pay income tax (in shares)", "terseLabel": "Shares redeemed to pay income tax (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r100", "r143", "r766", "r949" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short-Term Debt", "terseLabel": "Short-term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r123", "r210" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r164", "r182", "r183", "r184", "r212", "r236", "r237", "r239", "r241", "r248", "r249", "r287", "r317", "r319", "r320", "r321", "r324", "r325", "r355", "r356", "r357", "r358", "r359", "r494", "r580", "r581", "r582", "r583", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r609", "r630", "r648", "r721", "r722", "r723", "r724", "r725", "r859", "r876", "r884" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r14", "r31", "r167", "r197", "r198", "r199", "r216", "r217", "r218", "r221", "r229", "r231", "r247", "r291", "r297", "r360", "r417", "r418", "r419", "r441", "r442", "r466", "r468", "r469", "r470", "r471", "r473", "r482", "r499", "r500", "r501", "r502", "r503", "r504", "r520", "r564", "r565", "r566", "r586", "r648" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r216", "r217", "r218", "r247", "r528", "r578", "r597", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r628", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r648", "r772" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r216", "r217", "r218", "r247", "r528", "r578", "r597", "r601", "r602", "r603", "r604", "r605", "r606", "r609", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r623", "r624", "r625", "r626", "r628", "r631", "r632", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r645", "r648", "r772" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockAppreciationRightsSARSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.", "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)" } } }, "localname": "StockAppreciationRightsSARSMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r14", "r133" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Shares issued for vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r104", "r105", "r133", "r394" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "terseLabel": "Exercise of options (in shares)", "verboseLabel": "Common stock issued pursuant to stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://www.viemed.com/role/ShareholdersEquityOptionsNarrativeDetails", "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r14", "r104", "r105", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Shares issued for vesting of restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r14", "r31", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "auth_ref": [ "r14", "r104", "r105", "r133" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital).", "label": "Stock Repurchased and Retired During Period, Value", "terseLabel": "Shares redeemed to pay income tax" } } }, "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityIssuedandOutstandingShareCapitalDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r14", "r104", "r105", "r133", "r583", "r648", "r724" ], "lang": { "en-us": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "negatedTerseLabel": "Shares repurchased under share repurchase program (in shares)" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StockRepurchasedDuringPeriodValue": { "auth_ref": [ "r14", "r104", "r105", "r133", "r586", "r648", "r724", "r780" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Value", "negatedTerseLabel": "Shares repurchased under share repurchase program" } } }, "localname": "StockRepurchasedDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r105", "r108", "r109", "r124", "r611", "r627", "r649", "r650", "r766", "r781", "r878", "r889", "r939", "r954" ], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Shareholders' equity, ending balance", "periodStartLabel": "Shareholders' equity, beginning balance", "totalLabel": "TOTAL SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r149", "r150", "r151", "r275", "r276", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r50", "r51", "r52", "r154", "r155", "r157", "r158" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]", "terseLabel": "Vehicles" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r885" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Stock options and other dilutive securities (in shares)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]", "terseLabel": "Denominator calculation from basic to diluted:" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r235", "r241" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average number of shares (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of common shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r234", "r241" ], "calculation": { "http://www.viemed.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted-average number of common shares (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFINCOMEANDCOMPREHENSIVEINCOME", "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.viemed.com/role/EarningsPerShareDetails" ], "xbrltype": "stringItemType" }, "vmd_A2018SeniorCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2018 Senior Credit Facility", "label": "2018 Senior Credit Facility [Member]", "terseLabel": "2018 Senior Credit Facility" } } }, "localname": "A2018SeniorCreditFacilityMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_A2019TermNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2019 Term Note", "label": "2019 Term Note [Member]", "terseLabel": "2019 Term Note" } } }, "localname": "A2019TermNoteMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_A2022SeniorCreditFacilitiesClosingDateOfDecember312024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Senior Credit Facilities Closing Date Of December 31 2024", "label": "2022 Senior Credit Facilities Closing Date Of December 31 2024 [Member]", "terseLabel": "2022 Senior Credit Facilities Closing Date Of December 31 2024" } } }, "localname": "A2022SeniorCreditFacilitiesClosingDateOfDecember312024Member", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_A2022SeniorCreditFacilitiesClosingDateOfMarch312025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Senior Credit Facilities Closing Date Of March 31 2025", "label": "2022 Senior Credit Facilities Closing Date Of March 31 2025 [Member]", "terseLabel": "2022 Senior Credit Facilities Closing Date Of March 31 2025" } } }, "localname": "A2022SeniorCreditFacilitiesClosingDateOfMarch312025Member", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_A2022SeniorCreditFacilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2022 Senior Credit Facilities", "label": "2022 Senior Credit Facilities [Member]", "terseLabel": "2022 Senior Credit Facilities" } } }, "localname": "A2022SeniorCreditFacilitiesMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_A5YearRevolvingCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "5 Year Revolving Credit Facility", "label": "5 Year Revolving Credit Facility [Member]", "terseLabel": "5 Year Revolving Credit Facility" } } }, "localname": "A5YearRevolvingCreditFacilityMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_AccruedTradePayablesCurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Trade Payables, Current", "label": "Accrued Trade Payables, Current", "terseLabel": "Accrued trade payables" } } }, "localname": "AccruedTradePayablesCurrent", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_BuildingTermNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building Term Note [Member]", "label": "Building Term Note [Member]", "terseLabel": "Building Term Note" } } }, "localname": "BuildingTermNoteMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_BusinessCombinationConsiderationPayableCurrent": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Consideration, Payable, Current", "label": "Business Combination, Consideration, Payable, Current", "terseLabel": "Purchase price payable" } } }, "localname": "BusinessCombinationConsiderationPayableCurrent", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/CurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccruedLiabilities", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCurrentPortionOfLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Current Portion of Lease Liabilities", "terseLabel": "Current portion of lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesCurrentPortionOfLeaseLiabilities", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesAssets": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases Assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Leases Assets", "terseLabel": "Lease assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLeasesAssets", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentLiabilitiesLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-Current Liabilities, Lease Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Non-Current Liabilities, Lease Liabilities", "terseLabel": "Long-term lease liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCurrentLiabilitiesLeaseLiabilities", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_CARESActFundsReceivedPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CARES Act Funds Received", "label": "CARES Act Funds Received [Policy Text Block]", "terseLabel": "CARES Act Funds Received" } } }, "localname": "CARESActFundsReceivedPolicyTextBlock", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vmd_COVID19ResponseSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "COVID-19 Response Sales [Member]", "label": "COVID-19 Response Sales [Member]", "terseLabel": "COVID-19 response sales and services" } } }, "localname": "COVID19ResponseSalesMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_CoronavirusAidReliefAndEconomicSecurityGeneralDistributionPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, And Economic Security, General Distribution Payment Received", "label": "Coronavirus Aid, Relief, And Economic Security, General Distribution Payment Received", "terseLabel": "Proceeds from general distribution payment" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityGeneralDistributionPaymentReceived", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCARESActFundsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "vmd_CoronavirusAidReliefAndEconomicSecurityTargetedDistributionPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, And Economic Security, Targeted Distribution Payment Received", "label": "Coronavirus Aid, Relief, And Economic Security, Targeted Distribution Payment Received", "terseLabel": "Proceeds from targeted distribution payment" } } }, "localname": "CoronavirusAidReliefAndEconomicSecurityTargetedDistributionPaymentReceived", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCARESActFundsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "vmd_CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Coronavirus Aid, Relief, and Economic Security, Government Grant Received", "label": "Coronavirus Aid, Relief, and Economic Security, Government Grant Received", "terseLabel": "Government grant received" } } }, "localname": "CoronavirusAidReliefandEconomicSecurityGovernmentGrantReceived", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCARESActFundsReceivedDetails" ], "xbrltype": "monetaryItemType" }, "vmd_CovenantPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period", "label": "Covenant Period [Axis]", "terseLabel": "Covenant Period [Axis]" } } }, "localname": "CovenantPeriodAxis", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "stringItemType" }, "vmd_CovenantPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Covenant Period [Domain]", "label": "Covenant Period [Domain]", "terseLabel": "Covenant Period [Domain]" } } }, "localname": "CovenantPeriodDomain", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_DebtInstrumentFixedChargeCoverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Fixed Charge Coverage Ratio", "label": "Debt Instrument, Fixed Charge Coverage Ratio", "terseLabel": "Fixed charge coverage ratio" } } }, "localname": "DebtInstrumentFixedChargeCoverageRatio", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "pureItemType" }, "vmd_DebtInstrumentTotalLeverageRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Total Leverage Ratio", "label": "Debt Instrument, Total Leverage Ratio", "terseLabel": "Total leverage ratio" } } }, "localname": "DebtInstrumentTotalLeverageRatio", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "pureItemType" }, "vmd_DelayedDrawTermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Delayed Draw Term Loan Facility", "label": "Delayed Draw Term Loan Facility [Member]", "terseLabel": "Delayed Draw Term Loan Facility" } } }, "localname": "DelayedDrawTermLoanFacilityMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_DiscreteIncomeTaxExpenseBenefit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Discrete Income Tax Expense (Benefit)", "label": "Discrete Income Tax Expense (Benefit)", "negatedTerseLabel": "Discrete income tax benefit" } } }, "localname": "DiscreteIncomeTaxExpenseBenefit", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "vmd_EquipmentFinancingObligationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Financing Obligation", "label": "Equipment Financing Obligation [Member]", "terseLabel": "Equipment Financing Obligations" } } }, "localname": "EquipmentFinancingObligationMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/DebtSeniorCreditFacilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_EquipmentMedicalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment, Medical [Member]", "label": "Equipment, Medical [Member]", "terseLabel": "Medical equipment" } } }, "localname": "EquipmentMedicalMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentNarrativeDetails", "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "vmd_EquipmentSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment Sales [Member]", "label": "Equipment Sales [Member]", "terseLabel": "Equipment and supply sales" } } }, "localname": "EquipmentSalesMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_FurnitureAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture And Equipment [Member]", "label": "Furniture And Equipment [Member]", "terseLabel": "Furniture and equipment" } } }, "localname": "FurnitureAndEquipmentMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/PropertyandEquipmentScheduleofFixedAssetsDetails" ], "xbrltype": "domainItemType" }, "vmd_HomeMedicalProductsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Home Medical Products Inc", "label": "Home Medical Products Inc [Member]", "terseLabel": "Home Medical Products Inc" } } }, "localname": "HomeMedicalProductsIncMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails", "http://www.viemed.com/role/BusinessCombinationsSummarizestheConsiderationPaidandEstimatedFairValuesoftheAssetsAcquiredandLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "vmd_LeasePayments": { "auth_ref": [], "calculation": { "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease, Payments", "label": "Lease, Payments", "negatedTerseLabel": "Repayments of lease liabilities" } } }, "localname": "LeasePayments", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "vmd_LossContingencyNumberOfNonInvasiveVentilationAtHomePatients": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Number Of Non-Invasive Ventilation At Home Patients", "label": "Loss Contingency, Number Of Non-Invasive Ventilation At Home Patients", "terseLabel": "Number of patients" } } }, "localname": "LossContingencyNumberOfNonInvasiveVentilationAtHomePatients", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "integerItemType" }, "vmd_LossContingencyPercentOfNecessaryClaimsReviewedAndPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loss Contingency, Percent Of Necessary Claims Reviewed And Payable", "label": "Loss Contingency, Percent Of Necessary Claims Reviewed And Payable", "terseLabel": "Necessary claims reviewed and payable (percent)" } } }, "localname": "LossContingencyPercentOfNecessaryClaimsReviewedAndPayable", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "vmd_MedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicaid [Member]", "label": "Medicaid [Member]", "terseLabel": "Medicaid revenues" } } }, "localname": "MedicaidMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_MedicareAndMedicaidMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare And Medicaid [Member]", "label": "Medicare And Medicaid [Member]", "terseLabel": "Total Medicare and Medicaid" } } }, "localname": "MedicareAndMedicaidMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_MedicareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Medicare [Member]", "label": "Medicare [Member]", "terseLabel": "Medicare revenues" } } }, "localname": "MedicareMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesCustomerPercentagesDetails" ], "xbrltype": "domainItemType" }, "vmd_OmnibusPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Omnibus Plan", "label": "Omnibus Plan [Member]", "terseLabel": "Omnibus Plan" } } }, "localname": "OmnibusPlanMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "vmd_OtherDurableMedicalEquipmentRentalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Durable Medical Equipment Rentals [Member]", "label": "Other Durable Medical Equipment Rentals [Member]", "terseLabel": "Other durable medical equipment rentals" } } }, "localname": "OtherDurableMedicalEquipmentRentalsMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value", "terseLabel": "Fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityRestrictedStockUnitsDetails" ], "xbrltype": "monetaryItemType" }, "vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Forfeited", "negatedTerseLabel": "Expired / Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueForfeited", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "vmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options Aggregate Intrinsic Value Issued", "terseLabel": "Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueIssued", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityPhantomShareUnitsDetails" ], "xbrltype": "monetaryItemType" }, "vmd_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Shares Available For Grant, Percent Of Stock Outstanding", "terseLabel": "Percent of issued and outstanding shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfSharesAvailableForGrantPercentOfStockOutstanding", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityStockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "vmd_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/ShareholdersEquityOptionsStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "vmd_SolvetServicesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Solvet Services LLC", "label": "Solvet Services LLC [Member]", "terseLabel": "Solvet Services LLC" } } }, "localname": "SolvetServicesLLCMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesEquityInvestmentsDetails" ], "xbrltype": "domainItemType" }, "vmd_TermLoanFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term Loan Facility", "label": "Term Loan Facility [Member]", "terseLabel": "Term Loan Facility" } } }, "localname": "TermLoanFacilityMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/BusinessCombinationsNarrativeDetails" ], "xbrltype": "domainItemType" }, "vmd_VentilatorRentalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ventilator Rental [Member]", "label": "Ventilator Rental [Member]", "terseLabel": "Ventilator rentals, non-invasive and invasive" } } }, "localname": "VentilatorRentalMember", "nsuri": "http://www.viemed.com/20230630", "presentation": [ "http://www.viemed.com/role/SummaryofSignificantAccountingPoliciesRevenueRecognitionDetails" ], "xbrltype": "domainItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.L)", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(5))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(n))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-29", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//350-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "50", "Subparagraph": "(a)", "Topic": "405", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(k)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.C.Q3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "832", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(h))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-23", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 10))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 12))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 13))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 1)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column B))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column F))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "47", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482785/280-10-55-47", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r782": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r783": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r784": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r785": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r786": { "Name": "Form 20-F", "Paragraph": "a", "Publisher": "SEC", "Section": "16", "Subsection": "J", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r787": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r788": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r789": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "A", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "B", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r791": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "C", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r792": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "D", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r793": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Sentence": "E", "Subparagraph": "i", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r794": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r795": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "iii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r796": { "Name": "Form 20-F", "Paragraph": "2", "Publisher": "SEC", "Section": "6", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r797": { "Name": "Form 20-F", "Paragraph": "1", "Publisher": "SEC", "Section": "6", "Subparagraph": "ii", "Subsection": "F", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r798": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r799": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r801": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r802": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r803": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r804": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r805": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r806": { "Name": "Form 40-F", "Paragraph": "a", "Publisher": "SEC", "Section": "19", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r807": { "Name": "Form 40-F", "Paragraph": "b", "Publisher": "SEC", "Section": "19", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r808": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r809": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "i", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r811": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "ii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r812": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iii", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r813": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "iv", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r814": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Sentence": "v", "Subparagraph": "1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r815": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r816": { "Name": "Form N-CSR", "Paragraph": "a", "Publisher": "SEC", "Section": "18", "Subparagraph": "3", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r817": { "Name": "Form N-CSR", "Paragraph": "b", "Publisher": "SEC", "Section": "18", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r818": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r819": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r821": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r822": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r823": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r824": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subparagraph": "vi", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r825": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "3", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r826": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "4", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r827": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r828": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r829": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "5", "Publisher": "SEC", "Section": "402", "Subparagraph": "iv", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r831": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r832": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "6", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "v", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r833": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r834": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r835": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r836": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "B", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r837": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r838": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r839": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "i", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "ii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r841": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subparagraph": "iii", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r842": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "w", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r843": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r844": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r845": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "A", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r846": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "C", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r847": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "D", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r848": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "E", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r849": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "402", "Sentence": "F", "Subparagraph": "ii", "Subsection": "x", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Regulation S-K", "Number": "229", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r851": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r852": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "A", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r853": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "B", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r854": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "C", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r855": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "2", "Publisher": "SEC", "Section": "408", "Subparagraph": "D", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r856": { "Name": "Regulation S-K", "Number": "229", "Paragraph": "1", "Publisher": "SEC", "Section": "408", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r857": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r858": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(10))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r866": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r867": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r868": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r869": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r871": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r872": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(2))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.10)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 70 0001729149-23-000111-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001729149-23-000111-xbrl.zip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✇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end